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“I went to the woods because I wished to live deliberately, to front only the essential facts 
of life, and see if I could not learn what it had to teach, and not, when I came to die, 
discover that I had not lived. I did not wish to live what was not life, living is so dear; nor 
did I wish to practise resignation, unless it was quite necessary. I wanted to live deep and 
suck out all the marrow of life, to live so sturdily and Spartan- like as to put to rout all 
that was not life, to cut a broad swath and shave close, to drive life into a corner, and 
reduce it to its lowest terms, and, if it proved to be mean, why then to get the whole and 
genuine meanness of it, and publish its meanness to the world; or if it were sublime, to 
know it by experience, and be able to give a true account of it in my next excursion.”—
Henry David Thoreau (an excerpt from Walden) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is dedicated to my beloved grandmother Mary S. Bouffard (3/11/37-5/21/13)  
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ABSTRACT 
TNFα-induced programmed necrosis is a caspase-independent cell death program 
that is contingent upon the formation of a multiprotein complex termed the necrosome. 
The association of two of the components of the necrosome, receptor interacting protein 1 
(RIP1) and RIP3, is a critical and signature molecular event during necrosis.  Within this 
complex, both RIP1 and RIP3 are phosphorylated which are consequential for 
transmission of the pro-necrotic signal.  Namely, it has been demonstrated that RIP3 
phosphorylation is required for binding to downstream substrates.  Nevertheless, the 
regulatory mechanisms governing necrosome activation remain unclear.  Since necrosis 
is implicated in a variety of different diseases, understanding the biochemical signaling 
pathway can potentially yield future drug targets.  I was interested in identifying other 
regulators of necrosis in hope of gaining a better understanding of the necrosis signaling 
pathway and regulators of the necrosome.  To address this, I screened a cancer gene 
siRNA library in a cell line sensitive to necrosis.  From this, I independently identified 
CYLD as a positive regulator of necrosis.  Previous studies suggest that deubiquitination 
of RIP1 in the TNF receptor (TNFR)-1 signaling complex is a prerequisite for transition 
of RIP1 into the cytosol and assembly of the RIP1-RIP3 necrosome.  The deubiquitinase 
cylindromatosis (CYLD) is presumed to promote programmed necrosis by facilitating 
RIP1 deubiquitination in this membrane receptor complex.  Surprisingly, I found that 
TNFα could induce RIP1-dependent necrosis in CYLD-/- cells.  I show that CYLD does 
not regulate RIP1 ubiquitination at the receptor complex.  Strikingly, assembly of the 
RIP1-RIP3 necrosome was delayed, but not abolished in the absence of CYLD.  In 
addition to the TNFR-1 complex, I found that RIP1 within the necrosome was also 
xiii
ubiquitinated.  In the absence of CYLD, RIP1 ubiquitination in the NP-40 insoluble 
necrosome was greatly increased. Increased RIP1 ubiquitination correlated with impaired 
RIP1 and RIP3 phosphorylation, a signature of kinase activation.  My results show that 
CYLD regulates RIP1 ubiquitination in the NP-40 insoluble necrosome, but not in the 
TNFR-1 signaling complex.  Contrary to the current model, CYLD is not essential for 
necrosome assembly.  Rather, it facilitates RIP1 and RIP3 activation within the 
necrosome and the corollary is enhancement of necrosome functionality and subsequent 
necrosis.  My results therefore indicate that CYLD exerts its pro-necrotic function in the 
NP-40 insoluble necrosome, and illuminates the mechanism of necrosome activation. 
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CHAPTER I: Introduction 
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A brief comparison between apoptosis and programmed necrosis 
Programmed cell death is a critical function for the maintenance of cellular 
homeostasis.  Indeed, the emergence of multicellular organisms was likely contingent 
upon development of cell suicide programs to eliminate superfluous cells, damaged cells, 
pathogen infected cells, and transformed cells. It is not surprising that cell death is a 
lynchpin in a multitude of both physiological and patho-physiological contexts. The 
requirement of programmed cell death begins during embryogenesis and persists 
throughout the organism’s lifetime.  Indeed there are numerous examples of disastrous 
consequences attributed to the perturbation of cell death programs. For instance, loss of 
function mutations in the death receptor Fas (CD95), are responsible for causing 
autoimmune lymphoproliferative syndrome (ALPS).  The clinical manifestations of this 
disease include splenomegaly, lymphadenopathy, accumulation of an atypical mature T 
cell population that is double negative, autoimmunity, and increased probability of 
hematological tumors (Oliveira et al., 2008).  
Over the years apoptosis has become synonymous with programmed cell death 
while necrosis has been associated with an unregulated form of cell death.  This is logical 
considering apoptosis was the first name coined for programmed cell death and later was 
the first to be defined both genetically and biochemically (Kerr et al., 1972; Vaux et al., 
1988; Yuan et al., 1992).  However, even to this day many scientists still think of necrosis 
as an accidental form of cell death rather than programmed. Over the past several years 
mounting evidence has resulted in an increasing recognition of necrosis as a programmed 
form of cell death.  Depending on the group, it is either referred to as “programmed 
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necrosis” or “necroptosis”, which will hereafter be referred to as necrosis in the rest of 
this document (Chan et al., 2003; Degterev et al., 2005).   
One of the first studies suggesting that necrosis was programmed was in 1988.  
This group tested a variety of cell-lines for sensitivity to TNFα-induced cell death and 
used time-lapse videos in conjunction with chromium release or tritiated thymidine 
release assays to define loss of plasma membrane integrity or nuclear disintegration, 
respectively.  This study demonstrated that TNFα induced different types of cell death 
depending on the cell-line.  Some cells underwent cell death with apoptotic morphology 
and others underwent cell death with necrotic morphology (Laster et al. 1988). Another 
seminal finding, which supported necrosis qualifying as a type of programmed cell death, 
was that caspase-inhibition enhances TNFα-induced reactive oxygen species (ROS) 
production and necrotic cell death in the murine fibrosarcoma cell-line L929.  
Importantly, cell death was completely blocked when treated with a ROS scavenger.  
This established that necrosis is a caspase-independent cell death program and requires 
the generation of ROS for execution.  It also provided evidence that the necrosis 
signaling pathway is distinct from the apoptosis, which requires caspases (Vercammen et 
al., 1998).   
Over the past several years it has been revealed that necrosis can be initiated by a 
variety of different stimuli such as death receptors, pattern recognition receptors, virus 
infection, chemotherapeutic agents, and oxidative stress.  Hence, one of the major goals 
of the field has been to determine the core components of the necrotic machinery or 
independent signaling pathways that lead to the same type of cellular demise 
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(Vandenabeele et al., 2010; Vanlangenakker et al., 2012).  The discovery that the serine 
threonine kinases Receptor Interacting Protein 1 and 3 (RIP1/RIP3) are required for 
TNFα-induced necrosis provided the incipient illumination of the biochemical pathway 
(Chan et al., 2003; Cho et al., 2009, He et al., 2009; Holler et al., 2000; Zang et al., 
2009).  The molecular details will be covered later in this chapter.  
An accurate epithet of programmed necrosis is “Explosive cell death.”  As 
mentioned earlier, necrosis is a caspase-independent form of cell death.  Necrotic cells 
exhibit signs of both organelle and cellular swelling (oncosis), increased translucence of 
cytoplasm, irregular chromatin condensation, and eventually loss of plasma membrane 
integrity and release of the cellular contents into the surrounding extracellular 
environment (Vandenabeele et al., 2010).  Importantly, necrosis is a pro-inflammatory 
form of cell death because of the release of danger associated molecular patterns 
(DAMPs) such as Monosodium urate (MSU) microcrystals, ATP, and HMGB1.  The 
ramifications of the release of DAMPs from necrotic cells are activation of both the 
innate and adaptive immune responses. DAMPs elicit dendritic cell activation and 
subsequent homing to the lymph node where adaptive immune responses to dead cell 
associated antigens can be initiated.  Furthermore, DAMPS can also influence the 
production of cytokines such as the case with MSU and IL-1 production.  IL-1 signaling 
is particularly important in the inflammatory response initiated by dead cells (Rock et al., 
2011). 
A suitable epithet of apoptosis is “Bubbly cell death.”  Apoptosis is a caspase-
dependent pathway triggered by a myriad of stimuli such as death receptors, growth 
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factor withdrawal, cellular stress, and viral infection.  Caspases are cysteine proteases 
that cleave after aspartate residues.  They are zymogens, which get activated by signals 
leading to autoprocessing of apical or initiator caspases followed by a proteolytic casade.  
Namely, these caspases cleave and activate executioner caspases that target multiple 
cellular proteins for cleavage, which leads to apoptotic cell death (Boatright et al., 2003).  
Unlike necrotic cells, apoptotic cells maintain plasma membrane integrity, but lose 
control over separating components between the inner leaflet and outer leaflet of the 
plasma membrane.  Namely, phosphatidylserine, which is normally restricted to the inner 
leaflet of the plasma membrane, is also found in the outer leaflet during apoptosis. This 
acts as an “eat me” signal for professional phagocytic cells (Fadok et al., 1992).  
Apoptotic cells also round up and exhibit pyknosis, which is loss of cell volume.  The 
plasma membrane blebs, and packages intact organelles inside; thereby, facilitating the 
phagocytic process.  Therefore, under normal conditions apoptotic cells are cleared.  
Apoptotic cells are also morphologically characterized by chromatic condensation, and 
DNA fragmentation (karyorrhexis) due to caspase activated deoxyribonuclease (CAD) 
(Enari et al., 1998; Wyllie et al., 1980).  Prior to caspase activation, CAD is latent in the 
cytosol via interaction with inhibitor of caspase activated deoxyribonuclease (ICAD).  
During apoptosis, activated caspases cleave ICAD, thereby liberating CAD to translocate 
to the nucleus and degrade DNA (Enari et al., 1998).   
 
Biological relevance of programmed necrosis 
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The most compelling evidence for a physiological circumstance when necrosis is 
important is during viral infection.  Conceptually, the most straightforward function of 
necrosis is to eliminate cells infected with viruses, which have successfully subverted 
apoptosis, the default cell death program (Challa et al., 2010).  One of the first examples 
of necrosis functioning in a viral context was demonstrated with vaccinia virus infection.  
Mouse fibroblasts infected with vaccinia virus become sensitized to TNFα-induced 
necrosis.  Vaccinia virus encodes the caspase inhibitor B13R/Spi2.  Interestingly, mutant 
vaccinia virus lacking this caspase inhibitor was shown to be defective in stimulating 
mouse fibroblasts to undergo TNFα-induced necrosis (Li et al., 2000).  This suggested 
that necrosis is a second cell suicide program to eliminate viral propagation.  Importantly, 
both T cells and MEFs deficient of RIP3 were protected from TNFα-induced necrosis 
during vaccinia virus infection.  Furthermore, RIP3 deficient mice have impaired control 
over vaccinia virus infection as indicated by an increase in viral titer and death.  Hence, 
RIP3-mediated necrosis plays a role in controlling vaccinia virus infection with the driver 
being TNFα (Cho et al., 2009).  
In addition to vaccinia virus infection, studies have shown that necrosis also plays 
an anti-viral role during murine cytomegalovirus (MCMV) infection. Interestingly, 
MCMV is able to inhibit death receptor and PRR induced NFκB activation, apoptosis, 
and necrosis through viral inhibitor of RIP1 activation (vIRA), which is a protein 
encoded by the M45 gene (Mack et al., 2008; Upton et al., 2008; Upton et al., 2010; 
Upton et al., 2012).  vIRA contains a RIP Homotypic interaction Motif (RHIM), which 
allows binding and inhibition of RIP1 and RIP3 function (Upton et al., 2008). RIP1/RIP3 
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both contain a RHIM, which allows their association and is required for their TNFα 
driven pro-necrotic function (Cho et al., 2009).  vIRA binding to RIP1 is required for its 
suppression of both TNFα and TRIF dependent apoptosis (Upton et al., 2008). vIRA can 
also block TNFα-induced necrosis and TLR3-induced NFκB activation (Mack et al., 
2008).  Recombinant viruses containing M45, with mutations in the RHIM 
(M45mutRHIM) that abolish binding, were unable to control necrosis and therefore 
resulted in severe attenuation of the strains.  Importantly, infection of RIP3 knock-mice 
restored virulence of the recombinant virus demonstrating that RIP3-mediated necrosis is 
an important anti-viral mechanism in the context of MCMV infection (Upton et al., 
2010).  Unlike death receptor induced-necrosis, MCMV mediated necrosis is RIP1-
independent.  This was clarified when it was demonstrated that RIP3 forms RHIM-
mediated interactions with the cytosolic DNA-dependent activator of interferon 
regulatory factors (DAI) sensor, presumably circumventing the requirement of RIP1 for 
RIP3 activation.  Similar to infection of RIP3 knock-out mice, recombinant MCMV 
M45mutRHIM infection is no longer attenuated in DAI knock-out mice.  This highly 
suggests that vIRA normally suppresses DAI mediated necrosis through RHIM-mediated 
interactions with DAI and RIP3.  Since it is well established that RIP1 is upstream of 
RIP3 kinase activation in death receptor induced necrosis, this study provides evidence 
that other RHIM containing upstream activators of RIP3 can substitute for RIP1 (Upton 
et al., 2010; Upton et al., 2012).  MCMV also encodes viral inhibitor of caspase-8 
activation (vICA) as well as other inhibitors of programmed cell death demonstrating that 
other types of cell death must be evaded by MCMV (Skaletskaya et al., 2001).  
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There is also evidence that necrosis can be inimical to the health of the organism 
in certain contexts. For example, it is well known that necrotic cell death of neurons is a 
later stage consequence of ischemic reperfusion, making it an attractive target for 
therapeutic intervention. Several years ago Junying Yuan’s group screened a small 
chemical inhibitor library for necrosis, and identified the allosteric inhibitor of RIP1 
kinase activity, Necrostatin-1 (Nec-1) (Degterev et al., 2005; Degterev et al., 2008).  
Through structural activity relationship necroptosis assays they determined that 
alterations of specific chemical groups of Nec-1, which abrogated the anti-necrosis 
activity also abrogated Nec-1 inhibition of RIP1 kinases activity.  Furthermore, analogs 
with a reduced IC50 in necroptosis cell death assays also demonstrated enhanced 
inhibition of RIP1 kinase activity.  This provided compelling evidence that the anti-
necrosis activity of Nec-1 is attributed to inhibition of RIP1 kinase activity.  In a mouse 
model of ischemia brain injury, Nec-1 treatment alleviated infarct volume (Degterev et 
al., 2005).  Altogether, this study was the first to demonstrate that the necrosis pathway 
can be targeted for therapeutic intervention by inhibition of a critical kinase.  
In line with the requirement of RIP1 kinase activity to potentiate death receptor 
driven necrosis, auto-phosphorylation of RIP1 at Serine 161 is also required. Indeed, cells 
harboring a serine to alanine mutation at amino acid position 161 of RIP1, which 
abrogates auto-phosphorylation, have attenuated necrosis.  In fact, thus far all of the RIP1 
auto-phosphorylation sites identified are contained within the N-terminal kinase domain 
of RIP1.  This suggests that auto-phosphorylation may regulate RIP1 kinase activity.  
Indeed, mutant RIP1 S161A has impaired kinase activity in vitro.  This residue is within 
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the activation segment (T-loop), which occludes ATP access of the catalytic cleft.  
Through molecular modeling this group proposed that Nec-1 inhibits RIP1 kinase activity 
through stabilizing the inactive conformation of the T-loop.  Indeed, the phospho-
mimetic mutant RIP1 S161E that theoretically destabilizes the inactive state of the T-loop 
is no longer sensitive to Nec-1 inhibition in both kinase assays and necroptosis assays 
(Degterev et al., 2008).              
Necrosis can also have a multitude of deleterious effects when components of the 
apoptotic machinery are absent.  A number of studies have pointed to the requirement of 
components of the apoptotic machinery in actively suppressing necrosis in different 
cellular contexts. Reports have indicated that T cell specific deletion of key regulators of 
death receptor induced-apoptosis such as FADD and Capase-8 results in a proliferation 
defect (Ch’en et al., 2011; Lu et al. 2011).  This is contrary to the expectation of the loss 
of pro-death regulators.  This phenotype is explained by the pro-survival role of these 
apoptosis regulators, which is attributed to negative regulation of necrosis.  Namely, T 
cell stimulation results in the cleavage and inactivation of RIP1/RIP3 by the pro-
apoptotic proteins.  In T cells replete with FADD/Caspase-8 the necrosis pathway is 
actively suppressed.  In agreement with this model, reconstitution of RIP1 deficient 
Jurkat T cells with a cleavage resistant mutant RIP1 shifts TNFα-driven cell death from 
apoptosis to necrosis.  This provides evidence that caspase mediated cleavage of RIP1 
negatively regulates its pro-necrotic function in T cells.  Furthermore, using an in vivo 
mouse system with conditional expression of a dominant negative form of FADD 
(FADDdd) in T cells it was demonstrated that the proliferation defect could be rescued by 
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crossing the mice to RIP3 knock-mice (Lu et al., 2011).  Similarly, T cells from mice 
with a conditional knock-out of FADD or Caspase-8 were rescued from a proliferation 
defect via treatment with Nec-1 or genetic ablation of RIP3, respectively (Ch’en et al., 
2011; Osborn et al., 2010).  Altogether these studies demonstrated that the apoptotic 
regulators FADD and caspase-8 are required to actively suppress necrosis during T cell 
stimulation.  Furthermore, these double-knockout mice with rescued T cell proliferation 
developed lymphoadenopathy indicating that these cell death regulators are important for 
maintenance of T cell homeostasis (Lu et al., 2011).    
The requirement of the apoptotic machinery for actively suppressing the necrosis 
program was also found to be important during other physiological contexts such as 
embryogenesis and colon epithelial cell homeostasis.  Mice that are deficient of either 
FADD, Caspase-8, cFLIP are embryonic lethal.  This is seemingly counterintuitive 
considering that FADD and Caspase-8 are pro-apoptotic proteins and therefore the 
removal of such proteins should in theory promote cell survival.  Several groups provided 
an answer to this conundrum through establishing the importance of these proteins as 
negative regulators of excess necrosis during embryogenesis. Namely, developing double 
knock-out mice that lacked both FADD/RIP1 or caspase-8/RIP3 was able to rescue the 
embryonic lethality of the FADD or caspase-8 single knock-outs (Kaiser et al., 2011; 
Oberst et al., 2011; Zhang et al., 2011).  However, the embryonic lethality of cFLIP 
knock-out embryos cannot be rescued by developing cFLIP/RIP3 double knock-out mice 
because they are also embryonic lethal.  Astonishingly, cFLIP/RIP3/FADD triple knock-
out mice are viable.  This is attributed to the fact that cFLIP(L) inhibits both apoptosis 
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and necrosis and therefore the cFLIP/RIP3 double knock-out embryos undergo extensive 
apoptosis during embryogenesis, hence they are still embryonic lethal (Dillon et al., 
2012).   
cFLIP(L) and caspase-8 form a heterodimeric complex that is required for 
necrosis suppression during embryogenesis (Oberst et al., 2011).  One of the initial 
reports leading to this discovery was that bacterial artificial chromosome (BAC) 
transgene expression of a mutant caspase-8, which is resistant to cleavage between the 
large and small subunits, is sufficient to rescue the lethality of caspase-8 knock-out 
embryos (Kang et al., 2008).  The caspase-8 cleavage mutant is unable to form active 
homodimers, which are required for promoting apoptosis.  Interestingly, through in vitro 
cleavage assays it was demonstrated that although the cleavage resistant mutant was 
unable to form active homodimers, when force heterodimerized with cFLIPL it still 
maintained the potential to cleave RIP1.  Although, the Caspase-8 cleavage mutant lost 
its pro-apoptotic function, it still maintained its anti-necrotic function in a cFLIP-
dependent manner.  Since active caspase-8 homodimers are required for mediating 
apoptosis this study demonstrated that the pro-apoptotic and anti-necrotic (pro-survival) 
function of caspase-8 are not inextricably linked.  Importantly, the formation of 
cFLIP(L)/caspase-8 complexes is required during embryogenesis in order to actively 
suppress necrosis by cleaving RIP1 and RIP3.  In agreement with T cell conditional 
knock-out studies, early on the RIP3/caspase-8 double knock-out mice have normal 
mature T cells; however, older mice develop phenotypic aspects of the lympho-
proliferative disorder found in patients and mice that have functionally impairing 
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mutations of Fas or FasL. Namely, this results in the accumulation of B220+CD3+CD4-
CD8- cells (Lu et al., 2011; Oberst et al., 2011).   
Similar to embryogenesis, conditional deletion of FADD in intestinal epithelial 
cells leads to excess necrosis.  The corollary of excess necrosis is loss of colon integrity, 
the development of spontaneous colitis, enteritis of the small intestine, and loss of paneth 
cells.  Several lines of evidence support the notion that excess necrosis is the culprit.  
First, FADD deletion in intestinal epithelial cells leads to non-apoptotic death of crypt 
epithelial cells as determined by the lack of active caspase-3 staining in the epithelium.  
Second, the morphology of the cell death, as revealed by electron microscopy, was 
necrotic.  Third, crossing the FADD conditional knock-out mice to the RIP3 or 
cylindromatosis (CYLD) knock-out mice was able to rescue the colitis phenotype.  As 
these are both regulators of necrosis, it strongly suggests that the epithelial cell non-
apoptotic death was indeed necrosis.  However, the phenotype was only partially rescued 
by crossing the mice to TNFα knock-out mice. This may be attributed to the fact that 
other ligands can give rise to necrosis.  The colitis phenotype could be reverted in a germ 
free environment, or crossing with MYD88 KO mice, which is an important regulator 
downstream of many Toll-Like Receptors (TLRs).  This supports the notion that FADD 
is required to actively suppress necrosis of colon epithelial cells; loss of FADD results in 
excessive necrosis, loss of colon integrity, leading to invasion of the mucosa with the gut 
microflora, which activates TLR-driven production of pro-inflammatory cytokines, and 
ultimately chronic inflammation (Welz et al., 2011).   
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In the FADD conditional knock-out system there were some differences in the 
molecular determinants of pathology in the large intestine and small intestine.  FADD 
conditional knock-out mice developed enteritis (small intestine inflammation), 
compromised small intestine architecture, and loss of paneth cells, which could be 
rescued by RIP3 deficiency. However, unlike the colitis phenotype this could not be 
rescued by crossing to CYLD knock-out mice or a germ free environment.  These 
differences in molecular requirements for necrosis driven disease pathogenesis may be 
attributed to differential stimuli driving cell death in the colon as opposed to cell death in 
the small intestine (Welz et al., 2011).  As mentioned above, in certain contexts of 
necrosis induction, regulators such as RIP1 are dispensable.  It is therefore conceivable 
that in these cases CYLD is also dispensable since RIP1 is the primary target of CYLD in 
the context of necrosis.  This will be addressed in length later in the thesis.  It is also 
possible that there might be differential expression of compensatory RIP1 deubiquitinases 
in the large and small intestine.  This may account for the observed essential requirement 
and non-essential requirement for necrosis in the different compartments.     
Similar to FADD conditional deletion in epithelial cells, caspase-8 deletion in 
epithelial cells leads to spontaneous ileitis and loss of paneth cells with necrotic 
morphology. Interestingly, biopsies from the small intestines of Crohn’s disease patients 
exhibit necrotic morphology and loss of paneth cells. This suggests that necrosis may 
indeed be involved in driving the pathogenesis of Crohn’s disease; however, the specific 
causes of excessive necrosis and subsequent loss of paneth cells is unknown (Gunther et 
al., 2011).  One possibility is that certain viral infections may inactive the pro-
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apoptotic/anti-necrotic machinery in intestinal epithelial cells, and this may drive excess 
necrosis and disease.     
Similar to necrosis, apoptosis can also be deleterious to intestinal epithelium 
barrier integrity when critical negative regulators are absent.  Conditional deletion of 
NFκB Essential Modifier (NEMO) in intestinal epithelial cells also leads to a 
spontaneous colitis phenotype.  NEMO is the regulatory subunit of the IKK complex, 
which is required for TNFα driven NFκB activation.  Hence, deletion of NEMO in 
intestinal epithelial cells impairs NFκB activation, leading to apoptotic cell death of 
epithelial cells, loss of colon integrity, invasion of mucosa with gut microflora, and 
chronic inflammation (Nenci et al., 2007).  It has also been demonstrated that NEMO 
negatively regulates apoptosis in an NFκB-independent manner (Legarda-addison et al., 
2009).  Unlike the FADD conditional knock-out, crossing to mice devoid of CYLD does 
not rescue the phenotype.  One possibility for the dispensability of CYLD in this 
apoptotic pathway may be attributed to the possibility that NEMO is the primary target of 
CYLD in the context of TNFα-induced apoptosis.  This concept will be discussed in 
further detail later.  The colitis phenotype could also be rescued by crossing to TNFR-1 
knock-mice demonstrating that cell death is primarily TNFα driven in this system (Nenci 
et al., 2007). 
 
Signaling mechanisms required for programmed necrosis
Trimeric TNFα engagement of pre-assembled TNFR-1 homotrimers leads to the 
activation of different cellular programs resulting in potentially diametrically opposed 
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cell fates (Chan et al., 2000). Spatially, temporarily, and compositionally distinct 
complexes delineate the varying programs. Within minutes of TNFα stimulation, a 
TNFR-1 associated complex (Complex I) forms, resulting in NFκB activation and cell 
survival.  Several proteins compose this complex.  The death domain (DD) containing 
proteins TRADD and RIP1 are recruited to the complex, and interact with TNFR-1 DD 
domains in the cytoplasmic tail.  TRADD is required for NFκB activation and apoptosis, 
while it is dispensable for necrosis (Zheng et al., 2006).  During SMAC mimetic 
sensitization to TNFα-induced apoptosis TRADD actually appears to have a negative 
regulatory role (Wang et al., 2008).  The adapter and E3 ligase protein TRAF2 as well as 
the E3 ligases c-IAP1/2 are also recruited to Complex I. TRAF2 is required for 
recruitment of cIAP1/2 via its cIAP1/2 interacting motif (CIM) (Vince et al., 2009).  
RIP1 gets polyubiquitinated within the complex, which acts as a docking site for both the 
IKK complex and the IKK activating complex, which is composed of Tak1/Tab2/3 (Ea et 
al., 2006; Kanayama et al., 2004).  cIAP1/2 are responsible for RIP1 polyubiquitination 
and NFκB activation, while the TRAF2 RING domain is dispensable (Vince et al., 2009).   
Later during stimulation, Complex I transitions into a cytosolic complex 
(Complex II) lacking TNFR-1, which is the location of caspase-8 activation and initiation 
of the apoptosis program (Micheau et al., 2003).  The regulatory mechanisms of RIP1 
transition into Complex II will be extensively covered later.  Caspase-8 activation 
requires the adaptor protein FADD.  During caspase inhibition, the kinases Receptor 
Interacting Protein 1 and 3 (RIP1/RIP3) associate, and give rise to the formation of a 
complex dubbed the “necrosome.”  Components of the apoptotic-mediating Complex II 
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are also found in the necrosome.  This suggests that during caspase inhibition additional 
pro-necrotic proteins, such as RIP3, are recruited to Complex II and thereby give rise to 
the necrosome (Cho et al., 2009; He et al., 2009; Zhang et al., 2009). 
The first headway in defining the biochemical pathway leading to cellular demise 
by necrosis was made over a decade ago with the discovery that RIP1 is required.  RIP1 
is a serine-threonine kinase, and its pro-necrotic function requires its kinase activity.  It 
was demonstrated that RIP1 is required for necrosis induced by the death receptors Fas, 
TRAIL-R, and TNFR-1 (Holler et al., 2000).  The role of RIP1 in TNFR-1 signaling will 
be extensively covered in the following section. 
The role of the adaptor protein Fas Associated protein with Death Domain 
(FADD) in death receptor induced necrosis depends on the specific death receptor 
engaged.  FADD contains both a death effector domain (DED) and a death domain (DD) 
and is required for caspase-8 recruitment to TRAIL receptor, Fas, and it is a critical 
component of Complex II during TNFR-1 receptor signaling.  Whereas TRAIL and Fas 
ligand induced necrosis require FADD, TNFα-induced necrosis is enhanced in the 
absence of FADD (Chan et al., 2003; Holler et al., 2000).  Consistent with the role of 
FADD during FasL-induced necrosis, Jurkat cells deficient of caspase-8, which are 
resistant to apoptosis, can be sensitized to necrotic cell death by forced dimerization of 
FADD (Kawahara et al., 1998).  Forced dimerization of FADD or its DD in L929 cells 
induces RIP1-dependent necrosis, whereas forced dimerization of FADD DED induces 
apoptosis.  Removal of RIP1 shifts the FADD dimerization induced necrosis to apoptosis.  
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Conversely, forced dimerization of FADD DED can be shifted from apoptosis to necrosis 
upon treatment with zVAD through recruitment of RIP1 (Vanden Berghe et al., 2004).    
The requirement of RIP3 in TNFα-induced necrosis was independently 
discovered by three groups.  All groups screened siRNA libraries in necrosis sensitive 
cell lines and ascertained which genes when knocked-down confer protection (Cho et al., 
2009; He et al., 2009; Zhang et al., 2009).  It was discovered that RIP3 associates with 
RIP1 and other components of Complex II only in instances when caspases are inhibited.  
Therefore, RIP3 association with RIP1 is a signature biochemical event that occurs only 
during necrosis and not apoptosis.  The association between RIP1 and RIP3 was also 
demonstrated to be consequential for cellular demise via necrosis.  Both RIP1 and RIP3 
contain RHIM domains, which are required for their association and necrosis.  Namely, 
cells expressing RHIM mutants of either RIP1 or RIP3 were unable to transduce the pro-
necrotic signal.  The enzymatic activity of both kinases is also required for their pro-
necrotic function (Cho et al., 2003; He et al., 2009).  RIP1 is the upstream kinase as its 
enzymatic activity is required for its association with RIP3, but the kinase activity of 
RIP3 is not required for its association with RIP1.  In fact, it was demonstrated that 
kinase inactive RIP3 can act as a dominant negative when transfected in cells containing 
endogenous WT RIP3, presumably by associating with RIP1 and poisoning the 
necrosome (He et al., 2009).  In addition to association between RIP1 and RIP3, both 
proteins are phosphorylated specifically during necrosis.  Phosphorylation of RIP1 
requires the presence of RIP3, as RIP3 knock-out MEFs do not exhibit phosphorylated 
RIP1 during necrosis stimulation. Conversely, phosphorylation of RIP3 requires RIP1 
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kinase activity, as Nec-1 blocks RIP3 phosphorylation during necrosis.  This highlights 
the intricate nature of potential auto-phosphorylation and trans-phosphorylation events 
between RIP1 and RIP3 that occur during necrosis.  In vitro kinase assays suggests that 
RIP3 can trans-phosphorylate RIP1, but the converse was not observed (Cho et al., 2009).  
One of the phosphorylation sites of RIP3 was identified as serine 199; however, the 
functional requirement of this phosphorylation event during necrosis was not addressed.  
The phosphorylation event requires its own kinase activity, as RIP3 phosphorylation was 
not observed in complexes between kinase inactive RIP3 and RIP1 during necrosis 
signaling (He et al., 2009).  Clearly, more careful work needs to be conducted in order to 
truly understand the hierarchy of these phosphorylation events, and their functional 
impact on the necrosis signaling pathway. 
RIP3 is a necrosis specific regulator. Consistent with the biochemical data, RIP3 
knock-down does not confer protection against TNFα-induced apoptosis.  Since RIP1 is 
involved in TNFα-induced apoptosis when cells are treated with SMAC mimetic, RIP3 
possibly constitutes the divergence point of the biochemical pathway between necrosis 
and apoptosis (Cho et al., 2009; He et al., 2009; Wang et al., 2008).  The expression level 
of RIP3 directly correlates with the level of necrosis in a panel of cell lines.  Cell lines, 
which lack endogenous RIP3 are resistant to TNFα-induced necrosis.  Sensitivity to 
necrosis can be conferred by ectopic expression of WT RIP3, but not kinase dead RIP3 
(He et al., 2009). 
Additional components of the necrosome were recently identified.  The Mixed 
Linage Kinase Domain Like protein (MLKL) is yet another component of the necrosome.  
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The first group revealing its role in necrosis discovered it by analyzing the necrosome via 
mass spectrometry.  This group also screened a small chemical compound library to 
identify inhibitors of necrosis.  Interestingly, an inhibitor of MLKL was identified and 
dubbed Necrosulfanimide.  This group initially deemed MLKL as a kinase dead protein 
due to the lack of key amino acid residues important for phosphate binding, and 
magnesium ion coordination (Sun et al., 2012).  Shortly after, another group screening an 
shRNA library targeting kinases and phosphatases also revealed the pro-necrotic function 
of MLKL, and demonstrated that it was indeed kinase active.  However, MLKL proved 
to be a weaker kinase in in vitro assays in comparison to RIP1 and RIP3 (Zhao et al., 
2012).   
NSA was used to help determine the pro-necrotic molecular mechanism of 
MLKL. Unlike Nec-1, which blocks necrosome formation, NSA inhibits necrosis 
downstream of RIP1/RIP3 association.  This is supported by evidence that the inhibitor 
actually results in enhancement of RIP1/RIP3 association and phosphorylation, in spite of 
the fact that it blocks death.  Confocal microscopy provided further evidence that NSA 
blocks a step downstream of RIP1/RIP3 association.  Namely, HeLa cells stably 
transfected with fluorescently labeled RIP3 showed the transition from diffuse 
cytoplasmic to the formation of discrete punctae during necrosis. These RIP3 punctae 
increased in size over time.  In agreement with NSA blocking a molecular event 
downstream of RIP1/RIP3 association, treatment of these cells with NSA did not abolish 
the stimulus dependent formation of RIP3 punctae whereas Nec-1 treatment did.  Instead, 
NSA eliminated the size increase in the punctae.  The first clue as to the target of NSA 
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was revealed when MLKL was identified as an additional component of the necrosome 
through mass spectrometry.  The functional relevance of MLKL in mediating necrosis 
was validated, and its molecular mechanism was investigated.  Importantly, siRNA 
knock-down of MLKL was a pheno-copy of NSA treatment in respect to the 
enhancement of RIP1/RIP3 association and the abolishment of RIP3 punctae growth 
during necrosis (Sun et al., 2012; Zhao et al., 2012). This prompted the hypothesis that 
NSA targeted MLK.   
Indeed, it was demonstrated that NSA forms a covalent attachment to cysteine 86 
of MLKL, and this residue is required for the necrosis suppressive effect of NSA. In vitro 
kinase assays revealed that RIP3 can directly phosphorylate MLKL at threonine 357 and 
serine 358. Compound mutants of both phosphorylation acceptor sites abolished the pro-
necrotic function of MLKL. The phospho-mimetics of MLKL were functional in 
necrosis, and NSA could still block necrosis in cells stably transfected with them.  This 
suggests that the mechanism of NSA inhibition is independent of MLKL 
phosphorylation.  This is in agreement with data showing that NSA forms a covalent 
bond with MLKL in the N-terminal Coiled-Coil (CC) domain and the phosphorylation 
sites are in the C-terminal kinase like domain (Sun et al., 2012).  The mechanism of NSA 
suppression was revealed to be inhibition of recruitment of another component of the 
necrosome PGAMS (Wang et al., 2012).      
Akin to the requirement of RIP1 kinase activity for association with RIP3, it was 
demonstrated that RIP3 kinase activity is required for association with its substrate 
MLKL. It was also revealed that RIP3 undergoes auto-phosphorylation at serine 227 and 
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this modification is required for its pro-necrotic function and association with MLKL 
similar to RIP3 kinase activity (Sun et al., 2011).  In co-transfection experiments it was 
demonstrated that RIP3 is required for MLKL and RIP1 association.  This supports a 
model where MLKL is recruited to the necrosome via its association with RIP3.  
Furthermore, the weak kinase activity of MLKL appears to be required for its pro-
necrotic function, as a kinase dead mutant MLKL is insufficient to restore necrosis in 
cells with MLKL knocked-down.  The potential targets of MLKL have not been 
identified yet.  It was also demonstrated that MLKL is required for the late phase of JNK 
activation and ROS production during necrosis in HT-29 cells; however, both of these 
molecular events are dispensable for necrosis in this cell type.  In other cells types 
evidence suggests that JNK activation and ROS production are required for necrosis.  
Nevertheless, MLKL must be targeting something other than JNK and ROS production in 
HT-29 cells to transduce the pro-necrotic signal (Zhao et al., 2012). 
In addition to MLKL, the mitochondrial phosphoglycerate mutase/protein 
phosphatase (PGAM5) was found to be a component of the necrosome.  Due to 
alternative splicing, PGAM5 has two isoforms, PGAM5L and PGAM5S.  While 
PGAM5L can be found in the TritonX-100 soluble fraction, PGAM5S can only be found 
in the TritonX-insoluble SDS-soluble fraction.  This is potentially attributed to the fact 
that PGAM5S has additional exposure of hydrophobic amino acids.  Both isoforms are 
involved in necrosis and both PGAM5L/S associate with the RIP1/RIP3/MLKL complex 
during necrosis.  As is the case with MLKL recruitment to the necrosome, PGAM5L/S 
require the kinase activity of RIP3 to be recruited to the necrosome.  This places 
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PGAM5L/S downstream of RIP3 kinase activation.  Indeed, In vitro kinase assays 
revealed that RIP3 can phosphosphorylate PGAM5L and the corollary of this is 
activation of the phosphatase activity of PGAM5L.  Importantly, PGAM5 requires intact 
phosphatase activity in order to exert its pro-necrotic function (Wang et al., 2012).   
The necrosis inhibitor NSA differentially regulates the two isoforms of PGAM5.  
As previously discussed, NSA covalently modifies MLKL, but the mechanism 
accounting for its necrosis suppressing effect was not clarified.  Clues as to its 
mechanism were revealed when looking at necrosome association with and 
phosphorylation of PGAM5.  NSA treatment or MLKL knock-down does not abolish 
PGAM5L interaction with the necrosome, nor does it block phosphorylation of PGAM5L 
during necrosis.  This indicates that PGAM5L recruitment to the necrosome and 
phosphorylation is MLKL-independent.  However, NSA treatment or MLKL knock-
down both block PGAM5S association with the necrosome, PGAM5S phosphorylation, 
and mitochondrial fragmentation during necrosis.  This demonstrates that NSA blocks 
necrosis at the step of RIP1/RIP3/MLKL/PGAM5L complex association and activation 
of PGAM5S.  The downstream consequence of blocking this molecular event is impaired 
mitochondrial fragmentation (Wang et al., 2012).   
The functional relevance of mitochondrial fragmentation during necrosis still 
needs to be clarified; however some of the mechanistic details have been worked out.  
PGAM5S functions upstream of mitochondrial fragmentation during necrosis.  Some 
evidence suggests that it directly activates the mitochondrial fission machinery.  Drp-1 is 
a mitochondrial fission enzyme that harbors GTPase activity, and can be found at the site 
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of mitochondrial constriction during the process. Drp-1 is functionally involved in 
necrosis; however its participation in the observed mitochondrial fragmentation is 
inferred and has not been directly addressed.  Indeed, Drp-1 co-localizes with the 
mitochondria during necrosis, which suggests that its function in necrosis relates to the 
mitochondrial fragmentation process.  PGAM5 mediated dephosphorylation of Drp-1 
results in its dimerization, and activation of its GTPase activity, which promotes 
mitochondrial fission.  In the absence of PGAM5S, Drp-1 does not get activated via 
dephosphorylation; hence it does not mediate mitochondrial fission. Whether Drp-1 is the 
only target of PGAM5 in the context of necrosis still needs to be worked out (Wang et 
al., 2012). It is conceivable that PGAM5 promotes the activation of other components of 
the fission machinery or negatively regulates components of the mitochondrial fusion 
machinery.     
The phosphorylated forms of RIP1/3, PGAM5L, and Drp-1 transition into the 
SDS-soluble fraction during necrosis.  The SDS-soluble fraction is presumably where the 
necrosome engages the mitochondrial constriction points.  This suggests that the 
necrosome may indeed be recruited to mitochondria; however, microscopy studies have 
yet to reveal RIP3 colocalization with the mitochondria during necrosis (Wang et al., 
2008).  RIP3 kinase activity is required for the necrosome to transition into the SDS-
soluble fraction, which places RIP3 upstream of these mitochondrial events (Wang et al., 
2012).  This is not surprising considering that RIP3 was shown to be upstream of ROS 
production during necrosis (Cho et al., 2009). Additionally, PGAM5S is required for 
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PGAM5L and Drp-1 transition into the SDS-soluble fraction.  This places PGAM5S as 
the link between the necrosome and the mitochondria (Wang et al., 2012) (Fig. 1.1). 
Many different stimuli trigger necrosis, and not all require activation of the 
necrosome.  Interestingly, inducing necrosis with either the ROS generator t-butyl 
hydroxide (TBH), Hydrogen Peroxide, or the calcium ionophore A23187 resulted in 
necrosis that was independent of RIP1/3, and MLKL.  In contrast to the dispensability of 
some of the key players in death-receptor induced necrosis, PGAM5S/L and Drp-1 were 
required for necrosis induced by these stimuli.  This suggests that PGAM5S/L and Drp-1 
function at the intersection of multiple inducers of necrosis, and can be activated by 
necrosome-independent mechanisms.  Namely, these necrosis regulators are common to 
both the extrinsic death receptor mediated necrosis and intrinsic necrosis.  Indeed, TBH-
induced necrosis caused mitochondrial fragmentation as seen in death receptor induced 
necrosis. This highlights the potential importance of mitochondrial fragmentation as a 
common downstream event during necrosis induced by a multitude of stimuli (Wang et 
al., 2012). 
The requirement of specific mitochondrial events for the execution phase of 
necrosis appears to be cell-type specific.  Quenching mitochondrial ROS protects some 
cell-types from necrosis such as the mouse fibrosarcoma cell line L929 and MEFs, and 
yet confers no protection in other cell-types such as the human colon carcinoma cell line 
HT-29 (Lin et al., 2004; Vanlangenakker, et al., 2011; Wang et al., 2009).  Other reports 
have demonstrated the involvement of components of the mitochondrial transition pore 
complex such as adenine nucleotide translocase (ANT) and cyclophilin D (CYPD), and 
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the loss of cellular ATP during necrosis.  ANT regulates ADP and ATP exchange 
between the cytosol and mitochondria. One report demonstrates that RIP1 targets the 
inhibition of ANT during necrosis through disrupting its interaction with cyclophilin D.  
This accounts for the drop in cellular ATP levels, as ANT requires cyclophilin D for its 
function.  Although ROS production occurred during necrosis, quenching it had no 
bearing on either the drop in ATP levels or necrosis in the myelomonocytic cell-line 
U937 and monocytic leukemia THP-1.  Furthermore, mitochondrial release of 
cytochrome C was only observed in cells undergoing apoptosis and not necrosis (Temkin 
et al., 2006).  Cytochrome C is an activator of the apoptosome with Caspase-9 being the 
apical caspase. This is consistent with the notion that apoptotic pathways mediate 
different mitochondrial events than the necrosis pathway and may account for the 
morphological differences between the two cell death programs. Clearly, a lot of 
questions remain as to the effector mechanisms of necrosis.  Future studies should more 
rigorously address whether mitochondrial fragmentation is consequential for necrosis, 
and the mechanism behind how it leads to necrosis.  Namely, does it influence ROS 
production, loss in cellular ATP, or some other novel mechanism?    
The pro-inflammatory properties of RIP3 and other necrosis regulators extend 
beyond their role in necrosis.  Interestingly, a recent report demonstrated that in Caspase-
8 deficient dendritic cells multiple components of the necrosome promote NALP3 
inflammasome activation, independent of their effects on promoting necrosis.  caspase-8 
deficient DCs only require the priming signal (LPS) for IL-1β secretion.  Normally, DCs 
require an activation signal such as ATP to activate caspase-1 via the NALP3 
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inflammasome. This activation signal independent maturation of IL-1β was shown to 
require the necrosome components RIP3, MLKL, and PGAM5.  Importantly, death was 
not observed in caspase-8 deficient DCs during LPS stimulation.  This demonstrated that 
the pro-inflammatory properties of these necrosis regulators can also be attributed to cell 
death independent pathways.  Interestingly, these components of the necrosome were 
observed in complex with the NALP3 inflammasome during LPS treatment in caspase-8 
deficient DCs (Kang et al., 2013).           
TNFα and other ligands that engage death receptors are not the only triggers of 
programmed necrosis.  Recently, it was demonstrated that the TLR3 and TLR4 ligands 
poly(I:C) and LPS can induce necrosis (He et al., 2012; Zhang et al., 2009).  These 
receptors belong to a family of Pattern Recognition Receptors that are important for 
mounting anti-microbial defenses.  TLR3 functions solely through the adaptor protein 
TRIF, whereas TLR4 functions through both TRIF and MyD88.  Interestingly, 
macrophages stimulated with ligands for these TLRs and caspase inhibition with zVAD, 
undergo necrosis that requires both TRIF and RIP3.  TRIF, like RIP3, contains a RIP 
Homotypic Interaction Motif (RHIM).  The RIP3 RHIM was demonstrated to be required 
for stimulus dependent RIP3/TRIF interaction.  Namely, cells expressing a RHIM mutant 
RIP3 showed no signs of this molecular event.  The requirement of TRIF’s RHIM was 
not clarified in this study as well as the relevance of TRIF/RIP3 association in driving 
necrosis. In agreement with the absence of data suggesting the involvement of TRIF in 
TNFR-1 signaling, TNFα-induced necrosis in macrophages does not require TRIF.  This 
demonstrates that multiple receptors can give rise to necrosis, and utilize alternative 
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mechanisms for RIP3 activation.  Depending on the receptor used to trigger necrosis, 
there are differential requirements for signaling proteins.  Furthermore, ROS production 
was demonstrated to be a molecular event required for either TLR or TNFα driven 
necrosis in macrophages. Both RIP3 and TRIF are required for ROS production by TLRs 
and only RIP3 is required for ROS production by TNFα in macrophages.  Due to the 
dispensability of ROS for necrosis in other cell types, such as HT-29 cells, this highlights 
that necrosis employs death effector mechanisms that are cell-type specific (Wang et al., 
2012; Zhao et al., 2012). 
      
RIP1 ubiquitination and transition to the DISC
 
During TNFα signaling, RIP1 ubiquitination within Complex I is believed to 
negatively regulate its transition to Complex II. RIP1 ubiquitination within Complex I is 
required for NEMO binding and subsequent IKK activation, and therefore dictates the 
NFκB-dependent pro-survival function of RIP1 (Ea et al., 2006).  During TNFR-1 
complex formation c-IAP1/2 are recruited to the complex, and serve as functionally 
redundant E3 ligases responsible for ubiquitinating RIP1 (Mahoney et al., 2008; 
Varfolomeev et al., 2008). By promoting RIP1 ubiquitination, c-IAP1/2 aid in activating 
NFκB and cell survival.  Specifically, in MEFs with dual knock-down of c-IAP1/2, 
TNFα-induced RIP1 ubiquitination within the TNFR-1 complex is impaired as well as 
subsequent NFκB activation.  Similarly, treatment of cells with the SMAC mimetic BV6, 
which effectively depletes both c-IAP1/2, results in a loss of RIP1 ubiquitination within 
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the TNFR-1 complex, and a block in NFκB activation. In MEFs, genetic ablation of 
either c-IAP1 or c-IAP2 is insufficient to block activation. However, knock-down of the 
remaining E3 ligase c-IAP1 or c-IAP2 in the singly deficient MEFs abrogates activation.  
The same observations were made when addressing the anti-apoptotic function of c-
IAP1/2.  Knock-down of c-IAP2 in c-IAP1 deficient MEFs resulted in apoptosis while 
absence of only one of them has no effect. Reconstitution of c-IAP1/2 depleted cells with 
a catalytic inactive c-IAP1 was insufficient for restoring NFκB activation, but wild-type 
c-IAP1 was.  This demonstrates that impaired NFκB activation was indeed attributed to 
the lack of E3 ligases, and that the E3 ligase enzymatic activity is required for c-IAPs 
function in NFκB activation.  This supports the notion that both c-IAP1/2 play a 
functionally redundant role in promoting NFκB activation, and blunting apoptosis 
(Varfolomeev et al., 2008). 
It is well known that cancer cells subvert the cellular machinery responsible for 
programmed cell death.  In different types of cancer the chromosome loci harboring the 
anti-apoptotic genes cIAP1/2 and XIAP are amplified, mutated, or translocated.  XIAP is 
the only anti-apoptotic protein of the group that is known to directly inhibit caspases.  
Namely, it binds to Caspase-9 and thereby vitiates the intrinsic mitochondrial apoptosis 
pathway (Eckelman et al., 2006).  Normally, during the intrinsic mitochondrial apoptosis 
pathway, Second Mitochondria-derived Activator of Caspases (SMAC) is released from 
the mitochondrial intermembrane space and de-represses Caspase-9 by disrupting its 
association with XIAP, thereby promoting apoptosis.  SMAC binds to the BIR3 domain 
of XIAP via a specific tetra-residue (Srinivasula et al., 2001).  Many drug companies 
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have designed small chemical compounds, peptidomimetics, and peptides based on this 
tetra-residue of SMAC. These compounds are cell permeable, and have proved successful 
in sensitizing cancer cells to apoptosis.  Although these drugs are modeled after SMAC 
binding to XIAP, they also effectively target c-IAP1/2 for auto-ubiquitination, 
degradation mediated by the proteasome, and apoptosis (Bertrand et al., 2008; Fulda et 
al., 2012).         
The molecular details regarding the anti-apoptotic function of c-IAP1 and c-IAP2 
are not restricted to their effects on promoting NFκB activation.  By keeping RIP1 in an 
ubiquitinated state, c-IAP1/2 hinder RIP1 association with caspase-8, which blocks 
caspase activation and apoptosis (Fig1.2 and Fig1.3).  Treatment of certain cancer cells 
with a SMAC mimetic compound causes auto-ubiquitination of c-IAP1/2 followed by 
proteasome degradation, and cell death.  This is supported by data showing that SMAC 
mimetic co-treatment with proteasome inhibitors results in the accumulation of 
ubiquitinated c-IAP1/2 and abrogates caspase activation and cell death. In vitro 
ubiquitination assays reveal that SMAC mimetics directly activate the E3 ligase activity 
of c-IAP1/2.  In the absence of its cognate E3 ligases, RIP1 is predominately in an 
unmodified state.  Unmodified RIP1 has a higher propensity for associating with caspase-
8, and results in caspase activation, and apoptosis.  Since RIP1 ubiquitination is required 
for association with TAK1, SMAC mimetic treatment abrogates the RIP1/TAK1 
association (Bertrand et al., 2008; Kanayama et al., 2004).  TAK1 is not only involved in 
activating the IKK complex during TNFα signaling, but it has been demonstrated to 
negatively regulate programmed necrosis, as will be discussed in further detail 
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(Vanlangenakker, et al., 2011).  Cancer cell death sensitization was demonstrated to 
require autocrine production of death receptor ligands.  Prior to SMAC mimetic 
treatment, these cancer cells are impervious to death receptor induced death presumably 
due to hyper-ubiquitination of RIP1, which results in NFκB activation, upregulation of 
anti-apoptotic genes, and impaired RIP1 association with Caspase-8 (Bertrand et al., 
2008). 
In agreement with the aforementioned studies showing the anti-apoptotic function 
of c-IAP1/2, cells expressing an ubiquitin acceptor site mutant RIP1 (K377R) undergo 
enhanced Complex II formation and apoptosis (O'Donnell et al., 2007).  This predicts a 
deubiquitinase that regulates RIP1 ubiquitination; thereby, promoting Complex I to 
Complex II transition. Some studies suggest that the pro-death function of CYLD is 
attributed to de-ubiquitination of RIP1. Namely, CYLD regulates RIP1 ubiquitination 
resulting in complex I to II transition, and cellular demise via apoptosis (Wang et al., 
2008). 
A conundrum in the TNFα induced cell death field was the fact that the 
components of Complex II do not require de novo gene transcription and are expressed at 
significant levels prior to NFκB activation, whereas many of the anti-apoptotic proteins 
require NFκB driven expression.  This is not intuitive when considering the default 
TNFα-induced program is survival, but the survival components require new gene 
transcription whereas the pro-apoptotic proteins are constitutively expressed. This 
suggested the presence of additional NFκB-independent survival mechanisms to prevent 
unintended TNFα-driven cell death.  This conundrum was solved based on work from 
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Adrian Ting’s group on the NFκB-independent anti-apoptotic function of NEMO 
(Legarda-addison et al., 2009).   
NEMO is also a negative regulator of Complex I to Complex II transition.  
Initially, it was assumed that the pro-survival effect of NEMO was attributed to its role in 
NFκB activation and subsequent up-regulation of pro-survival genes such as cFLIP.  A 
report clarified that NEMO has an anti-apoptotic function independent of its function as a 
NFκB activator.  It was observed that Jurkat T cells expressing an IκBα super repressor, 
in which NFκB cannot be activated showed a lesser degree of TNFα driven apoptosis 
enhancement than cells deficient of NEMO.  This suggested that NEMO must have an 
additional pro-survival function independent of NFκB activation.  In agreement with this 
hypothesis, Jurkat T cells that are deficient of NEMO and express the IκBα super 
repressor show enhanced apoptosis as compared to cells only expressing the IκBα super 
repressor.  Reconstitution of the NEMO deficient/ IκBα super repressor cells with 
NEMO was able to repress apoptosis to the same level as cells only expressing the IκBα 
super repressor.  The molecular events that describe this cell death phenotype are that 
NEMO binds to ubiquitinated RIP1 and inhibits RIP1 association with caspase-8.  In 
other words, NEMO inhibits transition of RIP1 from Complex I to Complex II (Legarda-
addison et al., 2009). 
The NFκB-independent pro-survival function of NEMO extends beyond its 
regulation of apoptosis.  NEMO deficient Jurkat cells expressing an IκBα super repressor 
are more sensitive to TNFα-induced necrosis.  Just like in apoptosis, the necrosis 
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suppressive effect requires intact ubiquitin binding domains.  Specifically, mutations in 
the ubiquitin binding domain of NEMO that eliminate its ability to bind ubiquitin, also 
eliminates its necrosis suppressive function.  In agreement with the notion that NEMO 
binds to ubiquitinated RIP1 and thereby stifles necrosis, SMAC mimetic eliminated the 
protection observed in NEMO deficient cells reconstituted with wild-type NEMO.  The 
explanation for this observation is that the SMAC mimetic removes cIAPs and in doing 
so RIP1 is in a primarily unmodified state.  Since the NFκB-independent survival 
function of NEMO requires binding to ubiquitinated RIP1, NEMO can no longer exert its 
anti-necrotic effect when cells are treated with SMAC mimetic. In agreement with the 
requirement for NEMO binding to ubiquitinated RIP1 in order to block RIP1 transition to 
Complex II, cells expressing a mutant version of RIP1 (K377R), which removes a 
ubiquitin acceptor site, enhances TNFα-induced necrosis.  As expected, the necrosis 
enhancing effect of SMAC mimetic treatment was not pronounced in cells expressing 
K377R RIP1.  More evidence suggesting that RIP1 ubiquitination negatively regulates its 
pro-necrotic function came from experiments showing that cells expressing a dominant 
negative TRAF2, which have impaired RIP1 ubiquitination, also have enhanced necrosis 
(O’Donnell et al., 2012). Although, RIP1 ubiquitination negatively influences both 
apoptosis and necrosis, CYLD is dispensable for TNFα-induced apoptosis in NEMO 
deficient cells and yet required for necrosis in these same cells.  This is explained by the 
observation that CYLD is rapidly degraded in NEMO deficient cells during apoptosis, 
which is dependent on Caspase-8 mediated cleavage of CYLD (O’Donnell et al., 2011).            
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It is important to note that normally RIP1 is dispensable for TNFα-induced 
apoptosis when cells are sensitized with either the protein translation inhibitor 
cycloheximide (CHX) or blockade of NFκB via stable transfection of an IκB super 
repressor (O’Donnell et al., 2009; Wang et al., 2008).  Interestingly, this form of RIP1-
independent apoptosis is highly susceptible to the negative regulation by cFLIP, which is 
a NFκB target gene.  In fact, the requirement for NFκB inhibition in order to sensitize 
cells to die via TNFα-induced apoptosis is circumvented by cFLIP knockdown.  The 
other form of TNFα-induced apoptosis occurs when cIAPs are depleted and requires 
RIP1 and its functional kinase activity.  This form of apoptosis is more resistant to the 
anti-apoptotic effects of cFLIP, which has been attributed to the fact that a higher level of 
RIP1/Caspase-8/FADD complex formation occurs in these cells, and may override the 
repressive effects of cFLIP levels.  Indeed, this form of apoptosis does not require NFκB 
inhibition as it was activated in the presence of SMAC mimetic (Wang et al., 2008).  
Interestingly, in cells deficient of NEMO and expressing an IκB super repressor, TNFα-
induced apoptosis requires RIP1 (O’Donnell et al., 2009).  This suggests that the presence 
or absence of NEMO dictates whether apoptosis is RIP1-independent or RIP1-dependent, 
respectively.    
The pro-death function of RIP1 extends beyond its role in Complex II derived 
from TNFR-1.  This RIP1-dependent complex was identified by two separate groups and 
termed the “Ripotosome.” The groups did not use the same stimuli to induce cell death in 
their studies.  The first group used the chemotherapeutic agent Etoposide, and wanted to 
determine the biochemical mechanism responsible for its cytotoxic effects on cancer 
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cells.  They demonstrated Etoposide reduced the cellular levels of cIAP1/2 and XIAP, 
allowing for the formation of a RIP1-dependent complex.  It was demonstrated that this 
complex contains RIP1/FADD/Caspase-8 and can promote either apoptosis or necrosis 
depending on whether caspases are inhibited.  This complex shares compositional 
similarities with Complex II derived from the TNFR-1 pathway.  Interestingly, this 
complex was not derived from death receptor complexes as siRNA knock-down and 
neutralizing antibodies for death receptors such as TNFR-1 were insufficient for blocking 
death.  This revealed that in response to other stimuli, RIP1 could form alternative 
complexes that mediate cell death.   
Another distinguishing feature of this complex is that it is of higher molecular 
weight than the one originally characterized for TNFR-1 signaling (Micheau et al., 2003).  
The RIP1-dependent complex that formed from Etoposide/SMAC mimetic treatment was 
found in 2MDa fractions from gel sizing columns.  It was the RIP1 within these high 
molecular weight fractions that was in a complex with caspase-8, which warranted the 
nomenclature “Ripotosome” (Tenev et al., 2011).   
The other group characterizing the “Ripotosome” used the synthetic TLR-3 ligand 
poly(I:C) in addition to SMAC mimetic to induce apoptosis or necrosis, depending on 
additional treatment with zVAD.  Like the first group they demonstrated that the cell 
death was independent of autocrine TNFα signaling.  Similarly, this group found that 
RIP1 was required for the formation of the “Ripotosome” which contained RIP1, 
Caspase-8/10, FADD, and cFLIP.  They also demonstrated that TLR-3 stimulation and 
SMAC mimetic treatment resulted in the recruitment of the sole TLR-3 adaptor protein, 
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TRIF, to the complex, which has been demonstrated to mediate TLR-3 induced apoptosis 
as well as necrosis (He et al., 2012).  As with TNFα-mediated cell death, knock-down of 
caspase-8 or treatment with zVAD pushed the death towards RIP3-dependent necrosis.  
While RIP3 is solely required for Ripotosome-mediated necrosis, both apoptosis and 
necrosis require RIP1.  During apoptosis induced by poly(I:C) and SMAC mimetic, RIP1 
appears to play a scaffolding role, as its kinase activity is dispensable, but its presence is 
necessary. During necrosis, the kinase activity of RIP1 is required as cell death in the 
presence of zVAD can be inhibited with Nec-1 treatment.  Altogether, this data indicates 
that the Ripotosome is a death inducing hub downstream of a variety of stimuli, but 
distinct from the Complex II derived from TNFR-1 signaling (Feoktistova et al., 2011).   
The short and long c-FLIP isoforms were shown to be functionally distinct in 
their regulation of the Ripotosome.  The c-FLIPL isoform was shown to negatively 
regulate poly(I:C) induced apoptosis, while c-FLIPS promoted necrosis in addition to 
blocking apoptosis. Impaired apoptosis in c-FLIPL overexpressing cells was attributed to 
a block in Ripotosome formation.  Interestingly, in cells overexpressing c-FLIPS, 
treatment with the c-IAP antagonist caused spontaneous Ripoptosome formation and 
necrosis.  Furthermore, in cells overexpressing c-FLIPS there was a portion of the total 
cellular pool of c-FLIPS, caspase-8, and RIP1 in high molecular weight fractions (2 
MDa); however, complex formation of these proteins only occurred in the presence of 
SMAC mimetic.  These results provide evidence that different c-FLIP isoforms have 
diametrically opposed functions in respect to ripotosome-mediated cell death.  
Interestingly, in cells overexpressing c-FLIPS, inhibiting the proteasome with MG-132 
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resulted in the formation of the ripotosome, which is similar to treatment with SMAC 
mimetic alone.  In other words, this means that blocking proteasomal mediated 
degradation shares some of the molecular ramifications as eliminating cIAPs.  This 
suggests that the negative regulatory role of cIAPs during ripotosome formation is 
possibly due to targeting a select proportion of RIP1 for proteasomal degradation that is 
competent for participating in ripotosome formation (Feoktistova et al., 2011).  Since one 
report provides compelling evidence of RIP1/RIP3 amyloid fibril formation and 
functionality during necrosis, it is conceivable that cIAPs may function to eliminate their 
spontaneous formation in the cell (Li et al., 2012).  Whether the ripotosome contains 
amyloid RIP1 or RIP3 has not been tested.  This data also suggests that cell-type specific 
differences in the proportion of c-FLIP isoforms may dictate their sensitivity to 
Ripoptosome-mediated cell death both quantitatively and qualitatively.     
During TNFα stimulation RIP1 is ubiquitinated with a heterogeneous group of 
linkage types in the TNFR-1 complex.  As previously mentioned, RIP1 ubiquitination is a 
critical post-translational modification that brings NEMO complexes in proximity to 
TAK1 complexes and therefore supports IKK activation (Ea et al., 2006; Kanayama et 
al., 2004).  One report used an ubiquitin replacement strategy to elucidate the functional 
requirement of K63-linked polyubiquitin chains in TNFα-induced IKK complex 
activation.  In this report they were able to knock-down endogenous ubiquitin and replace 
it with ubiquitin in which the various ubiquitin acceptor site lysine residues were 
mutated.  Via this method they determined that K63-linked polyubiquitination is 
dispensable for IKK activation and subsequent IκB phosphorylation.  Consistent with this 
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data, the E2 conjugating enzyme Ubc13 was also found to be dispensable.  When in 
complex with an E3 ligase, Ubc13 is only capable of supporting K63-linked 
polyubiquitin chains.  However, the more promiscuous E2 UbcH5c, which aids in 
polyubiquitination of a variety of chain linkage types, was in fact required for TNFα-
induced NFκB activation.  They attributed the dispensability of K63-linked chains to the 
fact that RIP1 can still get ubiquitinated in NEMO complexes using this system. 
Furthermore, single mutations of all of the lysine residues in ubiquitin, as well as some 
double mutations, were still sufficient for TNFα-driven RIP1 ubiquitination. All this data 
strongly suggests that RIP1 can be ubiquitinated with a variety of linkage types that 
support its role in activating the IKK complex (Xu et al., 2009).  Further investigation 
regarding the potential influences of different ubiquitin linkage types on RIP1-mediated 
cell death is merited.   
The findings in the aforementioned study were bolstered by a later study, which 
used antibodies specific for different ubiquitin linkage types and mass spec analysis to 
demonstrate the heterogeneity of RIP1 ubiquitination linkage types both in vitro and in 
vivo.  In vitro assays indicated, that RIP1 could be ubiquitinated with K63, K48, and K11 
polyubiquitin via UbcH5c and cIAP1 and were quantified by mass spec.  Furthermore, in 
vivo experiments showed that RIP1 within the TNFR-1 complex could be ubiquitinated 
with these various ubiquitin chain linkages that was dependent on both UbcH5 and 
cIAP1.  Based on their findings in a yeast two hybrid study using cIAP1 as bait, they 
identified a variety of E2s, which it can interact with.  Using a variety of stimuli, which 
are known to disrupt cIAP1 stability through activation of its E3 ligase activity, auto-
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ubiquitination, and subsequent proteasome mediated degradation they demonstrated the 
requirement for UbcH5 and the dispensability of the other E2s, which can bind cIAP1.  
However, this does not negate the possibility that cIAP1 and other E2 enzyme pairs may 
function in other signaling paradigms where cIAP1 E3 ligase activity is required.  
Through in vitro binding assays it was also demonstrated that NEMO can bind to K11-
linked polyubiquitin chains with a dissociation constant in the low micromolar range. 
These findings bolster the notion that alternative linkages may function in the TNFα 
signaling pathway, but any individual linkage type by itself is dispensable (Dynek et al., 
2010). 
CYLD in the context of a myriad of biological processes
CYLD is a tumor suppressor with de-ubiquitinating enzymatic activity (Bignell et 
al., 2000; Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003). 
It’s involved in a myriad of biological processes such as skin homeostasis, progression of 
spermatogenesis, lymphocyte development, bone development, and multiple cancer types 
(Jin et al., 2008; Keats et al., 2007; Massoumi et al., 2006; Reiley et al., 2006; Reiley et 
al., 2007; Wright et al., 2007).  Furthermore, a group of overlapping autosomal dominant 
diseases are attributed to mutations that disrupt CYLD’s enzymatic activity; namely, 
familial cylindromatosis (FC), multiple familial trichoepithelioma (MFT), and Brooke 
Spiegler syndrome (BSS). These diseases are typified by benign tumors of the face, scalp, 
and neck (Young et al., 2006).  
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The first studies that characterized the signaling function of CYLD revealed that it 
acts as a negative regulator of JNK and NFκB activation by de-ubiquitinating adaptor 
proteins such as TRAF2, TRAF6 and components of the IKK complex that function 
downstream of a variety of cytokines (Brummelkamp et al., 2003; Kovalenko et al., 
2003; Trompouki et al., 2003). CYLD also negatively regulates the non-conical NFκB 
pathway thereby blocking cellular proliferation (Massoumi et al., 2006). Both in vitro and 
in vivo studies have revealed that CYLD deubiquitinates target proteins conjugated with 
K63-linked and linear polyubiquitin chains. These ubiquitin chain linkages are both 
topologically and functionally distinct from K48-linked chains. Unlike K48-linked 
polyubiquitin chains that target acceptor proteins for proteasomal degradation, K63-
linked chains provide binding sites for signaling proteins (Komander et al., 2009; Wright 
et al., 2007). 
CYLD is a negative regulator of innate anti-viral signaling pathways.  Namely, 
CYLD suppresses the induction of type I interferons (IFN) by the cytosolic RNA sensor 
RIG-I.  The mechanism of suppression is suggested to be through CYLD-mediated 
deubiquitination of RIG-I. Dendritic cells devoid of CYLD have constitutive 
hyperactivation of kinases that function downstream of RIGI, IKKε and TANK Binding 
Kinase 1 (TBK1) (Zhang et al., 2008). RIG-I is also hyperubiquitinated in dendritic cells 
devoid of CYLD.  This suggests that the ubiquitination status of RIG-I influences its 
signaling capacity.  Another report demonstrates that CYLD can also regulate the 
ubiquitination status of TBK-1, and interact with many of the signaling proteins 
downstream of RIG-I.  During SeV infection and TNFα treatment, CYLD levels rapidly 
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decrease suggesting a possible mechanism that ensures sufficient induction of type I IFN 
to eliminate viral propagation (Friedman et al., 2008). 
Multiple reports have revealed mechanisms, which regulate the functionality of 
CYLD in different signaling paradigms.  Diverse stimuli such as TNFα, LPS, and 
PMA/Ionomycin give rise to phosphorylation of CYLD.  These phosphorylation events 
are mediated by the IKK complex, and are inhibitory to CYLD functionality.  CYLD 
harbors a cluster of serine residues that can undergo stimulus dependent phosphorylation.  
Cells expressing compound mutants of CYLD, in which the phosphorylation sites are 
eliminated, have impaired ligand inducible ubiquitination of CYLD substrates.  This is 
presumably attributed to the inability of the IKK complex to suppress CYLD DUB 
activity, leading to the deubiquitination reaction dominating over the opposing 
ubiquitination reaction.  In result of impaired ubiquitination of key adaptor proteins, the 
cells have blunted TNFα-induced JNK activation.  In line with this model, mutations 
mimicking CYLD phosphorylation, abrogates the ability of CYLD to deubiquitinate 
TRAF2 in an overexpression system (Reiley et al., 2005).  
Similarly, IKKε, which is critical for type I interferon production downstream of 
PRRs and oncogenic in breast cancer, phosphorylates CYLD.  This phosphorylation 
event inhibits CYLD-mediated deubiquitination of TRAF2 and NEMO in overexpression 
systems.  Either CYLD knock-down or ectopic IKKε is sufficient to cause transformation 
of NIH 3T3 cells.  Co-transfection of S418A CYLD but not wild-type CYLD is able to 
partially suppress IKKε-mediated transformation.  The mechanism of transformation 
upon knock-down of CYLD in 3T3 cells is attributed to NFκB, as transformation can be 
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blocked via expression of an IκB super repressor (Hutti et al., 2009).  Altogether, these 
data point to an important regulatory mechanism of CYLD function in both physiological 
and pathophysiological scenarios.  Since CYLD tumor suppressive activity can be 
inhibited by phosphorylation, it is possible that critical phosphatases remove these 
inhibitory phosphates from CYLD thereby restoring CYLD enzymatic activity. These 
phosphatases would theoretically be tumor suppressors themselves. 
Protease-mediated cleavage of CYLD is yet another example of a regulatory 
mechanism, which impacts CYLD function.  In the context of TNFα signaling, CYLD is 
cleaved at aspartic acid residue 215 by caspase-8.  This leads to proteasomal degradation 
of the C-terminal fragment of CYLD and suppression of necrosis.  Interestingly, cells 
expressing D215A CYLD, which is resistant to caspase-8 cleavage, no longer require 
caspase inhibition for necrosis (O’Donnell et al., 2011).  This suggests that in contrary to 
popular belief, the necrosis suppressive function of caspase-8 is primarily through CYLD 
cleavage.  This is difficult to reconcile with the extensive genetic studies, which suggest 
that RIP1 and RIP3 are the primary targets of caspase-8 mediated necrosis suppression 
(Kaiser et al., 2011; Oberst et al., 2011).  
Multiple studies report that CYLD functions in the adaptive immune system.  
During T cell development, CYLD functions in TCR-proximal signaling events, which 
leads to productive double positive (DP) to single positive transition (SP).  Mice deficient 
of CYLD, have a dramatic reduction in the number of single positive thymocytes, and 
CD4 and CD8 T cells in the spleen.  This is attributed to a T cell intrinsic defect.  
Pertaining to signaling events, CYLD is important for promoting activated LCK 
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association with Zap70.  Indeed, double positive thymocytes from CYLD knock-out mice 
have impaired phosphorylation of Zap70 and Lat.  The authors demonstrate that CYLD 
deubiquitinates LCK in overexpression studies; however, whether this is responsible for 
the impaired association between activated LCK and Zap70 in CYLD deficient T cells 
has not been addressed (Reiley et al., 2006).   
In addition to regulating TCR proximal signaling events during T cell 
development, CYLD is also reported to play a role in regulating T cell activation.  
Namely, CYLD deficient T cells hyper-proliferate upon in vitro stimulation with anti-
CD3/CD28. In agreement with dysregulated T cell activation, CYLD knock-out mice 
develop signs of autoimmunity such as spontaneous inflammation of the colon.  Unlike 
thymocytes, naïve and memory T cells deficient of CYLD showed normal TCR-proximal 
signaling events; however, they had constitutive activation of the conical NFκB pathway 
and C-Jun N-terminal Kinase (JNK).  Adoptive transfer studies of CYLD-deficient T 
cells into a RAG1-/- host were able to recapitulate the spontaneous colon inflammation 
found in the CYLD deficient mice.  This demonstrates that the hyper-responsive CYLD-
deficient T cells were responsible for pathogenesis (Reiley et al., 2007). 
Another report demonstrated that the paracaspase Mucosa Associated Lymphoid 
Tissue 1 (MALT1) cleaves CYLD during TCR stimulation.  MALT1 is a component of 
the CARMA1-BCL10-MALT1 (CBM) complex, which is required for TCR-driven 
NFκB and MAP kinase activation.  Interestingly, MALT1 cleavage of CYLD is required 
for JNK activation, as Jurkat cells expressing a cleavage resistant mutant of CYLD 
(R324A) had impaired TCR-induced JNK activation.  Indeed, CYLD is constitutively 
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expressed in many cells, and in order to bypass its function in negatively regulating JNK 
activation, it must be inactivated.  The requirement of inactivation of negative regulators 
of T cell activation highlights that the steady-state signaling environment in T cells is not 
permissive to activation, and therefore ensures that T cells are not aberrantly activated 
(Staal et al., 2011). 
In addition to being required for conventional T cell development, CYLD also 
plays a role in regulating NKT cell development.  In NKT cells CYLD negatively 
regulates NFκB.  Contrary to expectation, hyper-activated NFκB in immature NKT cells 
(CD44-NK1.1- and CD44+NK1.1-) results in a large proportion of the cells succumbing to 
apoptosis.  Interestingly, excess NFκB activation suppresses the up-regulation of IL-7Rα 
and ICOS, which are required for survival of these cells. The reduction in immature NKT 
cells in CYLD knock-out mice was T cell intrinsic as clarified by bone marrow chimera 
experiments.  Furthermore, crossing the CYLD knock-out mice to mice expressing a 
IκBα super repressor, in which the NFκB pathway is blocked, was able to rescue the 
expression of IL-7Rα and ICOS. This demonstrated that the excess NFκB activation in 
NKT cells lacking CYLD was indeed responsible for altered expression of IL-7Rα and 
ICOS.  Importantly, the high level of apoptosis was also rescued (Lee et al., 2010). 
Reports have also implicated a role for CYLD in B cell homeostasis. There is a 
splice variant of CYLD, which lacks exon 7 and 8 and occurs naturally.  These exons 
encompass the TRAF2 and NEMO binding domains.  The splice variant can be found in 
many different cell types along with expression of full length CYLD. Transgenic mice 
overexpressing sCYLD and lacking full length CYLD have enlarged lymph nodes and 
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spleen attributed to the expansion of mature B cells. This phenotype is indeed B cell 
intrinsic, as it is recapitulated in mice with conditional expression of sCYLD in B cells.  
The expansion was not due to enhanced cell proliferation, but rather enhanced survival.  
B cells from mice expressing sCYLD expressed higher levels of the anti-apoptotic 
protein Bcl-2, which has been demonstrated as key for B cell survival.  Although the 
evidence for the potential mechanism accounting for the increase Bcl-2 expression level 
is tenuous, the authors point to an increase in NFκB activation and p38 pathways.  
Indeed, B cells expressing sCYLD have higher protein levels of p100, IκBα, RelB, which 
are target genes of NFκB, and they also have increased nuclear localization of Bcl-3, 
which functions as a co-activator in the non-canonical NFκB pathway (Hovelmeyer et al., 
2007). Altogether, unlike the negative regulatory function of CYLD on NFκB activation, 
the short splice variant activates NFκB.  It is possible that the ratio of CYLD splice 
variant expression in cells can influence their sensitivity to NFκB activating stimuli.      
In agreement with the effects of sCYLD in B cells, another report demonstrated 
that dendritic cells solely expressing sCYLD were hyper-activated both basally and 
during activation with LPS.  This was attributed to enhancement of NFκB activation and 
Bcl-3 nuclear translocation.  The consequence of hyper-activated dendritic cells was 
enhanced expansion of antigen specific T cells (Srokowski et al., 2009). 
Yet another biological context in which CYLD is important is bone homeostasis.  
CYLD is required to stifle RANKL-induced NFκB activation in pre-osteoclasts.  Mice 
deficient of CYLD, develop osteoporosis due to an overabundance of osteoclasts, which 
are instrumental in bone resorption.  Osteoclast differentiation is contingent upon 
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RANKL signaling.  Indeed pre-osteoclasts from CYLD-/- demonstrate hyper-activation of 
NFκB.  Interestingly, CYLD was found in endogenous complexes with TRAF6, and 
regulates the ubiquitination status of TRAF6.  Furthermore, CYLD and TRAF6 
association required the ubiquitin binding protein p62, which also has been demonstrated 
as a regulator to osteoclastogenesis (Jin et al., 2008).     
 
Current understanding of CYLD in cell death signaling 
CYLD is involved in promoting both TNFα-induced apoptosis and necrosis 
(Fujikura, et al., 2012; Hitomi, et al., 2008).  The pro-apoptotic function of CYLD is 
attributed to its role in promoting the formation of Complex II.  It has been shown that 
TNFα/SMAC mimetic induced Complex II formation is impaired in CYLD knock-down 
cells, which results in attenuation of apoptosis (Wang et al., 2008).  In agreement with 
CYLD’s role in Complex II formation, it is also required for caspase activation during 
TNFα-induced cell death. Overexpression of CYLD results in enhanced TNFα-induced 
caspase activation (Fujikura et al., 2012). In a more physiological context, some evidence 
indicates that the pro-apoptotic function of CYLD is through deubiquitination of RIP1 
during the early wave of apoptosis required for productive spermatogenesis.  CYLD-
mediated apoptosis is critical for this developmental process, as CYLD-/- mice are sterile.  
Interestingly, this report attributes the pro-apoptotic function of the CYLD-RIP1 
signaling axis to the indirect effect of negative regulation of the pro-survival pathway 
NFκB.  It was also demonstrated that CYLD is found in complexes with RIP1, and in 
CYLD deficient spermatocytes RIP1 is hyperubiquitinated. The purported consequence 
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of RIP1 hyperubiquitination is enhanced association between RIP1 and NEMO.  In 
accordance with enhanced RIP1/NEMO association, IP kinase assays from CYLD-/- 
spermatocytes revealed enhanced activation of the IKK complex.  Consistent with 
enhanced IKK activity, enhanced NFκB activation was demonstrated and the 
concomitant up-regulation of anti-apoptotic NFκB target genes.  The stimuli responsible 
for RIP1 ubiquitination in spermatocytes still must be elucidated (Wright et al., 2007).   
The same study demonstrated that in overexpression experiments, CYLD was 
capable of blocking TNFα-induced RIP1 ubiquitination at time-points during Complex I 
formation, but it was not ascertained whether this occurred in the TNFR-1 complex 
(Wright et al., 2007).  The current model for the pro-apoptotic mechanism of CYLD was 
formed based on this data, as well as the aforementioned evidence showing that RIP1 
ubiquitination interferes with its engagement with caspase-8 complexes. Altogether, the 
current model suggests that the pro-apoptotic function of CYLD is attributed to 
deubiquitination of RIP1 leading to Complex II assembly, caspase activation, and death.  
CYLD also has a pro-necrotic function, which is the central topic of this thesis. 
CYLD-mediated deubiquitination of RIP1 and subsequent transition of RIP1 from 
Complex I to Complex II has been implicated as its pro-necrotic mechanism (O’Donnell 
et al., 2011; O’Donnell et al., 2012; Vandenabeele et al., 2010) (Fig.1.4). However, the 
validity of this model has not been formally demonstrated.  One report indicated that 
CYLD is a target of caspase-8, and the cleavage event suppresses the necrosis program. 
A cleavage site mutant of CYLD bypasses the requirement for caspase inhibition and 
results in reduced RIP1 and NEMO association.  These complexes are pro-survival and 
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contingent upon RIP1 ubiquitination.  Indeed, the CYLD-mediated disruption of 
RIP1/NEMO complexes correlated with enhanced RIP1 recruitment to FADD.  
Furthermore, the reported CYLD-mediated disruption of RIP1/NEMO complexes implies 
that CYLD exerts its pro-necrotic function by targeting TNFR-1 associated RIP1 
(O'Donnell et al., 2011). 
 
Thesis objective     
The general aim of my thesis research has been to clarify the biochemical 
signaling pathway of TNFα-induced necrosis.  At the inception of this work, the sub-field 
of necrosis signaling was just taking off with the discovery of RIP3 as an important 
regulator of the process, and that RIP1/RIP3 interaction was a required molecular event 
(Cho et al., 2009; He et al., 2009; Zhang et al., 2009).  However, there was still a paucity 
of data regarding the regulation of RIP1/RIP3 association and their potential downstream 
targets.  Given the inchoate stages of the scientific communities understanding of 
necrosis signaling, it was an excellent opportunity for discovery.  My aim was to reveal 
new regulators of necrosis, so I screened a cancer gene siRNA library using a necrosis 
sensitive cell line.  This resulted in the independent discovery of CYLD as a positive 
regulator of necrosis.  It also yielded the discovery of FUS1 as a putative positive 
regulator of necrosis, which is a gene implicated in lung cancer (Deng et al., 2007).  The 
focus of my work then shifted to further characterizing the requirement of CYLD for 
TNFα-induced cell death in a variety of different cell-lines, as well as its role in other cell 
death programs.  I then ascertained the molecular mechanism accounting for the pro-
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necrotic function of CYLD.  This ended in the uncovering of an unexpected mechanism 
of CYLD-mediated necrosis, which illuminated the mechanism of necrosome activation.      
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Introduction 
 It is now well appreciated that death receptor ligands such as TNFα can give rise 
to necrotic cell death.  Necrosis is a caspase-independent form of programmed cell death.  
In fact, caspases play a role in actively suppressing the necrosis signaling pathway 
(Oberst et al., 2011).  The details regarding the biochemical signaling pathway leading to 
necrosis are currently under intense investigation.  Receptor interacting protein 1 (RIP1), 
was the first regulator identified to be required for TNFα-induced necrosis (Holler et. al 
2000 Nature).  RIP1 is a Serine/Threonine kinase.  The function of RIP1 was previously 
characterized as promoting NFκB, independent of its kinase activity (Kelliher et al., 
1998; Lee et al., 2004).  RIP1 kinase activity was subsequently shown to be required for 
its pro-necrotic function (Holler et al., 2000).  It was later revealed that RIP3 is also a 
pro-necrotic protein.  The interaction between RIP1 and RIP3 via their RHIMs is a 
required molecular event for TNFα-induced necrosis (Cho et al., 2009; He et al., 2009; 
Zhang et al., 2009).   
During conditions that are permissive of TNFα-induced cell death, RIP1 
dissociates from the receptor complex and forms a cytosolic death inducing signaling 
complex (DISC) or Complex II.  Within this complex caspase-8 is activated and gives 
rise to a proteolytic cascade involving subsequent activation of executioner caspases and 
the cleavage of a myriad of cellular substrates leading to apoptosis.  It is clear that both 
RIP1 and RIP3 are cleaved by caspase-8.  Therefore, the necrosis pathway is actively 
suppressed by the apoptosis pathway (Feng et al., 2007; He et al., 2009).  During caspase 
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inhibition, RIP1 and RIP3 are no longer cleaved allowing for the formation of a complex 
named the necrosome, which is critical for cellular demise via necrosis.  The kinase 
activity of RIP1 is required for association with RIP3.  Conversely, the kinase activity of 
RIP3 is dispensable for interaction with RIP1, but it is still required for necrosis.  The 
requirement for RIP3 kinase activity is due to an auto-phosphorylation event, which is 
required for recruitment and activation of downstream substrates (Sun et al., 2012).  RIP1 
and RIP3 undergo auto and trans-phosphorylation events within the necrosome.  The 
hierarchy and number of phosphorylation events still must be clarified (Cho et al., 2009; 
He et al., 2009; Zhang et al., 2009).  Recently, it was demonstrated that Mixed-linage 
kinase domain like protein (MLKL), PGAM5L, and PGAM5S, are components of the 
necrosome and substrates of RIP1/RIP kinase activity.  MLKL participates in the 
recruitment of PGAM5S to the necrosome.  This is supported by data demonstrating that 
NSA, the covalent inhibitor of MLKL, blocks MLKL/PGAM5S binding and subsequent 
necrosis.  Downstream of necrosome activation, PGAM5 activates the mitochondrial 
fission enzyme Drp-1 through dephosphorylation.  This leads to mitochondrial fission 
and death by necrosis (Sun et al., 2012; Wang et al., 2012).  It is important to mention 
that the role of mitochondrial fission in necrosis is still in its infancy, and much work is 
required to firmly establish its role and mechanism.  
In spite of the advancement of the scientific communities knowledge of the 
necrosis signaling pathway, much work is still required.  A number of unanswered 
questions remain.  Firstly, since RIP1 is presumably the apical kinase in this cell death 
paradigm, mechanistic details regarding the activation of its kinase activity is of great 
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importance. Secondly, are there additional components of the necrosome? Thirdly, what 
is the role of the mitochondria in necrosis, and what are the mitochondrial targets either 
activated or repressed downstream of the necrosome? Given our growing understanding 
of necrosis being involved in a variety of physiological and pathophysiological situations, 
clarifying the signaling pathway could potentially create therapeutic targets for many 
diseases.  
This study sought to identify other potential proteins involved in the TNFα-
induced necrosis signaling pathway.  It is well documented that cancer cells override cell 
suicide pathways.  Chromosomal abnormalities have been demonstrated to lead to 
increased expression levels of anti-apoptotic proteins such as cIAPs.  Therefore, a variety 
of therapeutic approaches exist to activate cell death pathways in cancer cells (Fulda et al. 
2012).  It is conceivable that necrosis plays a role in either the initiation, progression, or 
suppression of cancer.  Finding new players in the necrosis signaling pathway can 
potentially yield new drug targets for the treatment of cancer and beyond.  In order to 
identify potential signaling proteins involved in necrosis, a siRNA cancer gene library 
was screened.  This study independently identified the tumor suppressor CYLD as a 
regulator of necrosis, as well as the lung cancer tumor suppressor FUS1 as a putative 
regulator of necrosis. 
 
Results 
CYLD and FUS1 are putative regulators of necrosis 
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 In order to identify signaling regulators of necrosis, a cancer gene siRNA library 
was screened.  A Jurkat T cell line deficient of FADD, and stably transfected with TNFR-
2 was used in the screen.  These cells undergo necrosis with only TNFα treatment and are 
particularly sensitive to necrosis due to expression of the necrosis enhancing TNFR-2 
receptor.  Since FADD is required for caspase-8 activation, this cell-line does not require 
the use of the pan caspase inhibitor zVAD-fmk in order to induce necrosis (Chan et al., 
2003).  In addition to the experimental siRNA oligos, each plate included both positive 
and negative controls.  Namely, genes that have already been established as dispensable 
for necrosis and a gene previously established as essential for necrosis were used as 
controls.  Specifically, TR4, GFP, and non-targeting (scrambled) siRNA were used as 
negative controls in these cell death assays, and RIP1 was used as the positive control.  
For each gene there were two siRNA oligos in the library.  For transfection, the two 
siRNA oligos targeting the same gene were pooled.  This increased the chances of 
efficient knock-down.  For the majority of the genes, both two and three days post-
transfection, cells were stimulated to undergo necrosis and then assayed for cell death.  
Two different doses of TNFα were used for each siRNA oligo. All cells were also treated 
with the apoptosis inducer, Staurosporine (STS). In addition to being an apoptosis 
inducer through activation of caspase-3, STS also broadly inhibits kinases (Chae et al., 
2000).  Thus the death observed using this inducer is most likely independent of kinases.  
Since necrosis requires kinases to potentiate the pro-necrotic signal, STS-induced death is 
an appropriate negative control. This control was to ensure that knock-down of genes 
resulting in protection against TNFα-induced necrosis were not simply conferring 
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resistance to cell death in general.  This was therefore a specificity control for the 
necrosis signaling program. 
  A criterion was established in order to determine which genes qualified as 
putative regulators of necrosis.  For each plate of siRNA, the mean and standard 
deviation of the cell viability for each dose of TNFα was calculated. Any siRNA that 
conferred protection one standard deviation above the mean was included as a positive hit 
for a putative regulator of necrosis.  There were some instances when the knock-down 
conferred protection on day three post-transfection, but not two days post-transfection 
and vice versa.  These genes were still included in the list of positive hits.  The inclusion 
of the three-day transfection was to help eliminate the possibility of false negatives.  
Specifically, a negative hit attributed to a long protein half-life resulting in insufficient 
knock-down. After the screen was conducted, all of the positive hits (39 genes) were 
tested again for their ability to confer protection from necrosis and compiled in a table 
(Table 2.1A-C). There were two genes, which passed the validation round FUS1 and 
CYLD. An example of one of the graphs for a siRNA plate is included on the next page, 
and the remaining graphs are compiled in the appendix (Fig. 2.1; Appendix).   
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Discussion 
 This study revealed two putative genes involved in TNFα-induced necrosis, FUS1 
and CYLD.  Previous work demonstrated that FUS1 functions as a tumor suppressor in 
lung cancer.  Chromosomal deletions containing the FUS1 gene are frequently observed 
in lung cancer cells, which accounts for the loss of FUS1 mRNA and protein expression.  
Importantly, introduction of exogenous FUS1 into a panel of lung cancer cells was able 
to induce apoptosis.  This was through the activation of the intrinsic mitochondrial 
apoptosis pathway.  It has also been demonstrated that exogenous FUS1 can enhance the 
chemotherapeutic efficacy of Cisplatin. It appears to enhance the ability of the drug to 
cause MDM2 protein reduction, p53 protein elevation, and to trigger Apaf-1 dependent 
cancer cell death (Deng et al. 2008).   
Another study provided evidence that FUS1 can negatively regulate the kinase 
activity of c-Abl.  Indeed, a FUS1 peptide that corresponds to a region of the protein 
deleted in some lung cancer cell lines was able to inhibit c-Abl kinase activity in vitro.  
The FUS1 deletion mutant was unable to regulate c-Abl kinase activity in co-expression 
studies while the wild-type version could.  Importantly, c-Abl tyrosine kinase activation 
was oncogenic as blocking its activity with an inhibitor was able to block colony 
formation.  Exogenous introduction of FUS1 in a lung cancer cell line devoid of FUS1 
and expressing activated c-Abl effectively reduced the level of c-Abl kinase activity.  
This reveals a target pertinent to the tumor suppressive function of FUS1, as well as 
kinase inhibition as a mechanism of tumor suppression (Lin et al., 2007).   
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Some evidence suggests that FUS1 can function as a tumor suppressor in bone 
and soft tissue sarcomas.  Unlike the scenario in lung cancer cells, these sarcomas 
expressed FUS1 at the mRNA level, but not the protein level. Introduction of exogenous 
FUS1 was able to induce apoptosis in sarcomas with low levels of protein expression.  
This supports the notion that FUS1 may function as a tumor suppressor in other types of 
cancer, but the mechanism of reduced FUS1 protein expression is not attributed to 
chromosomal deletion in all cancer types.  One potential explanation for the deficiency of 
FUS1 protein expression in bone sarcomas is the expression of an oncogenic E3 ligase, 
which continuously targets FUS1 protein for proteasomal degradation (Li et al. 2011).  
Consistent with this hypothesis, it was demonstrated that the tumor suppressive function 
of FUS1 requires the post-translational modification N-myristoylation.  This is possibly 
explained by the fact that a mutant version FUS1, which cannot be modified with N-
myristoylation is susceptible to degradation by the proteasome and has altered subcellular 
localization (Uno et al. 2004).  Another report shows that FUS1 expression may also be 
blunted by the increased expression of miRNA in cancer cells that target the 3’UTR of 
FUS1 (Du et al. 2009).   
Our study potentially expands upon the know function of FUS1 from promoting 
the intrinsic mitochondrial apoptosis pathway in cancer cells to being involved in death 
receptor induced necrosis.  Future research must be conducted to confirm that FUS1 is a 
bona fide promoter of necrosis.  It is conceivable that FUS1 only regulates necrosis in 
specific cell-types; therefore, initial studies should establish whether it is in fact part of 
the core necrotic machinery.  Another important question to address is the molecular 
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mechanism accounting for the pro-necrotic function of FUS1.  Necrosis is an apoptosome 
independent form of cell death, which excludes the possibility that FUS1 is promoting 
necrosis through apoptosome formation.  Nevertheless, this may in fact provide an 
important clue as to the subcellular location where FUS1 exerts its pro-necrotic function.  
Given the paucity of data regarding the mechanism of FUS1-mediated apoptosis, the 
evidence that does exist provides rationale for investigating the effect of FUS1 on 
mitochondrial dynamics during necrosis.  Furthermore, the requirement of FUS1 to be 
myristoylated in order to promote apoptosis supports the notion that it requires membrane 
tethering.  One possibility is that FUS1 must be tethered to mitochondrial membranes in 
order to exert its cell death function and avoid degradation by the proteasome.   
One report demonstrates that the necrosome can promote mitochondrial 
fragmentation through the activation of the mitochondrial fission enzyme Drp-1 (Sun et 
al, 2012).  Given that other reports have implicated Drp-1 mediated mitochondrial fission 
in the kinetics of necrosis and apoptosis in C. elegans, it is tempting to speculate that 
FUS1 is involved in mitochondrial fission.  Namely, FUS1 may inhibit the fusion 
machinery or activate the fission machinery (Breckenridge et al., 2008; Jagasia et al., 
2005).  Since phosphorylation is an important regulatory mechanism of mitochondrial 
fission during necrosis, FUS1 may regulate kinases that antagonize fission.  Interestingly, 
the phosphatase PGAM5 is required for removal of an inhibitory phosphate group from 
Drp-1, which activates its GTPase activity and mitochondrial fission function.  Since a 
report indicates that FUS1 can inhibit the kinase activity of c-Abl, it is possible that FUS1 
can activate Drp-1 by inhibiting the kinase, which is responsible for phosphorylating 
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Drp-1 and keeping it inactive.  This hypothesis implies that PGAM5 and FUS1 both 
activate Drp-1, but through different molecular mechanisms.  In simplified terms, 
PGAM5 removes the inhibitory phosphate from Drp-1, and FUS1 might inactivate the 
kinase that phosphorylates and inhibits Drp-1.  The corollary of FUS1 mediated 
mitochondrial fission would either be the promotion of apoptosis, or alternatively, 
necrosis when caspases are inactivated.  This model implies that in the context of 
apoptosis the outcome of mitochondrial fission is activation of the apoptosome. 
Clearly, the pro-necrotic function of FUS1 needs to be clarified.  It will be of 
value to determine whether its participation in necrosis is cell-type specific or a general 
requirement for multiple cell types.  A cell-type specific scenario of the involvement of 
FUS1 in necrosis would possibly indicate that it acts in the execution phase of the cell 
death process.  This claim is based on the observation that ROS is not required for all 
cell-types to undergo necrosis, suggesting that necrosis may engage alternative 
mechanisms in its execution phase (Zhao et al., 2012).  If a general requirement for FUS1 
in the necrosis program is observed then this would suggest that it is part of the core 
necrotic machinery.  Once this is delineated, it would be most informative to determine 
the impact of FUS1 on necrosome formation.  If FUS1 has no impact on necrosome 
formation then it suggests its role is either in promoting necrosome functionality or a 
downstream event such as mitochondrial dynamics.  Given the dearth of knowledge 
regarding the role of mitochondrial dynamics during necrosis, and the link between FUS1 
and the mitochondria, elucidating the molecular mechanism of FUS1-mediated necrosis 
should be of great interest to the cell death field.  The implications of FUS1 as a regulator 
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of necrosis and a tumor suppressor for lung cancer make this an even more enticing topic 
of further research.  Ultimately, it will be of great interest to determine whether the pro-
necrotic function of FUS1 is responsible for its tumor suppressive effects.  This may 
provide rationale for studying the impact of necrosis on lung cancer.  
The other gene we identified in this screen was CYLD.  The following chapters 
will focus on the characterization of the requirement of CYLD in programmed necrosis 
and the molecular mechanism accounting for its pro-necrotic function.  During the time 
when we independently discovered the functional requirement of CYLD for programmed 
necrosis a model was proposed which explained the molecular mechanism.  The 
prevailing model was that CYLD regulation of RIP1 ubiquitination within the TNFR-1 
complex promotes RIP1 transition from the membrane associated pro-survival complex 
to the cytosolic death mediating complex (Vandenabeele et al., 2010).  My research 
sought to directly test whether this model indeed represented the molecular mechanism 
accounting for the pro-necrotic function of CYLD.  Due to the fact that this gene is 
covered extensively in other chapters, a detailed discussion will be postponed for the 
following chapters to avoid unnecessary redundancy. 
 
Materials and Methods 
Reagents used 
Recombinant human TNF was obtained from Biosource. The siRNA library screened 
was: Human Cancer siRNA Set V2.0 from Qiagen. 
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Transfection of siRNA and treatment to undergo necrosis 
FADD deficient Jurkat cells stably expressing exogenous TNFR2 (Chan et al., 2003) 
were transfected with 150 nM of the indicated siRNA using the HiPerfect transfection 
reagent (Qiagen) and following the manufacture’s protocol. Cells were stimulated to 
undergo necrosis at 48 and 72 hours post-transfection with 10ng/ml recombinant human 
TNFα for 6-14 hours. For the initial screen, cell viability was determined with CellTiter 
96® AQueous One Solution Cell Proliferation Assay (Promega) as per manufacturers 
instructions.  For the validation of positive hits yielded from the initial screen, cells were 
stained with 10ug/ml propidium iodide (PI) and analyzed via flow cytometry.  Any 
siRNA oligo that resulted in an increase in the percentage of PI negative cells after 
stimulated to undergo TNFα-induced necrosis passed this round of validation. 
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CHAPTER III: Characterization of the requirement of CYLD in 
programmed necrosis 
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Introduction: 
Cylindromatosis (CYLD) is an ubiquitin specific protease that is named after an 
inherited autosomal dominant disease caused by mutations resulting in truncations that 
abolish its enzymatic activity (Bignell et al., 2000).  CYLD is a bona fide tumor 
suppressor, and it is clear that its tumor suppressive function requires a functional 
enzymatic domain.  It is well documented that CYLD is involved in a diverse set of 
cellular signaling pathways downstream of many receptors and stimuli regulating cell 
survival and division.  Its functional involvement in these pathways is imparted by its 
ability to regulate the ubiquitination status and functionality of various signaling proteins 
that participate in these pathways.  More specifically, CYLD is a negative regulator of 
both the canonical and non-canonical NFκB pathways.  Therefore it regulates cell 
survival, inflammation, and cell cycle progression (Brummelkamp et al., 2003; 
Kovalenko et al., 2003; Trompouki et al., 2003; Massoumi et al., 2003).  
The most compelling evidence accounting for the tumor suppressive function of 
CYLD is its ability to negatively regulate the non-canonical NFκB pathway in 
keratinocytes.  When keratinocytes are exposed to UV or the chemical mutagen 12-O-
tetradecanoylphorbol-13 acetate (TPA), CYLD translocates to the perinuclear region 
from the cytoplasm.  In this subcellular location, CYLD deubiquitinates Bcl-3, which 
prevents its nuclear translocation and activation of cyclin D1 transcription and 
concomitant cell cycle progression.  Bcl-3 functions as a co-activator of the NFκB family 
members p50 and p52.  In fact, p50 and p52 only contain a DNA binding domain so 
when they homodimerize they mediate transcriptional silencing.  However, when these 
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proteins heterodimerize with Bcl-3 they are endowed with the ability to mediate 
transcriptional activation.  This is due to the fact that Bcl-3 provides the necessary 
transactivation domain which p50 and p52 lack.  The importance of this CYLD-mediated 
signaling event is highlighted by the fact that CYLD knock-out mice are more prone to 
developing skin tumors akin to patients with cylindromatosis (Massoumi et al., 2006).  
The tumor suppressive role of CYLD in cancer extends beyond the skin.  CYLD 
expression levels are reduced in a myriad of cancer types such as multiple myeloma, lung 
cancer, T cell acute lymphoblastic leukemia (T-ALL), hepatocellular carcinoma, and 
colon carcinoma (Annunziata et al., 2007; Espinosa et al., 2010; Hellerbrand et al. 2007; 
Keats et al. 2007; Zong et al., 2007).  The mechanism behind reduced CYLD expression 
in T-ALL is Notch-induced Hes1 expression.  Hes1 transcriptionally silences CYLD 
resulting in sustained NFκB activation (Espinosa et al., 2010).  As with skin cancer, the 
broad tumor suppressive role of CYLD is attributed to negative regulation of NFκB.  By 
negatively regulating NFκB, CYLD controls the expression level of anti-apoptotic 
proteins and thereby indirectly influences cell death (Brummelkamp et al., 2003).  
However, the data from our lab and others indicates that CYLD has a direct role in 
promoting death receptor induced cell death (Fujikura et al., 2012; O’Donnell et al., 
2011; Wang et al., 2008).  It is reasonable to postulate that the tumor suppressive function 
of CYLD in any of the number of types of cancer it’s implicated in, is not limited to 
negative regulation of NFκB.  The tumor suppressive function of CYLD may in part be 
due to its role in directly promoting death receptor mediated cell death. 
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The direct role of CYLD in promoting cell death is a more recent advancement in 
the understanding of how it influences cell fate.  CYLD is involved in both death receptor 
induced apoptosis and necrosis signaling pathways (Fujikura et al., 2012; O’Donnell et 
al., 2011). As discussed in the previous chapter, our group independently discovered 
CYLD as a regulator of necrosis via screening a human cancer gene siRNA library.  
Another group also recently identified CYLD through screening a mouse genome wide 
siRNA library (Hitomi et al., 2008).  As for its apoptotic function, one report shows that 
siRNA targeting CYLD confers protection from TNFα/SMAC mimetic induced 
apoptosis in a human pancreatic carcinoma cell line PANC-1.  In addition to CYLD 
knock-down conferring protection from apoptosis, it also caused impaired RIP1 
recruitment to Caspase-8.  The influence of CYLD on this molecular event was used to 
describe its pro-apoptotic function (Wang et al., 2008).  Consistently, another group also 
demonstrated that CYLD mediates Caspase-8 activation.  Overexpression of CYLD 
resulted in an enhancement of TNFα driven Caspase-8 activation in HeLa cells.  
Additionally, CYLD knock-down resulted in an impairment in TNFα driven Caspase-8 
activation.  The pro-apoptotic function of CYLD was attributed to its role in promoting 
the formation of the apoptotic DISC.  This study also demonstrated that CYLD was 
required for TNFα/SMAC mimetic driven Caspase-8 activation (Fujikura et al., 2012).   
The functional requirement for CYLD in apoptosis is at odds with another recent 
report, which showed that CYLD is a target of Caspase-8.  In this study, CYLD knock-
out MEFs ectopically expressing a Caspase-8 cleavage resistant CYLD underwent 
necrosis in the absence of Caspase-8 inhibition.  This group therefore linked Caspase-8 
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mediated suppression of necrosis with its ability to target CYLD for cleavage.  Cleavage 
of CYLD results in the proteasome mediated degradation of the C-terminal fragment 
containing the domain responsible for its enzymatic activity (O’Donnell et al., 2011).  
One potential model that is consistent with the available data is that CYLD drives 
Caspase-8 activation and then Caspase-8 activation cleaves and inactivates CYLD in 
order to prevent necrosis.  The timing of CYLD inactivation suggests that the pro-
necrotic function of CYLD is post-necrosome formation, which does not agree with the 
current model.  This concept will be discussed at length in the discussion section.  
In this chapter we sought to further characterize the functional role of CYLD in 
programmed necrosis.  A variety of different cell systems were used in order to 
thoroughly interrogate the pro-death function of CYLD.  We show that CYLD is 
involved in both TNFα-driven apoptosis and necrosis.  However, CYLD is not essential 
for both forms of cell death as indicated by a substantial amount of residual cell death 
that occurs in CYLD knock-out MEFs.  The residual necrosis is RIP1 kinase dependent, 
which was previously defined as a pro-necrotic enzymatic activity as it promotes 
necrosome formation (Cho et al., 2009; Degterev et al., 2005; He et al., 2009).  The 
requirement for RIP1 kinase activity therefore implies that the residual necrosis in the 
absence of CYLD still requires signal transduction through the necrosome.  Since the 
current model suggests CYLD is an essential upstream regulator of necrosome formation, 
our data provides rationale for reevaluating the molecular mechanism of CYLD during 
necrosis.  
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Results 
CYLD promotes but is not essential for TNFα-induced programmed necrosis 
Assembly of the RIP1-RIP3 “necrosome” is a key event in programmed necrosis (Cho et 
al., 2003).  The current model predicts that RIP1 in the TNFR-1 complex has to be de-
ubiquitinated before it can engage RIP3 to form the necrosome.  RIP1 is a known 
substrate of CYLD and this molecular event has been implicated as a consequential 
attribute of the necrosis signaling pathway (O’Donnell et al., 2011).  In order to further 
validate the screen results, transfection of two different CYLD targeting siRNA oligos 
were tested for their ability to confer protection from TNFα-induced programmed 
necrosis in FADD-deficient Jurkat cells (Fig. 3.1A).  Contrary to the expectation that 
CYLD is an essential member of the necrosis pathway (Vanlangenakker et al., 2011), we 
consistently observed weaker protection by siRNA against CYLD compared with 
siRNAs against RIP1 or RIP3 (Fig. 3.1A).  Knock-down of A20, another deubiquitinase 
that regulates RIP1 ubiquitination resulted in enhanced necrosis (Wertz et al., 2004).  
This is consistent with the notion that CYLD and A20 are not functionally redundant.  
This is also intuitive considering that A20 serves as an ubiquitin editing enzyme by first 
removing K63-linked polyubiquitin chains from RIP1 and then tagging RIP1 with K48-
linked polyubiquitin chains resulting in proteasomal degradation.  Since RIP1 is required 
for TNFα-induced necrosis, A20 should in fact function as a negative regulator through 
facilitating RIP1 degradation.  Our data supports this model, by showing that A20 does 
indeed function as a negative regulator of necrosis.  Similarly, HT-29 cells with stable 
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knock-down (kd) of CYLD (Fig. 3.1B) or L929 cells transfected with siRNA against 
CYLD also exhibited residual TNFα-induced necrosis (Fig. 3.1C-D).  
The residual cell death was not due to insufficient inhibition of CYLD expression, 
since CYLD-/- mouse embryonic fibroblasts (MEFs) also exhibited reduced but residual 
TNFα-induced programmed necrosis compared to CYLD+/+ MEFs (Fig. 3.2A).  CYLD-/- 
MEFs also displayed moderate resistance to apoptosis induced by TNFα and 
cycloheximide (CHX) (Fig. 3.2C-D).  Interestingly, the onset of cell death in CYLD-/- 
MEFs was kinetically impaired.  Although, death still occurred in the absence of CYLD, 
the magnitude of death did not reach levels observed in cells expressing CYLD (Fig. 
3.2B).  This may explain why some studies report CYLD as essential for necrosis 
because they looked at time-points prior to the onset of death in cells with reduced CYLD 
expression. 
 
CYLD is dispensable in other cell death pathways 
We next wanted to determine whether the involvement of CYLD in cell death was 
specific to the TNFR-1 signaling pathway.  To address this question we compared the 
cell death responses of CYLD+/+ and CYLD-/- MEFs sensitized to die via TRAIL, FasL or 
staurosporine (Fig 3.3A-C).  No difference in cell death was observed in CYLD-/- MEFs 
treated with these stimuli, as compared to wild-type MEFs.  This data indicates that 
CYLD specifically functions as a pro-death regulator downstream of TNFR-1 and not 
TRAIL, Fas, or the intrinsic mitochondrial apoptosis pathway.  This does not preclude the 
possibility that CYLD plays a role in cell death triggered by TLRs. 
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MEFs can be sensitized to undergo TNFα-induced necrosis through a variety of 
different treatment regimens.  We were interested in ascertaining whether alternative 
ways of necrosis sensitization would impact the residual necrosis observed in the absence 
of CYLD.  We therefore compared the death responses of CYLD+/+ and CYLD-/- MEFs 
to cells sensitized with either TNFα/zVAD/CHX, or TNFα/zVAD/LBW242.  Cell death 
sensitization by zVAD/LBW242 was of greater magnitude in the presence or absence of 
CYLD than zVAD/CHX (Fig. 3.4A).  Note that the same doses of TNFα were used for 
both types of sensitization.  The reduced requirement for CYLD-mediated necrosis in 
SMAC mimetic treated cells is presumably due to the effect SMAC mimetic has on RIP1 
ubiquitination.  Namely, SMAC mimetic reduces the levels of cIAP1/2, which are the E3 
ligases responsible for ubiquitinating RIP1 within the TNFR-1 complex (Varfolomeev et 
al., 2008).  Therefore, elimination of cIAPs reduces RIP1 ubiquitination and should 
theoretically absolve the requirement of CYLD in TNFα-induced necrosis.  Interestingly, 
the CYLD-independent necrosis is observed predominately in the more potent treatment 
regimens and is much less pronounced in cells just treated with TNFα/zVAD (Fig 3.4B). 
Strikingly, the residual necrosis in CYLD-/- MEFs was completely inhibited by the RIP1 
kinase inhibitor necrostatin-1 (Fig. 3.4C).  Hence, CYLD is not essential for RIP1-
dependent necrosis.  Rather, it plays an auxiliary role to promote efficient TNFα-induced 
programmed necrosis.  
Hydrogen peroxide is another inducer of programmed necrosis.  One report 
demonstrates that hydrogen peroxide triggered necrosis is independent of the 
RIP1/RIP3/MLKL necrosome, but dependent on the mitochondrial phosphatases 
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PGAM5S/L, which are downstream substrates of the necrosome (Xiaodong Wang 2012 
Cell).  Since our data suggests that CYLD is not essential for necrosome formation, as the 
current model predicts, we wanted to see whether CYLD functions downstream of 
hydrogen peroxide induced necrosis, which presumably activates the necrotic machinery 
downstream of the necrosome.  In order to address this question we compared the cell 
death responses of CYLD+/+ and CYLD-/- MEFs to hydrogen peroxide induced necrosis.  
Our data indicates that CYLD is dispensable for hydrogen peroxide induced necrosis 
(Fig. 3.5A).  This reveals that CYLD does not function downstream of ROS production 
during necrosis.  Additionally, we show that CYLD positively regulates ROS production 
as demonstrated by the use of the ROS indicator H2DCFDA.  Consistent with residual 
necrosis in the CYLD-/- MEFs, ROS production is only partially reduced as compared to 
CYLD+/+ MEFs (Fig. 3.5B).  This data supports the notion that CYLD acts upstream of 
ROS production during necrosis.  
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Figure 3.1 Partial protection against TNFα-induced necrosis by CYLD siRNAs. 
(A) CYLD promotes programmed necrosis and A20 negatively regulates it. FADD-
deficient Jurkat cells were transiently transfected with the indicated siRNAs.  Forty-eight 
hours post-transfection, the cells were treated with TNFα to induce necrosis.  Percentage 
cell loss was determined by staining with propidium iodide (PI) and flow cytometry. The 
right panels are Western blots showing the efficiency of gene silencing.  (B) HT-29 cells 
were stably transfected with either non-specific shRNA (control) or CYLD targeting 
shRNA (clones: G11-2 and G11-8).  Cells were treated with TNFα, LBW242 and zVAD-
fmk.  Cell viability was determined by MTS assay (Promega).  The right panels are 
Western blots that validate reduction in protein expression of CYLD in the selected 
clones.  (C-D) L929 cells were transfected with the indicated siRNAs.  Necrosis was 
induced with (C) TNFα or (D) TNFα and zVAD-fmk.  Cell viability was determined by 
MTS assay.  The panel below shows reduction in protein expression of the indicated 
siRNA transfected cells. 
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Figure 3.2 Residual TNFα-induced necrosis and apoptosis in CYLD-/- MEFs.                                    
(A) Wild type (CYLD+/+) and CYLD-/- MEFs were treated with cycloheximide (CHX), 
zVAD-fmk and the indicated doses of TNFα for 12-hours.  Cell loss was determined by 
staining with propidium iodide (PI) and analyzed via flow cytometry. The inset shows the 
absence of CYLD expression in CYLD-/- MEFs.  In (B), cells were treated with 10 ng/ml 
TNFα, CHX and zVAD-fmk and cell death was measured at the indicated time-points 
following treatment. (C) CYLD+/+ and CYLD-/- MEFs were treated with TNFα and CHX 
for 12 hours. Cell death was determined by PI staining and flow cytometry. (D) MEFs 
were treated with 10 ng/ml TNFα and CHX for the indicated times.
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Figure 3.3 CYLD is not involved in other death inducing stimuli in MEFs.  
(A-C) Wild type (CYLD+/+) and CYLD-/- MEFs were treated with (A) TRAIL, (B) FasL 
or (C) staurosporine (STS) for 12 hours.  Cell death was determined by PI exclusion and 
flow cytometry. 
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Figure 3.4 RIP1-dependent necrosis occurs in CYLD-/- MEFs.  
(A-B) Wild type (CYLD+/+) and CYLD-/- MEFs were treated with either cycloheximide 
(CHX) or SMAC mimetic (LBW242) in addition to zVAD-fmk (A) or zVAD-fmk alone 
(B) and the indicated doses of TNFα for 12 or 24 hours respectively.  Cell loss was 
determined by staining with propidium iodide (PI) and analyzed via flow cytometry.    
(C) Nec-1 inhibited TNFα-induced necrosis in CYLD-/- MEFs.    
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Figure 3.5 CYLD impacts TNFα-induced ROS production. 
(A) Wild type (CYLD+/+) and CYLD-/- MEFs were treated with H2O2 for 12 hours. Cell 
death was determined by PI exclusion and flow cytometry. (B) MEFs were treated with 
CHX, zVAD, and TNFα for the indicated time-points.  Cellular reactive oxygen species 
(ROS) were determined by measuring H2DCFDA fluorescence by flow cytometry.  
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Discussion      
Altogether our data demonstrates that CYLD functions as a positive regulator of 
both necrosis and apoptosis downstream of TNFR-1, but residual cell death still proceeds 
in the absence of CYLD.  The current model for the pro-necrotic mechanism of CYLD is 
that it exerts its function upstream of RIP1/RIP3 association, which is a critical molecular 
event for TNFα-induced necrosis (Cho et al. 2009; Vanlangenakker et al., 2011).  Since 
we report that CYLD is not essential for necrosis this weakens the plausibility of the 
current model. Furthermore, the CYLD-independent necrosis is still RIP1 kinase 
dependent. RIP1 kinase activity is essential for RIP1/RIP3 association and TNFα-
induced necrosis; therefore, the residual cell death in the absence of CYLD presumably 
still requires signal transduction through the RIP1/RIP3 necrosome.  The RIP1/RIP3 
necrosome is upstream of ROS production, which is a cell-type specific effector 
mechanism of the necrosis program (Cho et al., 2009).  Consistent with the kill assay 
data, we demonstrate that ROS production during TNFα-induced necrosis is attenuated, 
but not blocked in cells lacking CYLD.  Importantly, hydrogen peroxide induced 
necrosis, which is independent of the RIP1/RIP3 necrosome, was not altered in cells 
lacking CYLD.  This complementary data places the pro-necrotic function of CYLD 
upstream of ROS production. 
The onset of death observed in the CYLD-/- MEFs is kinetically delayed as 
compared to CYLD+/+ MEFs, but the magnitude of cell death remains attenuated even at 
later time-points.  This lends support to the notion that CYLD may regulate both an early 
and late molecular event required for the onset and magnitude of cell death respectively.     
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The functional requirement of CYLD in necrosis appears to be more pronounced 
than apoptosis due to the greater level of protection observed in CYLD-/- MEFs treated to 
undergo necrosis as compared to apoptosis. One possibility is that CYLD regulates more 
than one molecular event during necrosis while only one during apoptosis.  Since CYLD 
drives TNFα-induced Caspase-8 activation, and CYLD is a target of Caspase-8 this 
suggests that the pro-apoptotic function of CYLD is attributed to regulation of a 
molecular event preceding the formation of the apoptotic DISC (Fujikura et al., 2012; 
O’Donnell et al., 2011).  Consistent with this notion, CYLD has been shown to regulate 
apoptotic DISC formation (Wang et al., 2008).  In the next chapter we demonstrate that 
CYLD similarly regulates that kinetics of RIP1/RIP3 association as well as other 
components, which are also found in the apoptotic DISC.  The current understanding of 
the TNFα-induced apoptosis and necrosis pathways is that the two pathways diverge at 
the point of the cytosolic DISC.  All of this information potentially indicates that CYLD 
mediates an early molecular event that is common to both apoptosis and necrosis.  This 
overlapping mechanism would theoretically precede an additional necrosis specific 
signaling event.  In other words, CYLD would mediate a common molecular event 
required for apoptosis and necrosis and would mediate a later molecular event that is 
specific to necrosis.  Through simple addition, the comparison between one CYLD-
mediated molecular event during apoptosis and two CYLD-mediated molecular events 
during necrosis may explain the greater requirement for CYLD in necrosis.  
The regulation of DISC formation is most likely not through regulation of RIP1 
ubiquitination as TNFα/CHX induced necrosis is a RIP1 independent cell death pathway 
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(Lin et al., 2004).  Interestingly, cells deficient of NEMO, are not protected from TNFα-
induced apoptosis upon CYLD knock-down.  NEMO has also been reported to negatively 
regulate both apoptosis and necrosis through preventing DISC formation (O’Donnell et 
al., 2009; O’Donnell et al., 2012).  It has also been demonstrated that NEMO is a target 
of CYLD-mediated de-ubiquitination in overexpression studies (Hutti et al., 2009; 
Kovalenko et al., 2003).  This is potentially an interesting topic of future investigation.  If 
CYLD-mediated NEMO deubiquitination is indeed a common pro-apoptotic and pro-
necrotic molecular event, it would suggest that NEMO ubiquitination, like RIP1 
ubiquitination is inhibitory to the cell death program.  It would be interesting to 
determine whether mutating the NEMO ubiquitin acceptor site would abrogate its ability 
to suppress apoptosis and necrosis.  
In opposition to previous reports, our data demonstrates that necrosis can proceed 
independently of CYLD, albeit with a reduced level. A potential explanation for previous 
reports, which demonstrated that CYLD is essential for necrosis, may be that they only 
looked at early time-points prior to the onset of cell death in CYLD knock-down cells. 
Another possibility is that the CYLD-/- MEFs used in our study express a partially 
compensatory deubiquitinase that is not expressed in the cell-lines used by other groups.  
However, we also observe consistently weaker protection from necrosis conferred by 
siRNA knock-down of CYLD as compared to RIP3, in multiple different cell types.  
Irrespective of the potential explanation for these discrepant results, this is the first report 
demonstrating that CYLD is not essential for necrosis.  This non-essential function does 
not coincide with the current model.   
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It is also apparent that CYLD-independent necrosis is less prominent when cells 
are treated with just TNFα/zVAD.  The magnitude of cell death is also less pronounced 
in the CYLD+/+ MEFs.  This may be attributed to the fact that specific NFκB target genes 
might function in actively suppressing necrosis, and are upregulated during TNFα/zVAD 
treatment.  Indeed cFLIP has an anti-necrotic function when heterodimerized with 
Caspase-8 (Oberst et al., 2011). In this particular case Caspase-8 is inactivated which 
precludes the possibility that cFLIP is the anti-necrotic factor responsible for the reduced 
magnitude of TNFα-induced necrosis in MEFs treated with just TNFα/zVAD.  A more 
probable anti-necrotic factor is cIAP2, which has already been demonstrated to 
negatively regulate TNFα-induced cell death possibly through RIP1 ubiquitination 
(Varfolomeev et al., 2008).     
Nevertheless, this theoretical anti-necrotic protein appears to exert a more potent 
inhibitory effect on CYLD-independent necrosis.  Given that RIP1 kinase activity is 
required for driving necrosome formation and is still required for CYLD-independent 
necrosis, it is possible that the reason for the greater inhibitory effect may be due to the 
fact that it impairs RIP1 kinase activity (Cho et al., 2009).  In other words, MEFs devoid 
of CYLD possibly have impaired RIP1 kinase activation and when they are treated with 
just TNFα/zVAD a theoretical anti-necrotic factor further attenuates RIP1 kinase activity 
leading to a more dramatic impairment of CYLD-independent necrosis. Conversely, in 
cells replete with CYLD, RIP1 kinase activation might be higher than CYLD deficient 
MEFs, and therefore the upregulation of the theoretical anti-necrotic factor has less of a 
dramatic effect on necrosis. Future studies should try to identify this anti-necrotic protein.  
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Materials and Methods  
 
Tissue culture 
MEFs and L929 cells were grown in DMEM high sucrose medium supplemented with 
10% FCS, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin.  HT-29 
and Jurkat cells were grown in McCoy’s 5A medium and RPMI1640 media, respectively, 
supplemented with 10% FCS, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml 
streptomycin.  Stable clones of HT-29 cells were generated by transfection using 
lipofectamine 2000 (Invitrogen) of CYLD-specific and scrambled shRNAs from 
Thermoscientific/Open Biosystems.  Clones were selected by puromycin selection and 
checked for GFP expression via flow cytometry. GFP+ clones were tested for reduction of 
CYLD protein expression and used for subsequent experiments. 
Reagents used 
Antibodies used in the study were from BD Pharmingen (A20, RIP1, and β-actin), ProSci 
(RIP3), Santa Cruz Biotechnology (TRAF2 and CYLD) and Invitrogen (CYLD).  
Antibody against human RIP3 has been described before (Cho et al., 2009).  Necrostatin-
1 and zVAD-fmk were obtained from Enzo Life Sciences. H2DCFDA was obtained from 
Molecular Probes.  Recombinant human and mouse TNF were obtained from 
Biosource/Invitrogen.  The Smac mimetic LBW242 was a kind gift of D. Porter 
(Novartis).  Small interference RNAs used in the study are: human A20 (5’-
AGUACAAUAGGAAGGCUAAAUAAdTdA-3’, 5’-
GCAUGAGUACAAGAAAUGGCAGGAA-3’), human CYLD (5’-
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CUUAUUUUUAGCAAAGGUUCUACCCUU-3’, 5’-
UUGGUUUAUUAUGACUGGAUGAACCUU-3’), mouse CYLD (5’-
GGUUUAGAGAUAAUGAUUGGAAAGA-3’, 5’-
AGUGUUGAAAGUACAAUUCUCCUGC-3’, 5’-
UGAGUAGAUAGCAGUAAAGUCCUCC-3’), human RIP1 (5’-
UGCAGUCUCUUCAACUUGAdTdT-3’, 5’-
UGCUCUUCAUUAUUCAGUUUGCUCCAC-3’), mouse RIP3 (5’-
AAGAUUAACCAUAGCCUUCACCUCCCA-3’, 5’-
CCUUCGUUUCCUUUCCUCCUCUCUGUU-3’), human RIP3 (5’-
UAACUUGACGCACGACAUCAGGCUGGA-3’, 5’-
GCAGUUGUAUAUGUUAACGAGCGGUCG-3’), human TRAF2 (5’-
GGACCUGGCGAUGGCUGACdTdT), human TR4 (5’-
CCGGAGCUUCCCUCAUUUAdTdT-3’).  Mouse RIP1 siRNA sequences have been 
described (Cho et al., 2009). 
Transfection of DNA Plasmids and siRNA 
Jurkat cells were transfected with 150 nM of the indicated siRNA. For L929 cells, 20 nM 
siRNA was used per transfection.  All siRNA transfections were performed using the 
HiPerfect transfection reagent (Qiagen) as per manufacturer’s protocols.  Forty-eight 
hours later, cells were stimulated with TNF to induce necrosis.  
Cell death assays 
Wild type and CYLD-/- MEFs (kind gift from S.C. Sun (Reiley et al., 2006) were treated 
with 0.5 – 1 µg/ml cycloheximide (CHX) and 20 µM zVAD-fmk where indicated for 1 
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hour prior to stimulation with the indicated amounts of recombinant mouse TNFα 
(rmTNF), TRAIL, FasL, staurosporine, or H2O2.  In some instances, 5 – 10 µM the Smac 
mimetic LBW242 was used.  For FADD and caspase-8 deficient TNFR2+ Jurkat Cells 
[5],  programmed nNecrosis was induced by addition of the indicated amounts of 
recombinant human TNF (rhTNF).  HT-29 cells were treated with 5-10 µM LBW242 and 
20 µM zVAD-fmk for 1 hour prior to stimulation with 10 – 100 ng/ml rhTNF.  Cell death 
was determined by flow cytometry with propidium iodide staining or by CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (Promega). 
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PREFACE TO CHAPTER IV 
 
 
This chapter contains material from the following manuscript that is under review 
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CHAPTER IV: The pro-necrotic mechanism of CYLD 
100
Introduction 
 
 As revealed from the research of our lab and other groups, the tumor suppressor 
CYLD has a pro-necrotic function.  A model has been established that accounts for the 
molecular mechanism of CYLD in necrosis.  It is believed that CYLD regulates RIP1 
ubiquitination within the TNFR1 complex and thus promotes its transition from the pro-
survival membrane associated complex to the necrosome (Vandenabeele et al., 2010).  
This model was based on pieces of indirect evidence provided from other reports. There 
was already some evidence suggesting that RIP1 is a target of CYLD in certain biological 
contexts.  Namely, during spermatogenesis CYLD was shown to regulate RIP1 
ubiquitination and apoptosis; however, the trigger of the signaling pathway was not 
elucidated.  Moreover, it was demonstrated that CYLD is critical for mediating the early 
wave of spermatocyte cell death, which is important for productive spermatogenesis.  
This accounts for the fact that CYLD knock-out mice are sterile.  The pro-apoptotic 
function was credited to its effects on the negative regulation of NFκB. In other words, it 
was suggested that CYLD promoted death by inhibiting a cell survival pathway rather 
than direct involvement in a cell death signaling pathway.  The latter possibility was not 
formally tested.  In further support of RIP1 being a target of CYLD, it was demonstrated 
that CYLD regulates RIP1 ubiquitination in overexpression experiments (Wright et al., 
2007).   
CYLD was also demonstrated to mediate deubiquitination of other components of 
the TNF-R1 signaling complex.  This provided additional indirect evidence supporting 
the notion that CYLD targets RIP1 for deubiquitination within the TNFR1 complex based 
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on the location.  However, all of this data was based on overexpression studies rather 
than direct evidence for CYLD-mediated regulation within the TNFR-1 complex.  In fact, 
these reports did not demonstrate that CYLD actually gets recruited to the TNFR-1 
associated complex (Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et 
al., 2003).     
A number of reports establish that RIP1 ubiquitination promotes its pro-survival 
function through both NFκB-dependent and NFκB-independent pathways.  First, RIP1 
ubiquitination is required for the recruitment of the regulatory subunit of the IKK 
complex NEMO to the TNF-R1 complex.  The IKK complex phosphorylates IκBα, 
which targets it for K48-linked ubiquitination and subsequent proteasomal degradation. 
This allows for NFκB nuclear translocation, activation of gene transcription, and 
subsequent expression of anti-apoptotic proteins (Ea et al., 2006). In addition to 
promoting the recruitment of NEMO to the TNF-R1 complex, RIP1 ubiquitination was 
shown to prevent RIP1 transition to the cytosolic DISC.  Specifically, mutation of the 
RIP1 ubiquitin acceptor site at lysine residue 377 results in enhanced formation of the 
TNFα driven DISC (O’Donnell et al., 2007). NEMO also exerts an anti-apoptotic and 
anti-necrotic function independent of its function to promote NFκB activation.  This 
function is contingent upon binding to ubiquitinated RIP1 (Legarda-Addison et al., 2009; 
O’Donnell et al., 2012).  
Other reports then linked CYLD-mediated RIP1 deubiquitination to enhanced 
DISC formation.  During SMAC mimetic sensitized TNFα-induced apoptosis, CYLD 
promotes DISC formation as siRNA targeting CYLD impaired DISC formation.  
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However, this report did not demonstrate that CYLD in fact regulates RIP1 ubiquitination 
during TNF signaling, and naturally did not show where this potential deubiquitination 
step takes place.  Alternatively, another report has demonstrated a laddering pattern of 
RIP1 and RIP3 in the necrosome suggesting their ubiquitination.  This indicates that 
ubiquitination of the components of the necrosome may somehow play a role in its 
functionality (Cho et al., 2009).  This also suggests that CYLD may have a function in 
regulating ubiquitination of components of the necrosome, and thereby promote necrosis. 
In addition to RIP1 ubiquitination negatively regulating the formation of the 
apoptotic DISC and the necrosome, RIP1 kinase activity positively regulates necrosome 
formation.  Pre-treatment of cells with the RIP1 kinase inhibitor Nec-1 is able to block 
necrosome formation (Cho et al., 2009; He et al., 2009).  A few reports provide clues that 
indicate the potential mechanism of RIP1 kinase activation; however a comprehensive 
model is still at an inchoate stage.  First, overexpression studies of RIP1 in 293T cells 
revealed many putative RIP1 phosphorylation sites. Some of these phosphorylation 
events were due to auto-phosphorylation.  The auto-phosphorylation site at serine 161 
was shown to be important for RIP1 kinase activation.  Blocking the phosphorylation of 
this site by substitution with an alanine resulted in a partial defect in necrosis.  
Additionally, forced dimerization of wild-type but not kinase inactive RIP1 was able to 
induce necrosis in the absence of TNFα treatment.  This suggests that RIP1 derived from 
the TNFR-1 receptor complex becomes kinase active through regulation of its oligomeric 
state.  It is conceivable that oligomerization is an important step for auto-phosphorylation 
and subsequent activation of RIP1 kinase activity (Degterev et al., 2008).  Clearly, more 
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work must be done to define the RIP1 phosphorylation events during necrosis, their 
functionality, and their influence on other molecular events such as recruitment of 
components of the necrosome and regulation of RIP1 kinase activity.  In addition to 
necrosis, RIP1 kinase activity is also required for SMAC mimetic sensitized TNFα-
induced apoptosis (Degterev et al., 2005).     
RIP3 kinase activity is also required for necrosis.  Nec-1 can block an auto-
phosphorylation event of RIP3 at Serine 199.  This supports the notion that necrosome 
formation activates RIP3 kinase activity.  The functional requirement of that particular 
auto-phosphorylation event for necrosis was not ascertained (He et al., 2009).  However, 
it was recently discovered that RIP3 can be phosphorylated at Serine 227 during necrosis, 
and it is required for recruitment of another component of the necrosome, MLK-L.  This 
molecular event is consequential for necrosis, as a S227A mutant RIP3 is unable to 
promote necrosis (Sun et al., 2012). Furthermore, RIP1 and RIP3 were also demonstrated 
to form amyloid fibrils during necrosis.  These amyloid fibrils require intact RIP 
homotypic interaction motifs (RHIM) of RIP1 and RIP3.  Thioflavin T (ThT) and Congo 
red (CR), which bind to β-amyloid were able to partially inhibit TNFα-induced necrosis.  
This suggests that the amyloid fibrils are functionally relevant for transducing the pro-
necrotic signal.  It was demonstrated that the phosphorylated forms of RIP1 and RIP3 
were enriched in an NP-40 insoluble SDS-soluble fraction, which is suggestive of the 
amyloid fraction (Li et al, 2012).  
 In the previous chapter, evidence was presented that supported the notion that the 
existing model of CYLD-mediated necrosis is not correct.  This chapter covers work that 
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directly addresses the pro-necrotic mechanism of CYLD.  In this section it is 
demonstrated that CYLD does not regulate the ubiquitination status of RIP1 within the 
TNF-R1 complex like the current model suggests. Instead, CYLD regulates the 
ubiquitination status of RIP1 within the NP-40 insoluble necrosome.  It is also shown that 
RIP1 is in fact the primary target of CYLD in the context of TNFα-induced necrosis.    
Consistent with this finding, CYLD appears to regulate the kinetics of necrosome 
formation, but at later time-points the complex forms in the absence of CYLD.  As 
demonstrated in the previous chapter, CYLD is not absolutely essential for TNFα-
induced necrosis as CYLD knock-out MEFs have residual cell death.  Interestingly, 
necrosome formation catches up to levels observed in wild-type MEFs even though the 
level of cell death does not.  This is most likely attributed to impaired RIP1 kinase 
activation, as RIP1 kinase dependent RIP3 phopsphorylation is impaired in cells with 
CYLD knocked down.   
 
Results 
CYLD does not control RIP1 ubiquitination within the TNFR-1 complex 
Given the current model for CYLD-mediated necrosis, we set out to determine 
whether this was in fact accurate.  As established in the previous chapter, CYLD is not 
absolutely essential for necrosis.  This is not consistent with the model that CYLD is 
upstream of RIP1.  If CYLD was required for RIP1 transition from the TNFR-1 complex 
to the necrosome, CYLD should be essential for necrosis because RIP1/RIP3 association 
is an essential molecular event.  Nevertheless, we decided to determine whether we could 
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detect CYLD recruitment to the TNFR1 complex to gather evidence suggesting where it 
may exert its pro-necrotic function.  As previously reported, RIP1 recruited to the TNFR-
1 complex was heavily ubiquitinated (Fig. 4.1A).  In agreement with the current model, 
CYLD was also recruited to the TNFR-1 complex in a ligand-dependent manner (Fig. 
4.1A, compare lane 1, 3 and 5).  However, CYLD did not regulate the ubiquitination 
status of RIP1 within the TNFR-1 complex.  Hyper-ubiquitination of RIP1 within the 
TNFR1 complex was not observed in CYLD-/- MEFs (Fig. 4.1B, compare lanes 3-6).  
Polyubiquitinated RIP1 within the TNFR-1 signaling complex is important for assembly 
and activation of the IKK complex (Ea et al., 2006).  Consistent with the normal RIP1 
ubiquitination status, IκBα phosphorylation and degradation was normal in CYLD-/- 
MEFs (Fig. 4.1C).  From the previous chapter we concluded that CYLD and A20 are not 
functionally redundant RIP1 deubiquitinases.  Therefore the normal TNFR-1 associated 
RIP1 ubiquitination in CYLD-/- MEFs was not due to the compensatory effect of another 
RIP1 deubiquitinase A20, which we also detected within the TNFR-1 complex (Fig. 
4.1A, lane 5). 
 
Deubiquitination of RIP1 by CYLD facilitates programmed necrosis  
Recently, certain de-ubiquitinases, such as A20, have been shown to regulate cell 
signaling independent of their enzymatic activity (Skaug et al, 2011).  Because RIP1 
ubiquitination at the TNFR-1 complex was normal in CYLD-/- cells, we asked if CYLD 
similarly regulates programmed necrosis independent of its deubiquitinase activity.  We 
found that expression of GFP-tagged wild type CYLD, but not the deubiquitinase 
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inactive mutant C601S, enhanced TNFα-induced programmed necrosis in CYLD-/- MEFs 
(Fig. 4.2B).  Truncation mutants lacking the carboxyl terminal Ubiquitin Specific 
Protease (USP) domain also failed to restore programmed necrosis in CYLD-/- MEFs.  In 
contrast, the first and second CAP-Glycine (CG1 and CG2) domains were dispensable for 
programmed necrosis (Fig. 4.2A and C).  A previous report demonstrated that these 
domains were required for the function of CYLD in negatively regulating histone 
deacetylase-6 (HDAC6) enzymatic activity during TPA stimulation. Therefore, CYLD 
promotes an increase in acetylated tubulin in the perinuclear region, which enhances 
CYLD interaction with Bcl-3.  CYLD can then block cell cycle progression through 
regulating the ubiquitination status of Bcl-3 (Wickstrom et al, 2010).  The dispensability 
of these domains for necrosis demonstrates the differential requirement of CYLD 
domains for mediating its function in different signaling pathways.  It also reduces the 
likelihood that the pro-necrotic function of CYLD is due to an indirect effect in its 
function as a cell cycle regulator.  The third CAP-Glycine domain is required for the pro-
necrotic function of CYLD as the USP alone was not sufficient for enhancing death in the 
CYLD-/- MEFs.  Altogether, both CG3 and the deubiquitinase activity of CYLD are 
required to promote TNFα-induced programmed necrosis.   
Since the deubiquitinase function of CYLD is required for programmed necrosis, 
and yet RIP1 ubiquitination within the TNFR-1 complex was normal in CYLD-/- cells, we 
sought to determine if RIP1 is indeed the major substrate of CYLD during programmed 
necrosis.  In order to address this question we took advantage of knowledge regarding a 
previously characterized TNFα-dependent RIP1 ubiquitination site.  We reconstituted a 
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RIP1 deficient Jurkat cell-line with a RIP1 ubiquitin acceptor site mutant K377R.  
Importantly, we demonstrated that the RIP1 mutant K377R, which does not undergo 
TNFα driven RIP1 ubiquitination (Ea et al., 2006; Li et al., 2006), was not ubiquitinated 
upon TNFα stimulation in the TNFR-1 complex (Fig. 4.3A).  We posited that if the 
primary target of CYLD during TNFα-driven necrosis is indeed ubiquitinated RIP1, then 
the RIP1 K377R mutant cell-line should not be protected from CYLD knock-down.  
Consistently, unlike cells expressing wild type RIP1 (Fig. 3.1A), cells that express the 
K377R mutant were insensitive to CYLD siRNA mediated protection against TNFα-
induced necrosis.  In contrast, RIP3 siRNA reduced programmed necrosis in these cells 
(Fig. 4.3B).  Hence, we conclude that RIP1 is the major substrate of CYLD in 
programmed necrosis. 
 
CYLD regulates RIP1 ubiquitination in a spatially and temporally distinct compartment 
Since RIP1 is the major substrate of CYLD and yet RIP1 ubiquitination within the 
TNFR-1 signaling complex was not affected in CYLD-/- cells, we assessed the possibility 
that CYLD might regulate RIP1 ubiquitination in a different signaling compartment.  In 
order to analyze the total level of RIP1 ubiquitination without other contaminating 
factors, we boiled the cell extracts in 1% SDS prior to RIP1 immunoprecipitation.  Using 
this method, we detected RIP1 polyubiquitination in a TNFα-dependent manner in both 
wild type and CYLD-/- cells hours after the dissolution of the TNFR-1 signaling complex.  
In contrast to RIP1 recruited to the TNFR-1 signaling complex, RIP1 isolated from 
CYLD-/- cells using this method exhibited higher levels of ubiquitination than wild type 
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cells at all time points examined (Fig. 4.4A).  Moreover, the length of the 
polyubiquitinated species was longer in the CYLD-/- cells compared with that in wild type 
cells.  Similar results were obtained in HT29 cells with stable expression of shRNA 
against CYLD (Fig. 4.4B).  Hence, RIP1 was indeed hyper-ubiquitinated in CYLD-/- 
cells.   
Ubiquitin-like modifications of RIP1 and RIP3 were previously detected in the 
late-forming cytosolic necrosome (Cho et al., 2009).  This suggests that CYLD might 
regulate RIP1 ubiquitination within the necrosome instead of the TNFR-1 complex.  To 
confirm that RIP1 was ubiquitinated in the necrosome, we performed sequential 
immunoprecipitations, first with RIP3, followed by immunoprecipitations with different 
ubiquitin antibodies.  We found that RIP1 within the necrosome was indeed modified by 
ubiquitination via K48 as well as K63 linkages (Fig. 4.4C).  The RIP1-RIP3 necrosome is 
an amyloid-like structure that is enriched in the NP-40 insoluble fraction (Li et al, 2012).  
To determine the role of CYLD in necrosome ubiquitination, we performed differential 
detergent lysis, first with NP-40, followed by extraction of the NP-40 insoluble material 
with SDS.  Despite equal pull-down of RIP1 in wild type and CYLD-/- cells, we found 
that RIP1 in the NP40-insoluble fraction, but not the NP-40 soluble fractions, was hyper-
ubiquitinated in CYLD-/- cells compared with wild type cells (Fig. 4.5D, compare lanes 
3-4 and 5-6).  These results suggest that CYLD regulates RIP1 ubiquitination in the 
necrosome. 
 
CYLD controls the kinetics of necrosome formation and activation 
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We next examined the consequence of this hyper-ubiquitinated form of RIP1 in 
necrosis signaling.  Surprisingly, we found that the assembly of the RIP1-RIP3 
necrosome was delayed, but not abolished in the CYLD-/- MEFs (Fig. 4.5A, lanes 5-8).  
Similar observations were made in CYLD-kd HT-29 cells (Fig. 4.5B-C).  Consistent with 
the requirement of CYLD for TNFα-induced apoptosis (Fig. 3.1), recruitment of RIP1 
and FADD to caspase-8 was similarly delayed in CYLD-kd HT29 cells (Fig. 4.6A).  
Additionally, RIP1 recruitment to FADD was delayed, but at later time-points caught up 
in CYLD-kd HT29 cells.  The recruitment of RIP1 to FADD was contingent upon RIP1 
kinase activity in both the control shRNA HT29 cells and CYLD-kd cells (Fig. 4.6B 
compare lanes 6 and 12 top panel).  This supports the findings presented in the previous 
chapter that the residual cell death in the CYLD-/-  MEFs is RIP1 kinase dependent.  
Altogether, CYLD promotes, but is not essential for assembly of the RIP1-RIP3 
necrosome and other components of the necrosome. 
Sequential detergent extraction with NP-40 and SDS revealed that RIP1 and 
especially RIP3 accumulated in this fraction in a TNFα-dependent manner (Fig. 4.7A, 
bottom panels).  Both RIP1 and RIP3 are phosphorylated as they become activated within 
the necrosome (Cho et al. 2009; He et al., 2009).  These phosphorylated species are 
enriched in the NP-40 insoluble compartment (Li et al., 2012).  In agreement with our 
previous observation, phospho-RIP1 and phospho-RIP3 as indicated by mobility shift 
were detected in the NP-40 insoluble SDS fraction as early as 2 hours post stimulation in 
wild type cells (Fig. 4.7A, lane 3).  In contrast, appearance of phospho-RIP1 and 
phospho-RIP3 was not apparent until 4 hours post-stimulation (Fig. 4.7A, lane 6).  The 
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delayed phosphorylation of RIP1 and especially RIP3 was more apparent in CYLD-kd 
HT29 cells (Fig. 4.7B).  Sequential detergent extraction in HT29 cells provided further 
support for enrichment of phospho-RIP1 and phospho-RIP3 in the SDS fraction, as they 
were not detectable in the NP-40 soluble fraction.  Furthermore, the kinetic delay in the 
phosphorylated species was pronounced in the CYLD-kd cell extracts (Fig. 4.7C).    
The preferential phosphorylation in the SDS fraction suggests that the kinase 
activity of the necrosome was activated in this compartment.  Because SDS inhibited 
RIP1 and RIP3 kinase activity (unpublished observation), we modified our protocol to 
determine the kinase activity of the necrosome in the NP-40 insoluble compartment (Fig. 
4.8A).  We used differential centrifugation to isolate RIP1 complexes from NP-40 
insoluble pellets.  We confirmed that similar to the differential detergent lysis with NP-40 
and SDS (Fig. 4.7A), the insoluble pellet fractions obtained with this method exhibited 
ligand-dependent accumulation of the necrosome components RIP1, RIP3 and CYLD 
(Fig. 4.8B).  Importantly, TNFα-induced and RIP1-associated kinase activity was 
detected in the insoluble P10 and P25 fractions (Fig. 4.8C, top panel, lanes 5-8 and 9-12).  
In contrast, despite the higher background activity, no TNFα-induced kinase activity was 
observed in the soluble S25 fractions (Fig. 4.8C, top panel, lanes 1-4).  The induction of 
kinase activity correlated with recruitment of RIP3 to the complex (Fig. 4.8C, middle 
panel).  Consistent with our previous report, this activity was transient and disappeared 
by 6 hours post-stimulation (Cho et al., 2009).  Moreover, RIP1-associated ubiquitination 
was strongly induced in the P10 and P25 compartments concomitant to recruitment of 
CYLD to the RIP1 complex (Fig. 4.8C, bottom panels and Fig. 4.8D).  In contrast, 
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ubiquitination was not induced in the S25 fractions.  These results indicate that the 
assembly and activation of the necrosome is regulated in the NP-40 insoluble 
compartment. 
 
Ubiquitination hinders RIP1 autophosphorylation 
  In addition to induction of kinase activity, we observed that RIP1-associated 
ubiquitination was strongly induced in the NP-40 insoluble compartments (Fig. 4.8C).  
Paradoxically, the increase in RIP1-associated ubiquitination correlated with the 
recruitment of CYLD to RIP1 (Fig. 4.8C, bottom panels).  Inducible ubiquitination was 
not detected in the soluble fractions.  The E3 ligases cIAP1 and cIAP2 promote RIP1 
ubiquitination in the TNFR-1 complex (Bertrand et al., 2008; Mahoney et al., 2008; 
Vince et al., 2007).  Even when Smac mimetic (SM) was used to eliminate cIAP1 and 
cIAP2 expression, TNFα stimulated the re-expression of cIAP2 (Fig. 4.9A).  This is 
consistent with the fact that cIAP2 is a NF-κB target gene and that Smac mimetic 
mediated degradation of cIAP2 requires cIAP1 (Darding et al., 2011).  In support of this 
model, binding between RIP1, cIAP1, cIAP2 and TRAF2 was detected in a ligand-
dependent manner late during necrosis (Fig. 4.9B).  These results suggest that the E3 
ligases responsible for RIP1 ubiquitination in the TNFR-1 complex may be responsible 
for ubiquitination of components of the necrosome.  Over-expression of RIP1 in 293T 
cells revealed that polyubiquitinated RIP1 was not an effective substrate in RIP1 auto-
phosphorylation assays (Fig. 9C).  Hence, we provide evidence that RIP1 
polyubiquitination within the necrosome sterically hinders RIP1 kinase activation.   
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Phosphorylated CYLD associates with RIP1 during necrosis 
 Up to this point the work in this chapter has revealed that CYLD regulates the 
ubiquitination status of RIP1 within the necrosome, and therefore the focus has been on 
CYLD-mediated regulation of RIP1.  We were interested in the possibility that the 
converse was true, whether RIP1 mediates regulation of CYLD.  Interestingly, in addition 
to constitutive interaction between CYLD and RIP1 in MEFs, stimulus dependent 
association between a slower migrating CYLD and RIP1 was observed.  This slower 
migrating CYLD was validated as phosphorylated CYLD, as it could be collapsed to 
normal migration by treatment with phosphatase (Fig4.10, upper panel, compare lanes 3 
and 4).  This phosphorylation of CYLD was dependent on RIP1 kinase activity because 
Nec-1 abolished the slower migrating CYLD (Fig4.10 upper panel, compare lanes 3 and 
5).   
We next wanted to determine whether this CYLD phosphorylation event was at 
Serine 418, a previously identified site that negatively regulates CYLD-mediated 
deubiquitination of TRAF2 and NEMO in overexpression studies.  This phosphorylation 
event can be mediated by the kinase IKKε, which is oncogenic.  Inactivation of CYLD 
deubiquitination of its targets by IKKε is one mechanism in which it promotes 
transformation.  Inactivation of CYLD results in hyperactivation of NFκB (Hutti et al., 
2009).  Similarly, during TNFα stimulation a cluster of serine residues are 
phosphorylated, one of which being Serine 418.  These phosphorylation events are 
mediated by the conventional IKK complex, and impair CYLD-mediated 
deubiquitination of TRAF2.  Exogenous expression of a compound mutant of CYLD 
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with all serine residues substituted with alanine results in impaired TNFα-induced 
TRAF2 ubiquitination, resulting in impaired NFκB activation (Reiley et al., 2005).   
We stably expressed S418A HA-CYLD in CYLD-/- MEFs to address whether this 
was the site phosphorylated during necrosis.  Interestingly, RIP1 associated CYLD 
phosphorylation still occurred with this phospho-acceptor site mutated (Fig. 4.10B, top 
panel, compare lanes 1 and 3).  CYLD phosphorylation was still observed when the cells 
were treated with CHX/zVAD, albeit with reduced amounts (Fig. 4.10B, top panel, 
compare lanes 3 and 4).  This is consistent with a previous report demonstrating 
enhanced DISC formation in cells sensitized to TNFα induced death with SMAC 
mimetic as compared to CHX (Wang et al., 2008).  It also demonstrates that 
phosphorylation of CYLD during necrosis is not specific to SMAC mimetic sensitization.  
Altogether, this suggests that S418 is not the sole phosphorylation site, but does not 
exclude the possibility that CYLD gets phosphorylated at multiple amino acid residues 
during necrosis.  Since RIP1 kinase activity is pro-necrotic, and CYLD phosphorylation 
during necrosis is RIP1-dependent this suggests the possibility that the phosphorylation 
event may actually enhance the pro-necrotic function of CYLD.  
 
CYLD interaction with RIP1 is indirect 
Up to this point the data presented has indicated that CYLD interacts with RIP1 
both constitutively in some cell-lines and in a TNFα-dependent manner during necrosis.  
In order to further define the nature of this interaction and potential interaction with other 
components of the necrosome, we utilized two different overexpression systems. Co-
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expression of CYLD and RIP3 in 293T cells did not reveal interaction, whereas RIP3 and 
RIP1 interaction was observed using the same system (Fig4.11A compare lanes 4 and 5). 
This indicates that CYLD does directly interact with a component of the necrosome.  
Furthermore, it is unclear whether CYLD can be found in RIP3 complexes during 
necrosis, but our data indicates that CYLD interacts with RIP1 during time-points when 
the necrosome is present.  Similar to lack of interaction between CYLD and RIP3, co-
expression of CYLD and RIP1 in 293T cells did not reveal interaction. Consistent with 
previous reports, CYLD interaction with TRAF2 was observed using the same system 
(Fig. 4.11B compare lanes 4 and 5)(Kovalenko et al., 2003).  In agreement with the 
results observed in the 293T system, recombinant baculovirus derived CYLD and RIP1 
did not interact when the crude lysates from separately transduced SF9 cells were mixed 
and subjected to an in vitro binding assay.  Importantly, RIP3 was co-immunoprecipitated 
with RIP1 using this same method.  This ensured that the lack of interaction between 
RIP1 and CYLD wasn’t attributed to experimental conditions (Fig. 4.11C compare lanes 
5 and 6).  Additionally, recombinant baculovirus derived CYLD and RIP3 did not 
interact (Fig.4.11D compare lanes 5 and 6).  In summary, CYLD interaction with RIP1 is 
indirect as suggested by two different overexpression systems.  This is in agreement with 
one report that showed RIP1 and CYLD interaction during TNFα-induced apoptosis 
required the adaptor protein CLIPR-59 (Fujikura et al., 2012). 
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Figure 4.1 CYLD does not regulate RIP1 ubiquitination within the TNFR-1 
complex.  
(A) Recruitment of CYLD and A20 to the TNFR-1 complex.  The TNFR1 complex was 
purified by immunoprecipitation (IP).  The recruitment of RIP1, CYLD and A20 was 
assessed via Western Blot.  Control IPs with isotype-matched IgG were included to show 
the specificity of binding to TNFR-1.  (B) CYLD+/+ and CYLD-/- MEFs were treated with 
TNFα for the indicated times.  The TNFR-1 complex was immuneprecipitated, and   
recruitment of polyubiquitinated RIP1 was determined by Western blot. (C) IκBα 
phosphorylation and degradation was normal in CYLD-/- MEFs.  
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Figure 4.2 CYLD deubiquitinase activity and CG3 are required for TNFα-induced 
necrosis. (A) Schematic diagram of wild-type CYLD and deletion mutants used in the 
experiments. (B-C) CYLD-/- MEFs were transiently transfected with the indicated GFP-
tagged CYLD mutants.  Necrosis was induced with TNFα, CHX and zVAD-fmk.  Cell 
death was determined in the GFP+ population by PI staining and flow cytometry.  The 
panel to the right of (C) is a Western blot showing the GFP-tagged CYLD mutants were 
expressed at similar levels and of the correct size. 
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Figure 4.3 Poly-ubiquitinated RIP1 is the major substrate for CYLD in TNFα-
induced necrosis.  
(A) K377R RIP1 is recruited to the TNFR-1 complex and ubiquitination is impaired. WT 
TNFR2+ Jurkat cells or RIP1 deficient TNFR2+ Jurkat cells reconstituted with K377R 
GFP-RIP1 were treated with rhTNFα for the indicated time-points. Complex I was 
isolated via TNFR-1 immunoprecipitation. The ubiquitination status of RIP1 within 
Complex I was assessed via Western blot. (B) K377R RIP1 mutant bypasses the 
requirement for CYLD in necrosis. RIP1 deficient TNFR2+ Jurkat cells reconstituted with 
K377R GFP-RIP1 were transfected with the indicated siRNA oligos and treated with 
rhTNFα. % cell loss was determined via PI exclusion and flow cytometry.  The inset 
shows reduction in protein expression of CYLD and RIP3 in siRNA transfected cells by 
Western blot. 
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Figure 4.4 CYLD regulates the ubiquitination status of RIP1 in the necrosome.  
(A-B) CYLD regulates RIP1 ubiquitination during necrosome formation. CYLD+/+ and 
CYLD-/- MEFs or (B) control and CYLD-kd HT-29 cells were treated with TNFα, the 
SMAC mimetic LBW242, and zVAD-fmk for the indicated time-points. A denaturing 
RIP1 IP was conducted in 1% SDS as described in the methods.  The level of RIP1 
ubiquitination was examined by Western blot.  NS: non-specific band.  (C) Necrosome-
associated RIP1 contains ubiquitin chains of different linkage types. Cells were treated 
with TNFα and zVAD-fmk for 3 hours or left untreated.  RIP3 immune complexes were 
denatured in urea, followed by immunoprecipitation with the indicated antibodies against 
ubiquitin.  The ubiquitination of RIP1 within the necrosome was determined by Western 
blot. (D) Selective accumulation of poly-ubiquitinated proteins in RIP1 complexes in the 
NP-40 insoluble compartment.  WT MEFs or CYLD-/- MEFs were treated to undergo 
necrosis with TNFα, zVAD-fmk, and CHX for the indicated times.  Cells were lysed in 
NP-40 lysis buffer and insoluble material was solubilized with SDS.  RIP1 was 
immunoprecipitated from both fractions followed by Western blot with the indicated 
antibodies.  
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Figure 4.5 CYLD regulates the kinetics of RIP1-RIP3 necrosome assembly.  
(A) WT or CYLD-/- MEFs were treated with TNFα, LBW242 and zVAD-fmk for the 
indicated times.  RIP3 complexes were immunoprecipitated and recruitment of RIP1 was 
determined by Western blot.  (B) HT-29 cells expressing non-specific shRNA (NS) or 
CYLD shRNA were treated with TNFα, LBW242 and zVAD-fmk.  RIP1 recruitment to 
RIP3 was determined by Western blot. 
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Figure 4.6 CYLD regulates the kinetics of assembly for multiple components of the 
necrosome. 
(A) HT-29 cells were treated with TNFα, LBW242 and zVAD-fmk.  Caspase-8 
complexes were isolated via immunoprecipitation.  The recruitment of RIP1 and FADD 
to Caspase-8 was determined by Western blot. (B) HT-29 cells were treated with TNFα, 
LBW242 and zVAD-fmk. Where indicated, cells were also pre-treated with Nec-1. 
FADD complexes were immunoprecipitated.  The recruitment of RIP1 to FADD was 
determined by Western blot.   
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Figure 4.7 Impaired RIP1 and RIP3 phosphorylation in the absence of CYLD. 
(A) MEFs were treated with TNFα, zVAD-fmk and LBW242.  Cell lysates were 
extracted by sequential detergent lysis in NP-40 and SDS as described in methods.  RIP1 
and RIP3 in each fraction were examined by Western blot.  Note that phosphorylated 
RIP1 and RIP3 (p-RIP1 and p-RIP3) were exclusively detected in the SDS fractions.  (B) 
HT-29 cells stably expressing non-specific (NS) shRNA or CYLD shRNA were treated 
with TNFα, LBW242 and zVAD-fmk for the indicated times.  Unmodified and phospho-
RIP1 and phospho-RIP3 were analyzed by Western blot.  (C) Same cells and treatment as 
in (B).  Cell lysates were extracted by sequential detergent lysis in NP-40 and SDS as 
described in methods.  The phosphorylation status of RIP1 and RIP3 was determined by 
Western blot.    
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Figure 4.8 Induction of RIP1 associated kinase activity in the NP-40 insoluble 
compartment. 
(A) Schematic flowchart showing the procedures by which the different NP-40 soluble 
and insoluble fractions were obtained.  (B) Accumulation of necrosis signaling proteins 
in the NP-40 insoluble fractions.  FADD deficient Jurkat cells stably transfected with 
TNFR-2 were treated to undergo necrosis with rhTNFα for the indicated time-points.  
The indicated fractions were analyzed for levels of RIP1, RIP3 and CYLD via Western 
blot.  β-actin was used as an internal control.  (C) The kinase activity of the necrosome is 
selectively activated in the NP-40 insoluble fractions.  Cell lysates were subjected to 
differential centrifugation as described in (A).  RIP1 complexes were obtained via IP and 
subjected to in vitro kinase assays using histone H1 as the substrate.  RIP1 ubiquitination 
and recruitment of RIP3 and CYLD were determined by Western blot (lower panels).  
(D) Induction of kinase activity in the NP-40 insoluble fraction is partially dependent on 
RIP1 kinase activity.  The P10 fractions were prepared, and RIP1 complexes were 
isolated.  Where indicated, 30 µM of Nec-1 was added to the in vitro kinase assay.  (E) 
Densitometry quantification of RIP1 ubiquitination in the different fractions in (C).  
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Figure 4.9 Poly-ubiquitinated RIP1 is a poor substrate for autophosphorylation. 
(A) TNFα induced expression of cIAP2.  Wild type MEFs were stimulated with TNFα, 
zVAD-fmk and SM as indicated.  Expression of cIAP1 and cIAP2 was analyzed via 
Western blot using a pan-cIAP antibody.  (B) Cellular IAPs associate with 
polyubiquitinated RIP1 during necrosis induction.  TRAF2 complexes were purified from 
TNFα, CHX, and zVAD-fmk treated cells.  Western blot shows that polyubiquitinated 
RIP1 at 2, 4 and 6 hours post-stimulation were present with the cIAP1/2-TRAF2 
complex.  (C) Polyubiquitinated RIP1 is refractory to autophosphorylation.  HEK293T 
cells were transfected with GFP tagged RIP1.  RIP1 was immunoprecipitated with 
antibody against GFP.  The immune complex was tested for autophosphorylation in in 
vitro kinase assay (left).  The Western blot on the right panel shows unmodified and 
ubiquitinated RIP1 species.  Note that the ubiquitinated species were not phosphorylated 
in the kinase assay. 
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Figure 4.10 RIP1 kinase dependent phosphorylation of CYLD during TNFα-
induced necrosis. 
(A) Wild-type MEFs were treated with TNFα, LBW242 and zVAD-fmk.  Where 
indicated, cells were pre-treated with Nec-1 or the immune complexes were treated with 
phosphatase.  RIP1 complexes were isolated by IP.  The recruitment of CYLD to RIP1 
was determined by Western blot. (B) CYLD-/- MEFs stably expressing S418A HA-
CYLD were pre-treated with zVAD-fmk and either LBW242 or CHX, and then 
stimulated with TNFα for the indicated time.  RIP1 complexes were isolated by IP.  The 
recruitment of CYLD to RIP1 was determined by Western blot.    
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Figure 4.11 CYLD does not directly bind to RIP1 or RIP3. 
(A) 293T cells were transfected with the plasmids encoding the indicated genes.  RIP3 
was immunoprecipitated and association with either CYLD or RIP1 was determined by 
Western blot. (B) Similar to (A) but instead CYLD was immunoprecipitated and 
association with RIP1 or TRAF2 was determined by Western blot. (C) SF9 cells were 
transduced separately with the indicated recombinant baculovirus.  Lysates from 
transductions were mixed as shown, RIP1 was immunoprecipiated, and association with 
CYLD and RIP3 was determined through Western blot. (D) Same as in (C) but RIP3 was 
immunoprecipitated.        
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Discussion 
Protein ubiquitination plays key roles in cell death and innate immune signaling 
pathways (O’Donnell et al., 2011).  Polyubiquitinated RIP1 in the TNFR-1 complex was 
shown to prevent RIP1 association with caspase-8 resulting in inhibition of apoptosis 
(O’Donnell et al., 2007).  SMAC mimetic treatment causes cIAP1/2 degradation, the E3 
ligases for RIP1.  This sensitizes cells to TNFα-induced apoptosis.  CYLD was shown to 
be required for the formation of the DISC in this cell death context, which was presumed 
to be CYLD-mediated deubiquitination of residual ubiquitinated RIP1 within the TNFR-1 
complex (Wang et al., 2008).  A similar role for polyubiquitinated RIP1 has been 
proposed to inhibit necrosome formation (O’Donnell et al., 2011; O’Donnell et al., 2012).   
Hence, CYLD was thought to promote necrosis by de-ubiquitination of RIP1 in the 
TNFR-1 membrane complex.  In contrast to this prevailing model, we show that RIP1 
ubiquitination in the TNFR-1 complex was unaffected in CYLD-/- cells.  Moreover, the 
RIP1-RIP3 necrosome was formed, albeit with delayed kinetics, in CYLD-/- or CYLD-kd 
cells.  CYLD was recruited to the necrosome in a TNFα-dependent manner.  However, 
this interaction is likely to be indirect, as expression of CYLD in 293T cells or in 
baculovirus did not reveal a strong interaction between CYLD and RIP1.  Adaptors such 
as the recently reported CLIPR-59 may mediate the interaction between RIP1 and CYLD 
(Fujikura et al., 2012).    
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In contrast to RIP1 ubiquitination in the TNFR-1 complex, RIP1 ubiquitination in 
the necrosome was indeed increased in the absence of CYLD.  In particular, the 
necrosome isolated from the NP-40 insoluble fraction showed strong induction of 
ubiquitination in response to TNFα, suggesting that CYLD may instead regulate RIP1 
ubiquitination in this compartment.  This model is consistent with the recent discovery 
that caspase-8 mediated cleavage of CYLD limits TNFα-induced programmed necrosis, 
since caspase-8 is present in the necrosome, but not the TNFR-1 complex (O’Donnell et 
al., 2011).  Because CYLD is not essential for necrosome assembly, but rather facilitates 
its activation, our results also explain why genetic inactivation or siRNA silencing of 
CYLD was not as effective as inactivating RIP1 or RIP3 in blocking programmed 
necrosis in cells or in FADD-/- or caspase-8-/- mice (Bonnet et al., 2011; Welz et al.,2011).  
A consequence of increased RIP1 ubiquitination in CYLD-/- cells is impaired 
RIP1 and RIP3 phosphorylation and activation.  The polyubiquitin chains on RIP1 may 
sterically prevent autophosphorylation of RIP1 or limit access of an upstream RIP1 
activating kinase.  Alternatively, it may sterically restrict RHIM-mediated amyloid 
complex assembly, which facilitates kinase activation (Li et al., 2012).  Regardless of the 
mechanism, it is surprising that CYLD deficiency led to a substantial reduction in 
necrosis and yet necrosome assembly was only marginally affected.  The precise reason 
for this difference is unknown at present.  However, it is noteworthy that the levels of 
RIP1, RIP3 and CYLD in the NP-40 fractions decreased as programmed necrosis ensued 
(Fig. 4.7A).  While some of the loss could be attributed to relocation of these factors to 
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the NP-40 insoluble fractions, direct lysis with SDS buffer revealed that protein 
degradation might also contribute to their loss (Fig. 4.7B).  This necrosis-induced 
degradation of signaling regulators was impaired in CYLD-/- cells. 
Another fascinating prospect offered by the data presented in this chapter is the 
reciprocal regulation between CYLD and RIP1 during necrosis.  The data strongly 
supports the notion that polyubiquitinated RIP1 is a target of CYLD, and is suggestive of 
CYLD being a RIP1 substrate.  Although, CYLD phosphorylation is RIP1 kinase 
dependent, whether CYLD is directly phosphorylated by RIP1 has not been formally 
demonstrated.  The kinetics of RIP1-associated CYLD phosphorylation is consistent with 
our understanding that RIP1 kinase activation occurs post-TNFR-1 complex dissolution 
(Cho et al., 2009).  Ascertaining whether this phosphorylation event is consequential for 
the necrosis program is of critical importance.  
Given that RIP1 kinase activity is required for necrosis, the most straightforward 
possibility is that CYLD phosphorylation is pro-necrotic. This is in contrast to 
IKKγ(NEMO)-dependent phosphorylation of CYLD, which inhibits its function.  In 
addition to NEMO inhibiting CYLD, it has been shown to negatively regulate TNFα-
induced necrosis (Reiley et al., 2005; O’Donnell et al., 2012).  Future studies should 
investigate the possibility that NEMO exerts its anti-necrotic function through 
inactivation of CYLD.  Interestingly, RIP1-mediated phosphorylation of associated 
CYLD does not occur at early time-points during TNFR-1 complex formation (Fig4.10A, 
top panel, compare lanes 2 and 3).  This was the time when the inhibitory 
phosphorylation of CYLD by the IKK complex was previously observed.  The CYLD 
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phosphorylation event occurs prior and during necrosome formation (Fig4.10A, top two 
panels, compare lanes 3,6, and 7).  This provides the basis for a potentially interesting 
mode of CYLD regulation during TNFα signaling.  Perhaps, early during necrosis 
signaling phosphatases remove inhibitory phosphates from CYLD, which is followed by 
RIP1 kinase dependent addition of activating phosphates on CYLD.  Since this study 
establishes CYLD-mediated RIP1 deubiquitination as a molecular event consequential 
for necrosis, it is also tempting to speculate the existence of a positive feedback 
regulatory mechanism where RIP1 activates CYLD and CYLD deubiquitinates RIP1 
resulting in further RIP1 activation.   
However, it is plausible that CYLD phosphorylation is anti-necrotic and serves as 
a regulatory mechanism to suppress aberrant necrosis.  If the latter scenario is correct, it 
would be suitable to dub RIP1 an “ambivalent kinase” because it mediates both pro-
necrotic and anti-necrotic phosphorylation events.  This may suggest that additional 
factors dictate the targets RIP1 phosphorylates and the overall decision of which 
opposing cellular outcome predominates, survival or death.  Namely, these additional 
factors could be in the form of intervening pro-survival pathways, or supportive pro-
death pathways.  The potential junction between the necrosis pathway and other 
pathways may allow the cell to integrate additional information such as its metabolic 
status before making the decision to commit suicide.  It is also possible that CYLD 
activates RIP1 and then RIP1 phosphorylates and inactivates CYLD.  This could serve as 
a regulatory mechanism to ensure that CYLD does not deubiquitinate other components 
of the necrosome, which may require ubiquitination for transducing the necrotic signal.         
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      In this report we show that in spite of CYLD recruitment to the TNFR1 
complex, it does not regulate RIP1 ubiquitination within this compartment.  This may be 
attributed to the fact that the IKK complex is activated within the TNFR1 complex, and 
the IKK complex negatively regulates CYLD-mediated deubiquination of target proteins 
(Reiley et al., 2005).  It is unclear whether the TNFR1 complex associated CYLD 
transitions into the necrosome and is ultimately responsible for deubiquitinating RIP1.  
Alternatively, CYLD may be recruited to the necrosome independent of a “rite of 
passage” through the TNFR1 associated complex. 
The USP domain is necessary, but not sufficient for the pro-necrotic function of 
CYLD.  We show that a portion of CYLD harboring the third Cap Glycine domain and a 
TRA2 interaction motif, in addition to an enzymatically active USP, is sufficient for the 
pro-necrotic function of CYLD.  Naturally, further deletion analysis would be needed to 
determine how much of this portion of CYLD is functionally relevant (Fig. 4.2A).  It is of 
value to note that the third Cap Glycine domain of CYLD is required for binding to 
NEMO (Kovalenko et al., 2003).  In order, TRAF2 contains an N-terminal RING domain 
followed by a stretch of Zinc fingers, and the TRAF-N and TRAF-C subdomains.  The 
TRAF-N subdomain is required for binding to RIP1, and both the TRAF-N and TRAF-C 
subdomains are required for binding to CYLD (Takeuchi et al., 1996; Kovalenko et al., 
2003).  Since our data indicates that CYLD does not bind directly to RIP1, it is tempting 
to speculate that CYLD is brought into contact with RIP1 through a mutual association 
with TRAF2.  Consistent with this notion, we demonstrate ligand dependent association 
between TRAF2 and RIP1 during necrosis (Fig 4.9B).  A previous report revealed that 
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expression of a dominant negative TRAF2 causes enhanced TNFα-induced necrosis.  
The authors explained this phenotype by impaired RIP1 ubiquitination in cells expressing 
the dominant negative TRAF2.  The mutant TRAF2 used in this study was a deletion 
mutant lacking its RING domain (O’Donnell et al., 2012).  Importantly, the RING 
domain of TRAF2 is not required for its interaction with CYLD or RIP1 (Kovalenko et 
al., 2003; Takeuchi et al., 1996).  This suggests that the enhanced necrosis caused by 
dominant negative TRAF2 may not be due solely to lack of anti-necrotic RIP1 
ubiquitination via TRAF2 E3 ligase activity, but rather through the retained binding of 
RIP1/TRAF2/CYLD complex, which promotes RIP1 deubiquitination. 
 
Materials and Methods 
Reagents used 
Antibodies used in the study were from BD Pharmingen (A20, cIAP1/2, FADD, RIP1, β-
actin and TNFR-1), Cell Signaling (p-IκBα and total IκBα), Millipore EMD (K48 and 
K63-specific ubiquitin antibodies), ProSci (RIP3), Santa Cruz Biotechnology (caspase 8, 
TRAF2, CYLD) and Invitrogen (CYLD and total ubiquitin antibody).  Antibody against 
human RIP3 has been described before [16].  Necrostatin-1 and zVAD-fmk were 
obtained from Enzo Life Sciences. Recombinant human and mouse TNF were obtained 
from Biosource/Invitrogen.  The Smac mimetic LBW242 was a kind gift of D. Porter 
(Novartis).  Small interference RNAs used in the study are: human CYLD (5’-
CUUAUUUUUAGCAAAGGUUCUACCCUU-3’, 5’-
UUGGUUUAUUAUGACUGGAUGAACCUU-3’), human RIP3 (5’-
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UAACUUGACGCACGACAUCAGGCUGGA-3’, 5’-
GCAGUUGUAUAUGUUAACGAGCGGUCG-3’), human TR4 (5’-
CCGGAGCUUCCCUCAUUUAdTdT-3’).   
 
Tissue culture 
MEFs were grown in DMEM high sucrose medium supplemented with 10% FCS, 2 mM 
glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin.  HT-29 and Jurkat cells 
were grown in McCoy’s 5A medium and RPMI1640 media, respectively, supplemented 
with 10% FCS, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. 
SF9 cells were maintained in serum free Sf-900 II SFM supplemented with 100 units/ml 
penicillin, and 100 µg/ml streptomycin.  Stable clones of HT-29 cells were generated by 
transfection using lipofectamine 2000 (Invitrogen) of CYLD-specific and scrambled 
shRNAs from Thermoscientific/Open Biosystems.  Clones were selected by puromycin 
selection and checked for GFP expression via flow cytometry. GFP+ clones were tested 
for reduction of CYLD protein expression and used for subsequent experiments. 
 
Cell death assays 
For FADD and caspase-8 deficient TNFR2+ Jurkat Cells (Chan et al., 2003),  
programmed nNecrosis was induced by addition of the indicated amounts of recombinant 
human TNF (rhTNF). Cell death was determined by flow cytometry with propidium 
iodide staining or by CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega). 
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Transfection of DNA Plasmids and siRNA 
Jurkat cells were transfected with 150 nM of the indicated siRNA. All siRNA 
transfections were performed using the HiPerfect transfection reagent (Qiagen) as per 
manufacturer’s protocols.  Forty-eight hours later, cells were stimulated with TNFα to 
induce necrosis.  
For DNA plasmid transfection into MEFs, 2.5 x 105 cells per well of 12-well plate were 
plated the day before transfection.  Transfection was performed using the Lipofectamine 
LTX transfection reagent (Invitrogen) as per manufacturer’s protocol.  CYLD deletion 
mutants were generated by PCR amplification and cloning into pEGFP-C1 vector.  
Integrity of the mutant clones was confirmed by sequencing. 
For 293T cells, three hours prior to transfection cells were plated at 3 x 105 cells/well of 
12-well plate.  Cells were subsequently transfected with 1 µg/well (12-well plate) of the 
indicated plasmid DNA using the Fugene6 or Fugene HD transfection reagent (Roche) as 
per manufacturer’s protocol. 
 
Recombinant Baculovirus generation and Transduction 
 Recombinant baculovirus encoding either hRIP1, hRIP3, hCYLD were generated using 
the BaculoDirectTM Baculovirus Expression System as per manufactures protocol.  
Transduction of SF9 cells was conducted as per manufactures protocol.  
 
Immmunoprecipitations and Western Blots 
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For immunoprecipitations in MEFs, six million cells on two 10 cm tissue culture dishes 
were used per sample.  For HT-29 cells, one plate of cells was used per sample.  For 
Jurkat cells, 100 – 150 million cells were used.  Cells were harvested and lysed in either 
Complex II lysis buffer (150 mM NaCl, 20 mM Tris-Cl [pH 7.5], 1% NP-40, 1 mM 
EDTA, 3 mM NaF, 1 mM βb-glycerophosphate, 1 mM sodium orthovanadate) or RIPA 
lysis buffer (150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS, and 50 mM Tris pH 8.0) supplemented with 5 µM iodoacetamide, 2 µM N-
ethylmaleimide, 1X Complete protease inhibitors (Roche) and Phosphatase inhibitor 
cocktail I (Sigma).  For denaturing IPs, cells were lysed in 1% SDS, 50 mM TrisCl 
pH7.4, 5 mM EDTA, 10 mM DTT, 15 U/ml DNase I supplemented with Complete 
protease inhibitors (Roche), and phosphatase inhibitor cocktail II (Sigma).  After 
clearance with Sepharose 6B beads, lysates were mixed with specific 
immunoprecipitation antibodies as indicated for 4 hours to overnight at 4oC.  Immune 
complexes were then washed, boiled, and resolved on a 4-12% Bis-Tris NuPAGE gel 
(Invitrogen).  For sequential IP, the washed immune complex was resuspended in RIPA 
buffer supplemented with 6 M urea.  After rotation at room temperature for 30 minutes, 
lysates were diluted 10-fold in RIPA buffer without urea and incubated with different 
ubiquitin antibodies.   
For differential centrifugation, cell lysates were centrifuged at 1,000g for 10 minutes.    
The resulting supernatants were centrifuged at 10,000g for 10 minutes.  The resulting 
pellet was washed in 1 ml lysis buffer and centrifuged at 10,000g for an additional 10 
minutes yielding the P10 fraction.  The supernatant following first spin at 10,000g was 
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transferred to a new tube and spun at 25,000g. The resulting supernatant and pellets were 
the S25 and P25 fractions.  
 
In vitro kinase assays 
The IP complexes were incubated for 30 minutes at 30°C in kinase reaction buffer (20 
mM HEPES [pH 7.5], 2 mM DTT, 1 mM NaF, 1 mM Na3VO4, 20 mM β-
glycerophosphate, 20 mM MgCl2, 20 mM MnCl2, 1 mM EDTA, and 200 – 400 µM ATP) 
supplemented with 10 µCi [32P] γ-ATP and 5 µM Histone H1.   Reactions were quenched 
by boiling in sample loading buffer.  Phosphorylation of Histone H1 was visualized by 
autoradiography. 
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PREFACE TO CHAPTER V 
 
 
The conclusions in this chapter are primarily based on findings in the following 
manuscript that is under review for publication: 
 
 
David M. Moquin, Thomas McQuade, Francis Ka-Ming Chan. CYLD Deubiquitinates 
RIP1 in the Necrosome to Facilitate Kinase activation and Programmed Necrosis 
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CHAPTER V: Discussion 
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Overview  
 The work presented in this thesis documents the independent finding of the 
functional involvement of CYLD in TNFα induced necrosis.  It was originally believed 
that CYLD was an essential component of the TNFα induced necrosis signaling pathway 
(Vanlangenakker et al., 2011).  The work here demonstrates that CYLD is not essential 
for TNFα induced necrosis, as attenuated necrosis proceeds in the absence of CYLD.  
The CYLD-independent necrosis is RIP1 kinase dependent supporting the notion that the 
pathway is still transduced through the necrosome.  Furthermore, CYLD controls the 
kinetics of necrosis, as indicated by a delay in the onset of necrosis in CYLD deficient 
MEFs.  This delay in necrosis is congruent with the biochemical data.  Namely, 
RIP1/RIP3 necrosome formation is kinetically delayed in cells deficient of CYLD.  
Interestingly, although necrosis is attenuated in CYLD deficient MEFs, the RIP1/RIP3 
necrosome eventually catches up to levels observed in cells expressing CYLD.  We 
demonstrate that RIP1 is indeed the primary target of CYLD in the context of necrosis.  
In opposition to the previous model proposed for the pro-necrotic mechanism of CYLD, 
it does not regulate the ubiquitination status of RIP1 within the TNFR-1 complex.  
Instead, CYLD is recruited to RIP1 complexes during necrosome formation, and 
regulates the ubiquitination status of RIP1 within an NP-40 insoluble fraction.  The 
corollary of this is activation of the necrosome as demonstrated by the reduced 
phosphorylation status of RIP1 and RIP3 in CYLD deficient cells.  Consistently, we 
provide evidence that unmodified RIP1 is a better substrate for auto-phosphorylation than 
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polyubiquitinated RIP1.  Altogether, this thesis independently reveals the pro-necrotic 
function of CYLD and provides a new model for the molecular mechanism governing 
this function (Fig 5.1). 
 
The involvement of CYLD in TNFα-induced cell death  
 Previous studies suggested that CYLD is an essential player in the TNFα-induced 
signaling pathway (Vanlangenakker et al., 2011).  Our studies indicate that necrosis 
proceeds in the absence of CYLD, but is kinetically impaired and has a decreased 
magnitude.  The discrepancy between the results can potentially be answered by the fact 
that our data shows a kinetic delay in the onset of necrosis in CYLD deficient MEFs.  
Previous groups may have used time-points when CYLD-independent necrosis had not 
yet commenced and thus reported that CYLD was essential for necrosis.  Genetic 
evidence supports the notion that CYLD is not essential for necrosis.  Specifically, 
conditional deletion of FADD in epidermal keratinocytes results in RIP3 dependent 
programmed necrosis resulting in inflammatory skin lesions.  Crossing these mice with 
RIP3 knock-out mice was sufficient for rescuing the phenotype while crossing to CYLD 
knock-out mice resulted in only a partial rescue.  Therefore, in vivo evidence suggests 
that CYLD is not essential for necrosis, which is in agreement with our findings (Bonnet 
et al., 2011).   
The non-essential function of CYLD in TNFα-induced necrosis raises questions 
regarding the validity of the current model that is used to describe the mechanism behind 
its pro-necrotic function.  The current model places CYLD upstream of necrosome 
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formation.  Both RIP1 and RIP3 are essential for TNFα-induced necrosis, and require 
their RHIM domains in order to associate and transduce the necrotic signal (Holler et al., 
2001; Cho et al., 2009).  The fact that necrosis can occur independently of CYLD 
suggests that its purported role as a driver of necrosome formation is moot (Fig 1.1).  In 
other words, if CYLD was required for RIP1/RIP3 association this would predict that it 
should also be an essential component of the necrosis signaling pathway since RIP1/RIP3 
association is a critical molecular event.  Supporting this notion, RIP1 kinase activity is 
still required for CYLD-independent TNFα-induced necrosis.  Hence, RIP1 kinase 
activity must still be activated in the absence of CYLD. This data provided us with 
important clues that the presumed model accounting for the pro-necrotic function of 
CYLD was incorrect.  The biochemical data is consistent with these findings.   
Interestingly, our studies indicate a greater requirement for CYLD in necrosis 
than apoptosis.  The apoptotic target of CYLD has been proposed to be polyubiquitinated 
RIP1; however, it is clear the TNFα-induced apoptosis is RIP1 independent when 
sensitized with CHX (Lin et al., 2004).  This makes it unlikely that RIP1 is the target of 
CYLD during apoptosis.  Nevertheless, it has been demonstrated that CYLD promotes 
TNFα driven caspase activation (Fujikura et al., 2012).  In addition to regulating caspase 
activation, CYLD is a target of caspase-8 cleavage (O’Donnell et al., 2011). This implies 
that the pro-apoptotic function of CYLD precedes caspase-8 activation since cleavage 
results in degradation of the C-terminal fragment. CYLD-mediated caspase activation is 
likely explained by its role in regulating DISC formation (Wang et al., 2008).  Similarly 
our data indicates that CYLD also regulates the kinetics of necrosome formation; 
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however, in the absence of CYLD it catches up to levels found in cells replete with 
CYLD.  Therefore, the kinetic delay in cell death is congruent with the kinetic delay in 
necrosome formation.  The fact that the level of necrosome formation catches up, but the 
magnitude of cell death does not, suggests that CYLD mediates two separate molecular 
events leading to necrosis.  One molecular event is early and results in the regulation of 
the kinetics of necrosome formation, and the other molecular event is later and 
determines the functionality of the necrosome.  For apoptosis the data indicates that the 
only molecular event CYLD mediates is prior to DISC formation where caspase-8 is 
activated.  Altogether, the greater requirement for CYLD in necrosis may reflect the fact 
that it is mediating two molecular events, one early and one later, while CYLD may only 
mediate an early pro-apoptotic molecular event.   
What is the potential early molecular event CYLD regulates?  Since CYLD 
regulates both the kinetics of apoptotic DISC formation and necrosome formation, it is 
tempting to speculate that the early molecular event it mediates is the same for apoptosis 
and necrosis.  Our current knowledge of the TNFα cell death pathway suggests that the 
divergence point between apoptosis and necrosis occurs at the DISC.  This predicts that 
the preceding steps in the pathway are similar.  Corroborating this hypothesis, our study 
shows that CYLD deficiency not only leads to a delay in RIP1/RIP3 association, but also 
delayed association between FADD/RIP, caspase-8/RIP1, and caspase-8/FADD, which 
are also components of the apoptotic DISC (Micheau et al., 2003).  It has not been 
formally demonstrated whether the deubiqutinase activity of CYLD is required for its 
pro-apoptotic function.  This would perhaps suggest that CYLD regulates the 
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ubiquitination status of a shared protein/s required for promoting either apoptotic DISC 
formation or necrosome formation during caspase inhibition.   
One intriguing candidate for the target of CYLD during the potential early 
overlapping pro-apoptotic and pro-necrotic molecular event is polyubiquitinated NEMO.    
Several lines of evidence suggest that this may be the case.  First, NEMO has already 
been demonstrated to be a target of CYLD in overexpression studies (Kovalenko et al, 
2003). Second, NEMO is a negative regulator of both TNFα-induced apoptosis and 
necrosis (O’Donnell et al, 2009; O’Donnell et al, 2012). Third, CYLD knock-down does 
not confer protection from TNFα-induced apoptosis in NEMO deficient cells. Fourth, 
linear ubiquitination of NEMO via LUBAC promotes TNFα-induced NFκB activation 
and negatively regulates TNFα-induced apoptosis (Tokunaga et al., 2009).  Fifth, our 
study demonstrates that CYLD is recruited to the TNFR-1 complex shortly after TNFα 
stimulation.  Since this is the complex where NEMO binds to polyubiquitinated RIP1 and 
NEMO itself gets ubiquitinated within this complex, the target and substrate are both 
temporally and spatially in sync during TNFα signaling.  Clearly, more direct evidence is 
needed to substantiate this potential molecular event.  Future studies should evaluate 
whether CYLD regulates the ubiquitination status of NEMO within the TNFR-1 
complex, and address the functional consequences for the pro-apoptotic and pro-necrotic 
signal.  The expectation would be that NEMO ubiquitination regulates the kinetics of 
apoptotic DISC formation or necrotic DISC formation (Fig. 5.2).   
A previous report indicates that the pro-apoptotic function of CYLD is attributed 
to its role in negatively regulating NFκB (Brummelkamp et al., 2003).  However, our 
154
study provides two lines of evidence in opposition to this. First, the use of CHX to 
sensitize cells to TNFα-induced apoptosis should eliminate the effects of NFκB 
activation on apoptosis. Second, we did not observe differences in TNFα-induced NFκB 
activation in CYLD deficient MEFs as compared to wild-type.   
Can the early target of CYLD that promotes apoptotic DISC formation and 
necrosome formation simply be RIP1? The data from our study is not consistent with this 
model.  We demonstrate that CYLD does not regulate the ubiquitination status of RIP1 
within the TNFR-1 complex.  Instead we demonstrate that CYLD regulates the 
ubiquitination status of RIP1 within the NP-40 insoluble necrosome.  Therefore, our 
temporal and spatial data regarding CYLD-mediated RIP1 deubiquitination is 
incongruent with a model in which ubiquitinated RIP1 is the early target of CYLD 
accounting for its effects on necrosome formation.  Additionally, sensitizing cells to 
apoptosis with TNFα and CHX is RIP1 independent (Li et al., 2004).  In our study we 
show that CYLD is functionally involved in apoptosis induced via this stimuli.  This data 
disqualifies RIP1 as a likely target of CYLD responsible for apoptotic DISC and 
necrosome formation. 
 
CYLD-mediated regulation of the necrosome      
The CYLD regulated molecular event that occurs later and is specific to necrosis 
is better characterized by the work presented in this thesis.  We demonstrate that RIP1 is 
polyubiquitinated with both K63 and K48 linked chains in the necrosome.  Importantly, 
in vitro deubiquitinase activity of CYLD is specific to K63 and linear chains opposed to 
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K48 chains (Komander et al., 2009).  We show that CYLD does not regulate the 
ubiqutination status of RIP1 within the TNFR-1 complex nor does it regulate RIP1 
ubiquitination within the NP-40 soluble fraction at later time-points following 
dissociation of RIP1 from the TNFR-1 complex.  Instead, we show that CYLD regulates 
the ubiquitination of RIP1 within an NP-40 insoluble fraction following TNFR-1 
complex dissociation.  Namely, hyperubiquitinated RIP1 is only observed in CYLD 
deficient MEFs at later time-points in the NP-40 insoluble fraction.  This fraction was 
previously demonstrated to harbor enriched phosphorylated RIP1 and RIP3, which are 
consequential modifications for the necrosis signaling program (Degterev et al., 2008; Li 
et al., 2013).  The ramification of this deubiquitination event is not regulation of 
RIP1/RIP3 association, but rather full activation of RIP1 and RIP3 as indicated by 
phosphorylation.   
In addition to revealing that CYLD regulates RIP1 ubiquitination within the NP-
40 soluble fraction, we also reveal that induction of RIP1 kinase activity is most 
pronounced in the equivalent P10/P25 fractions. The equivalence of the NP-40 insoluble 
fraction and the P10/P25 fractions is supported by the fact that accumulation of 
components of the necrosome was observed for both these fractions.  Importantly, 
induction of RIP1 ubiquitination is also most pronounced in these fractions, and CYLD 
can be found in RIP1 complexes from these fractions.  Induction of RIP1 ubiquitination 
is also most pronounced in the P10/P25 fractions.  This places CYLD in the same 
location as its relevant substrate during necrosis.  Altogether, this data suggests that 
CYLD-mediated regulation of RIP1 ubiquitination occurs in the same fraction where 
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RIP1 kinase activity is induced.  This provides a link between CYLD-mediated RIP1 
deubiquitination with induction of full RIP1 kinase activation.  Preliminary experiments 
suggest that CYLD regulates the induction of RIP1 kinase activity in the P10/P25 
fractions.   
It is clear that RIP1/RIP3 association occurs within the NP-40 soluble and S25 
fractions.  Since RIP1 kinase activity is required for RIP1/RIP3 association, this predicts 
that RIP1 must be kinase active in the NP-40 soluble or S25 fraction.  Interestingly, our 
data shows that RIP1 is indeed active in the S25 fraction even prior to necrosis signaling, 
but no distinguishable induction was observed during necrosis.  This could possibly be 
explained by a low signal to noise ratio in the S25 fraction.  The pool of activated RIP1 
post-stimulation might be too small to observe an increase in RIP1 kinase activity over 
background.  Conversely, in the P10/P25 fractions, kinase active RIP1 may be enriched 
thereby increasing the signal to noise ratio.  The lower background prior to necrosis 
stimulation may be attributed to a smaller fraction of kinase active RIP1 in the P10/P25 
fractions than the S25 fraction prior to stimulation.  Future studies should focus on 
elucidating the stages of RIP1 kinase activation during necrosis.  The lower levels of 
RIP1 phosphorylation observed in the NP-40 soluble fraction are consistent with the lack 
of observed RIP1 kinase activity in the comparable S25 fraction.  Since some evidence 
suggests that RIP1 kinase activation is promoted by autophosphorylation, it is 
conceivable that a hierarchy of RIP1 phosphorylation events track with the extent of 
RIP1 kinase activation throughout the course of necrosis.  Early during necrosis, RIP1 
autophosphorylation may not be to the extent found when the necrosome has formed.  
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This could be due to a smaller percentage of RIP1 being autophosphorylated, a fewer 
number of sites phosphorylated on RIP1, or a combination of the two.  Indeed, it has been 
demonstrated that during necrosis detection of RIP1 phosphorylation only occurs in cells 
replete with RIP3 (Cho et al., 2009).  This suggests a model of RIP1/RIP3 reciprocal 
kinase activation.  It is possible that RIP1/RIP3 formation of amyloid fibrils augments 
kinase activation and phosphorylation of downstream substrates.  We show that CYLD 
regulates the ubiquitination status of RIP1 within the NP-40 insoluble fraction where 
RIP1/RIP3 amyloid fibrils are presumably enriched (Li et al., 2012).  This potentially 
indicates that CYLD may regulate amyloid fibril formation, and should be the emphasis 
of further research. 
 
RIP1 ubiquitination in the necrosome    
How does RIP1 ubiquitination within the necrosome interfere with molecular 
events required for necrosis?  We provide evidence that unmodified RIP1 is a better 
substrate for autophosphorylaton than ubiquitinated RIP1.  Previous work found that 
RIP1 autophosphorylation is required for full activation of its kinase activity (Degterev et 
al., 2008).  Substituition of the RIP1 autophosphorylation site at Serine 161 with an 
alanine results in a reduction in kinase activity and a partial defect in its ability to 
promote necrosis.  The functional relevance of the other autophosphorylation sites still 
needs to be clarified.  It is tempting to speculate that compound mutations of multiple 
RIP1 autophosphorylation sites may further impair RIP1 kinase activity and functionality 
during necrosis.  Since our data shows that RIP1 and RIP3 phosphorylation are impaired 
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in CYLD knock-down HT-29 cells and eventually catches up in MEFs, it is conceivable 
that RIP1 ubiquitination may block some autophosphorylation sites leading to partial 
impairment of RIP1 kinase activity.  This would explain our results showing a reduction 
in RIP1/RIP3 phosphorylation in the absence of CYLD.  The fact that phosphorylation 
begins to catch up is consistent with the nonessential function of CYLD in necrosis.  
Further supporting this model, RIP3 phosphorylation requires RIP1 kinase activity; so 
impaired RIP1 kinase activity due to hyperubiquitination and a concomitant impairment 
in autophosphorylation would be expected to result in impaired RIP3 phosphorylation 
(Cho et al., 2009; He et al., 2009). In agreement with this we provide evidence that RIP3 
phosphorylation is indeed impaired in CYLD knock-down cells. 
It is feasible that alternative models may explain how hyperubiquitinated RIP1 
due to CYLD deficiency results in impaired necrosome functionality.  K63-linked 
polyubiquitin chains act as binding platforms for proteins containing ubiquitin binding 
domains or proteins that bind to adaptors containing ubiquitin binding domains.  Our data 
indicates that hyperubiquitinated RIP1 within the NP-40 insoluble fraction is inhibitory 
for necrosis.  In this case hyperubiquitinated RIP1 associated with the necrosome may 
either allow for binding of negative regulators of necrosis, prevent the binding of positive 
regulators of necrosis, or both.  It is presumed that NEMO inhibits TNFα-induced 
necrosis through binding to polyubiquitinated RIP1 within the TNFR-1 complex 
(O’Donnell et al., 2012).  However, since we demonstrate that RIP1 is decorated with 
K63-linked polyubiquitin chains within the necrosome, it is possible that NEMO exerts 
its anti-necrotic function in the necrosome.  This would perhaps mean that the 
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hyperubiquitinated RIP1 found in CYLD deficient cells, results in enhanced recruitment 
of NEMO to the necrosome.  The necrosomes formed in the absence of CYLD would 
therefore be different in composition due to higher levels of a negative regulator of 
necrosis.  Ultimately, this may stifle necrosome functionality and account for the 
attenuated magnitude of necrosis in the absence of CYLD.  Cells expressing CYLD 
would theoretically have functionally competent necrosomes due to removal of 
polyubiquitin chains from RIP1 leading to reduced recruitment of a negative regulator of 
necrosis.   
Similar to NEMO, TAK1 was demonstrated to negatively regulate TNFα-induced 
necrosis through regulation of necrosome formation (Vanlangenakker et al., 2011).  
TAK1 binds to polyubiquitinated RIP1 via the ubiquitin binding proteins TAB2/3 
(Kanayama et al., 2004).  Although TAK1 was demonstrated to regulate necrosome 
formation it was not addressed whether it could exert its anti-necrotic function directly in 
the necrosome.  Additionally, ABIN-1 (A20 binding and inhibitor of NFκB) is yet 
another potential candidate for being recruited to the necrosome and negatively 
regulating its functionality.  It was demonstrated to inhibit TNFα-induced cell death 
through preventing FADD and Caspase-8 association, which is required for apoptosis. 
ABIN-1 contains a NEMO ubiquitin binding domain (NUB).  It was shown that ABIN-1 
binds to the apoptotic DISC through a NUB-mediated interaction with polyubiquitinated 
RIP1.  ABIN-1 requires an intact NUB in order to negatively regulate cell death.  
Whether or not ABIN-1 similarly negatively regulates programmed necrosis has not been 
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determined, but it is possible that it could also bind to polyubiquitinated RIP1 within the 
necrosome (Oshima et al., 2009)               
CYLD mediated deubiquitination of necrosome associated RIP1 may also 
promote the recruitment of positive regulators of necrosis.  Recently, the mitochondrial 
phosphatase PGAM5S/L and MLKL were demonstrated to also be components of the 
necrosome, downstream substrates of RIP1/RIP3, and functionally required for TNFα-
induced necrosis (Sun et al., 2011; Wang et al., 2012).  It is conceivable that 
hyperubiquitinated RIP1, due to CYLD deficiency, could result in steric hindrance of the 
recruitment of these pro-necrotic proteins.  Preliminary experiments suggest that during 
necrosis MLKL recruitment to RIP3 complexes is impaired in cells with CYLD knocked 
down.  For a diagram of additional potential effects of hyperubiquitinated RIP1 refer to 
Figure 5.3.         
In addition to demonstrating that CYLD regulates RIP1 ubiquitination within the 
necrosome, we also show that CYLD controls the expression level of components of the 
necrosome at later time-points during necrosis in the NP-40 soluble fraction.  Although, 
our data indicates that some of the loss of expression can be accounted for by transition 
into the NP-40 insoluble fraction, loss of expression is still observed in cells directly 
lysed with SDS containing buffer.  This suggests that components of the necrosome are 
degraded.  It is unclear whether this degradation has any bearing on the necrosis signaling 
pathway, but it is attenuated in cells either lacking CYLD or with reduced expression.  
CYLD may promote the degradation of components of the necrosome either directly or 
indirectly.  
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One possibility is that CYLD may promote the degradation of RIP1 through 
removing K63 polyubiquitin chains, which are non-degrading chains and this may then 
allow for an associated E3 ligase to target RIP1 with K48 linked polyubiquitin chains, 
which act as degradation signals.  This would be akin to a report that demonstrated a 
functional interaction between CYLD and the E3 ligase ITCH.  In this report they 
showed that CYLD removes K63-linked polyubiquitin chains from TAK1, and the E3 
ligase ITCH then tags TAK1 with K48-linked chains (Ahmed et al., 2011).  However, it 
is difficult to reconcile this model with our finding that CYLD regulates NP-40 insoluble 
RIP1 ubiquitination.  Given this model the expectation would be that in CYLD deficient 
cells there should be a greater accumulation of RIP1 within the NP-40 insoluble fraction 
as compared to cells expressing CYLD.  This is due to the fact that K63-linked hyper-
ubiquitinated RIP1 would be resistant to K48-linked polyubiquitination and degradation.  
Furthermore, our data indicates that CYLD does not regulate RIP1 ubiquitination within 
the NP-40 soluble fraction disfavoring the possibility that the impaired degradation in 
CYLD deficient cells is due to hyperubiquitinated K63-linked polyubiqutinated RIP1.  
It is also possible that decreased expression of necrosome components could be a 
consequence of necrosis rather than a cause of necrosis.  Future studies should clarify 
whether the degradation of components of the necrosome influences the pro-necrotic 
signal. 
 
Implications of CYLD phosphorylation  
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This thesis also provides evidence of mutual regulation between CYLD and RIP1.  
In addition to demonstrating CYLD-mediated RIP1 deubiqutination, we also demonstrate 
RIP1-dependent phosphorylation of CYLD.  For the total cellular pool of CYLD, RIP1 
kinase dependent phosphorylation was not detectable. We only observed phosphorylated 
CYLD when it was associated with RIP1 complexes during necrosis.  This 
phosphorylation event was not blocked in CYLD deficient cells reconstituted with S418A 
CYLD.  In overexpression studies, S418 phosphorylation was demonstrated to negatively 
regulate CYLD-mediated deubiquitination of its targets TRAF2 and NEMO (Hutti et al., 
2009).  This suggests that RIP1 mediates alternative CYLD phosphorylation events.  
Supporting this notion, we do not observe phosphorylated CYLD in RIP1 complexes 
during TNFR-1 complex formation, but we observe it after complex dissolution and 
during necrosome formation.  Since we demonstrate that CYLD deubiquitinase activity is 
required for its pro-necrotic function, we suggest that this phosphorylation event may 
enhance the ability of CYLD to deubiquitinate RIP1. Theoretically this may provide a 
feed-forward mechanism where ubiquitinated RIP1 with weak kinase activity, promotes 
CYLD phosphorylation resulting in enhanced CYLD-mediated RIP1 deubiquitination.  
The denouement of this molecular interplay would be enhanced RIP1 
autophosphorylation, enhanced kinase activation, and necrosis.   
This work provides the inception of several avenues of fascinating research that is 
contingent upon first determining the functionality of this CYLD phosphorylation event.  
One avenue of interest is elucidating the mechanism for how phosphorylation of CYLD 
impacts its ability to deubiquitinate its targets.  Several potential mechanisms are 
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possible.  First, CYLD phosphorylation may directly enhance deubiquitinase activity 
through inducing a conformational change that may enhance active site binding of the 
transition state. Second, CYLD phosphorylation may alter the orientation between its 
active site and its substrate resulting in an optimal orientation for processing.  Third, it 
may simply enhance binding with its substrate.  Fourth, it may alter the binding of other 
factors, which influence the ubiquitination reaction. A specific example may be reduced 
binding of the antagonizing E3 ligase, which ubiquitinates the target protein thus driving 
the reaction more towards deubiquitination.  As mentioned previously, a functional 
interaction between CYLD and the E3 ligase ITCH, has been reported (Ahmed et al., 
2011). 
Another potential avenue of interest for future research is determining the role of 
phosphatases in regulating CYLD activity and necrosis.  Since phosphorylation of CYLD 
is emerging as a recurring theme of regulating the activity of CYLD, there is precedence 
for investigating potential phosphatases involved in this process.  One report indicates 
that CYLD interacts with the phosphatase PP2A and the mitotic kinase Aurora-B.  In this 
case CYLD promotes PP2A dephosphorylation and inhibition of Aurora-B kinase 
activity.  This was independent of CYLD enzymatic activity (Sun et al., 2010).  It is 
conceivable that PP2A also dephosphorylates CYLD thereby regulating TNFα induced 
cell death.  There is a paucity of data involving the potential role of PP2A in TNFα-
induced cell death.  However, one report demonstrates that inhibition of PP2A impairs 
death receptor induced apoptosis (Harmala-Brasken et al., 2003). Naturally, phosphatases 
that remove inhibitory phosphate groups from CYLD would be predicted to have a pro-
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necrotic function, as CYLD enzymatic activity is required in this context.  Since the IKK 
mediated inhibitory phosphorylation of CYLD presumably takes place in the TNFR-1 
complex, it is tempting to speculate that this accounts for the lack of CYLD-mediated 
RIP1 deubiquitination in this compartment (Reiley et al., 2005).  Nevertheless, whether 
this phosphorylation event regulates the ability of CYLD to deubiquitinate RIP1 has not 
been formally tested.  Conversely, phosphatases that remove activating phosphate groups 
from CYLD would be predicted to have an anti-necrotic function.  Furthermore, 
phosphatase mediated regulation of the necrosis signaling pathway clearly extends 
beyond regulation of CYLD.  Since the TNFα induced necrotic signaling program 
involves a cascade of phosphorylation events, there are multiple steps along the pathway 
where phosphatases have the opportunity to impart influence on necrosis. 
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APPENDIX: Cancer gene siRNA library screen data 
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Cell cycle plate 2a (3 days post-transfection)
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Cell cycle plate 6a (3 days post-transfection)
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Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
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Cell cycle plate 6b (2 days post-transfection)
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Cell cycle plate 6b (3 days post-transfection)
TNF (1ng/ml) TNF (100ng/ml)
Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
Linear (Cutoff 100ng/ml TNF)
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Cell cycle plate 7a (2 days post-transfection)
TNF (1ng/ml) TNF (100ng/ml)
Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
Linear (Cutoff 100ng/ml TNF)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Re
lat
ive
 ce
ll v
iab
ilit
y
Cell cycle plate 7a (3 days post-transfection)
TNF (1ng/ml) TNF (100ng/ml)
Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
Linear (Cutoff 100ng/ml TNF)
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Cell cycle plate7b (2 days post-transfection)
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Cell cycle plate 7b (3 days post-transfection)
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Cell cycle plate7c (2 days post-transfection)
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Cell cycle plate 7c (3 days post-transfection) 
TNF (1ng/ml) TNF (100ng/ml)
Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
Linear (Cutoff 100ng/ml TNF)
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Cell cycle plate 8a (2 days post-transfection)
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Cell cycle plate 8a (3 days post-transfection)
TNF (1ng/ml) TNF (100ng/ml)
Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
Linear (Cutoff 100ng/ml TNF)
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Cell cycle plate 8b (2 days post-transfection)
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Cell cycle plate 8b (3 days post-transfection)
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Cell cycle plate 9 (2 days post-transfection)
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Cell cycle plate 9 (3 days post-transfection)
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Linear (Cutoff 100ng/ml TNF)
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Angiogenesis plate 2a (2 days post-transfection)
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Angiogenesis plate 2a (3 days post-transfection)
TNF (1ng/ml) TNF (100ng/ml)
Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
Linear (Cutoff 100ng/ml TNF)
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Angiogenesis plate 2b (2 days post-transfection)
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Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
Linear (Cutoff 100ng/ml TNF)
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Angiogenesis plate 2b (3 days post-transfection)
TNF (1ng/ml) TNF (100ng/ml)
Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
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Angiogenesis plate 3a (2 days post-transfection)
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Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
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Angiogenesis plate 3a (3 days post-transfection)
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Angiogenesis plate 3b (2 days post-transfection)
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Angiogenesis Plate 3b (3 days post-transfection)
TNF (1ng/ml) TNF (100ng/ml)
Staurosporine (500ng/ml) Linear (Cutoff 1ng/ml TNF)
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Angiogenesis plate 4a (2 days post-transfection)
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